

Vanderbilt University Medical Center

**Consolidated Financial Statements and
Supplementary Information, Including
Uniform Guidance Reports and Schedule
Years Ended June 30, 2020 and 2019**

Ernst & Young LLP



**Vanderbilt University Medical Center
Index to Consolidated Financial Statements
June 30, 2020 and 2019**

	Page
Report of Independent Auditors	1
Consolidated Financial Statements	
Consolidated Balance Sheets	3
Consolidated Statements of Operations	4
Consolidated Statements of Changes in Net Assets	5
Consolidated Statements of Cash Flows	6
Notes to Consolidated Financial Statements	7
Supplementary Information	
Schedule of Expenditures of Federal Awards and State Financial Assistance	44
Notes to the Schedule of Expenditures of Federal Awards and State Financial Assistance.....	85
Uniform Guidance Reports and Schedule	
Report of Independent Auditors on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance With <i>Government Auditing Standards</i>	86
Report of Independent Auditors on Compliance With Requirements for Each Major Federal Program and Report on Internal Control Over Compliance Required by the Uniform Guidance	88
Schedule of Findings and Questioned Costs.....	91



Ernst & Young LLP
Suite 2100
222 2nd Avenue South
Nashville, TN 37201

Tel: +1 615 252 2000
ey.com

Report of Independent Auditors

The Board of Directors
Vanderbilt University Medical Center

Report on the Financial Statements

We have audited the accompanying consolidated financial statements of Vanderbilt University Medical Center, which comprise the consolidated balance sheets as of June 30, 2020 and 2019, and the related consolidated statements of operations, changes in net assets, and cash flows for the years then ended, and the related notes to the financial statements.

Management's Responsibility for the Financial Statements

Management is responsible for the preparation and fair presentation of these consolidated financial statements in conformity with U.S. generally accepted accounting principles; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free of material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express an opinion on these financial statements based on our audits. We conducted our audits in accordance with auditing standards generally accepted in the United States and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our opinion, the financial statements referred to above present fairly, in all material respects, the consolidated financial position of Vanderbilt University Medical Center as of June 30, 2020 and 2019, and the consolidated results of its operations and its cash flows for the years then ended in conformity with U.S. generally accepted accounting principles.



Adoption of ASU No. 2016-02, Leases (Topic 842)

As discussed in Note 2 to the consolidated financial statements, Vanderbilt University Medical Center changed its method of accounting for leases as a result of the adoption of Accounting Standards Update No. 2016-02, *Leases (Topic 842)*, effective July 1, 2019. Our opinion is not modified with respect to this matter.

Supplementary Information

Our audits were conducted for the purpose of forming an opinion on the consolidated financial statements as a whole. We have not performed any procedures with respect to the audited consolidated financial statements subsequent to October 13, 2020. The Schedule of Expenditures of Federal Awards and State Financial Assistance as required by Title 2 U.S. *Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* is presented for purposes of additional analysis and is not a required part of the consolidated financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the consolidated financial statements. The information has been subjected to the auditing procedures applied in the audits of the consolidated financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the consolidated financial statements or to the consolidated financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States. In our opinion, the information is fairly stated, in all material respects, in relation to the consolidated financial statements as a whole.

Other Reporting Required by Government Auditing Standards

In accordance with *Government Auditing Standards*, we also have issued our report dated October 13, 2020, on our consideration of Vanderbilt University Medical Center's internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements and other matters. The purpose of that report is solely to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing, and not to provide an opinion on the effectiveness of Vanderbilt University Medical Center's internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering Vanderbilt University Medical Center's internal control over financial reporting and compliance.

October 13, 2020, except for our report on the Schedule of Expenditures of Federal Awards and State Financial Assistance, for which the date is June 14, 2021.

Vanderbilt University Medical Center
Consolidated Balance Sheets
June 30, 2020 and 2019

<i>(\$ in thousands)</i>	<u>2020</u>	<u>2019</u>
Assets		
Current assets:		
Cash and cash equivalents	\$ 1,170,526	\$ 574,748
Current investments	232,178	115,941
Patient accounts receivable	470,550	482,485
Grants and contracts receivable	60,031	58,750
Inventories	104,603	75,407
Other current assets	118,439	89,311
Total current assets	<u>2,156,327</u>	<u>1,396,642</u>
Restricted cash	11,806	11,938
Noncurrent investments	539,173	491,047
Noncurrent investments limited as to use	113,526	103,609
Property, plant, and equipment, net	1,525,103	1,395,095
Operating lease assets	846,695	-
Other noncurrent assets	53,347	48,067
Total assets	<u>\$ 5,245,977</u>	<u>\$ 3,446,398</u>
Liabilities and Net Assets		
Current liabilities:		
Current portion of long-term debt	\$ 14,321	\$ 8,568
Line of credit	100,000	-
Accounts payable and other accrued expenses	309,162	304,188
Medicare accelerated payments	222,445	-
Estimated payables under third-party programs	45,957	24,877
Accrued compensation and benefits	238,039	214,382
Current portion of operating lease liabilities	70,062	-
Current portion of deferred revenue	4,827	14,965
Current portion of medical malpractice self-insurance reserves	12,577	12,012
Total current liabilities	<u>1,017,390</u>	<u>578,992</u>
Long-term debt, net of current portion	1,841,290	1,506,877
Noncurrent portion of operating lease liabilities	797,811	-
Fair value of interest rate exchange agreements	100,342	67,901
Noncurrent portion of medical malpractice self-insurance reserves	47,682	44,328
Noncurrent portion of deferred revenue	4,027	7,773
Other noncurrent liabilities	35,449	26,345
Total liabilities	<u>3,843,991</u>	<u>2,232,216</u>
Net assets		
Net assets without donor restrictions controlled by Vanderbilt University Medical Center	1,208,796	1,050,509
Net assets without donor restrictions related to noncontrolling interests	6,635	7,776
Total net assets without donor restrictions	<u>1,215,431</u>	<u>1,058,285</u>
Net assets with donor restrictions	186,555	155,897
Total net assets	<u>1,401,986</u>	<u>1,214,182</u>
Total liabilities and net assets	<u>\$ 5,245,977</u>	<u>\$ 3,446,398</u>

The accompanying notes are an integral part of these consolidated financial statements.

Vanderbilt University Medical Center
Consolidated Statements of Operations
Years Ended June 30, 2020 and 2019

<i>(\$ in thousands)</i>	<u>2020</u>	<u>2019</u>
Operating revenues		
Patient service revenue	\$ 4,031,720	\$ 3,820,871
Academic and research revenue	552,822	519,447
Other operating revenue	301,143	157,011
Total operating revenues	<u>4,885,685</u>	<u>4,497,329</u>
Operating expenses		
Salaries, wages, and benefits	2,495,795	2,290,910
Supplies and drugs	1,046,398	892,211
Facilities and equipment	273,405	268,974
Services and other	740,255	701,079
Depreciation and amortization	126,654	106,524
Interest	60,771	56,529
Total operating expenses	<u>4,743,278</u>	<u>4,316,227</u>
Income from operations	<u>142,407</u>	<u>181,102</u>
Nonoperating revenues and expenses		
Income from investments	27,224	30,106
Gift income	20,702	14,416
Earnings of unconsolidated organizations	4,865	4,031
Unrealized loss on interest rate exchange agreements, net of cash settlements	<u>(37,152)</u>	<u>(17,480)</u>
Total nonoperating revenues and expenses	<u>15,639</u>	<u>31,073</u>
Excess of revenues over expenses	158,046	212,175
Excess of revenues over expenses attributable to noncontrolling interests	<u>(4,074)</u>	<u>(4,075)</u>
Excess of revenues over expenses attributable to VUMC	153,972	208,100
Other changes in net assets without donor restrictions		
Change in noncontrolling interest's net assets	(1,141)	2,052
Net assets released from restriction for capital	4,773	35,110
Other changes	<u>(458)</u>	<u>(182)</u>
Total changes in net assets without donor restrictions	<u>\$ 157,146</u>	<u>\$ 245,080</u>

The accompanying notes are an integral part of these consolidated financial statements.

Vanderbilt University Medical Center
Consolidated Statements of Changes in Net Assets
Years Ended June 30, 2020 and 2019

<i>(\$ in thousands)</i>	<u>2020</u>	<u>2019</u>
Net assets without donor restrictions		
Net assets without donor restrictions at the beginning of the period	\$ 1,058,285	\$ 813,205
Excess of revenues over expenses	153,972	208,100
Change in noncontrolling interest's net assets	(1,141)	2,052
Net assets released from restriction for capital	4,773	35,110
Other changes	(458)	(182)
Change in net assets without donor restrictions	<u>157,146</u>	<u>245,080</u>
Net assets without donor restrictions at the end of the period	<u>\$ 1,215,431</u>	<u>\$ 1,058,285</u>
Net assets with donor restrictions		
Net assets with donor restrictions at the beginning of the period	\$ 155,897	\$ 114,425
Contributions	45,079	85,331
Restricted investment income	1,727	1,665
Net assets released from restrictions for operations	(13,788)	(10,596)
Net assets released from restriction for capital	(4,773)	(35,110)
Other changes	2,413	182
Change in net assets with donor restrictions	<u>30,658</u>	<u>41,472</u>
Net assets with donor restrictions at the end of the period	<u>\$ 186,555</u>	<u>\$ 155,897</u>
Total net assets		
Beginning of the period	\$ 1,214,182	\$ 927,630
Change in total net assets	<u>187,804</u>	<u>286,552</u>
End of the period	<u>\$ 1,401,986</u>	<u>\$ 1,214,182</u>

The accompanying notes are an integral part of these consolidated financial statements.

Vanderbilt University Medical Center
Consolidated Statements of Cash Flows
Years Ended June 30, 2020 and 2019

<i>(\$ in thousands)</i>	<u>2020</u>	<u>2019</u>
Cash flows from operating activities		
Change in total net assets	\$ 187,804	\$ 286,552
Adjustments to reconcile change in total net assets to net cash provided by operating activities:		
Depreciation and amortization	126,654	106,524
Amortization of debt issuance costs, and original issue premium and discount	709	26
Loss on disposal of assets	1,116	485
Undistributed equity in earnings of equity method affiliates	(1,754)	343
Net realized and unrealized gain on investments	(8,662)	(10,721)
Purchases of trading securities	(392,111)	(231,753)
Sales of trading securities	242,191	220,535
Change in split-interest trusts	260	194
Unrealized loss on interest rate exchange agreements	32,441	13,695
Restricted contributions for endowments and property, plant, and equipment	(14,073)	(25,683)
Increase (decrease) in cash due to changes in:		
Patient accounts receivable	11,935	(8,100)
Accounts payable and other accrued expenses	21,141	38,073
Medicare accelerated payments	222,445	-
Other assets and other liabilities, net	6,755	(95,548)
Net cash provided by operating activities	<u>436,851</u>	<u>294,622</u>
Cash flows from investing activities		
Purchase of property, plant, and equipment	(238,291)	(195,197)
Purchases of long-term securities	(255,581)	(340,184)
Sales and maturities of long-term securities	239,623	232,230
Acquisition of hospital	(19,252)	-
Proceeds on sale of property, plant, and equipment	5	220
Net cash used in investing activities	<u>(273,496)</u>	<u>(302,931)</u>
Cash flows from financing activities		
Proceeds from issuance of long-term debt	463,600	-
Draws on line of credit	100,000	-
Debt issuance costs	(1,645)	-
Repayment of long-term debt	(133,070)	(5,000)
Principal payments under capital lease obligations	(4,334)	(1,831)
Restricted contributions for endowments and property, plant, and equipment	14,073	25,683
Distributions to noncontrolling interests	(6,333)	(2,022)
Net cash provided by financing activities	<u>432,291</u>	<u>16,830</u>
Net change in cash, cash equivalents, and restricted cash	595,646	8,521
Cash, cash equivalents, and restricted cash		
Beginning of the period	<u>586,686</u>	<u>578,165</u>
End of the period	<u>\$ 1,182,332</u>	<u>\$ 586,686</u>

The accompanying notes are an integral part of these consolidated financial statements.

Vanderbilt University Medical Center

Notes to Consolidated Financial Statements

June 30, 2020 and 2019

1. Description of Organization

Vanderbilt University Medical Center (“VUMC”) is a Tennessee not-for-profit corporation incorporated in March 2015 to operate an academic medical center, including a comprehensive research, teaching, and patient care health system (the “Medical Center”). Until April 29, 2016, the Medical Center operated as a unit within Vanderbilt University (“the University” or “VU”), as a part of the University’s administrative structure, with the same governing board, legal, financial, and other shared services.

VUMC began operations effective April 30, 2016, following the closing of the sale of the Medical Center by the University (the “Acquisition”). VUMC owns and operates three hospitals located on the main campus of the University in Nashville, Tennessee: Vanderbilt University Adult Hospital (“VUAH”), Monroe Carell Junior Children’s Hospital at Vanderbilt (“MCJCHV”), and Vanderbilt Psychiatric Hospital (“VPH”). In addition, VUMC partially owns Vanderbilt Stallworth Rehabilitation Hospital (“VSRH”), also located on the main campus of the University, through a joint venture with Encompass Health Corp. (formerly called HealthSouth Corp.) in which VUMC holds a 50% interest, which includes a 1% interest held by Vanderbilt Health Services, LLC, (“VHS”), a VUMC wholly owned subsidiary. Effective August 1, 2019, VUMC acquired a fourth hospital from Community Health Systems, Inc.: Tennova Healthcare – Lebanon, now known as Vanderbilt Wilson County Hospital (“VWCH”). VUAH, MCJCHV, VPH, and VWCH are licensed for 1,420 beds, and VSRH is licensed for 80 beds.

VUMC consists of two major operating divisions and an administrative overhead division. The operating divisions include the Clinical Enterprise and Academic Enterprise divisions. The administrative overhead division is referred to as Medical Center Administration (“MCA”).

The Clinical Enterprise division includes the professional clinical practice revenues and related expenses of Vanderbilt Medical Group (“VMG”), and technical revenues and associated expenses for the operation of VUMC’s hospitals and clinic facilities, including VUAH, MCJCHV, VPH, and VWCH. The Clinical Enterprise also includes VHS.

- VUAH is a quaternary care teaching hospital licensed for 726 acute care and specialty beds. VUAH, a Level I trauma center, provides advanced patient care and serves as a key site for medical education and clinical research conducted by physician faculty. VUAH includes a comprehensive burn center, the Vanderbilt Transplant Center, the Vanderbilt Heart and Vascular Institute, and the Vanderbilt Ingram Cancer Center.
- MCJCHV is a pediatric quaternary care teaching hospital licensed for 343 beds (159 acute and specialty, 65 pediatric intensive care, and 119 neonatal intensive care). MCJCHV is the region’s only full-service pediatric hospital, with over 30 pediatric specialties. MCJCHV serves as a site for medical education and clinical research conducted by pediatric physician faculty, houses the only Level IV neonatal intensive care center and the only Level 1 pediatric trauma center within the region, and is a regional referral center for extracorporeal membrane oxygenation (heart and lung failure).
- VPH is a psychiatric hospital licensed for 106 beds and provides both inpatient and outpatient partial hospitalization psychiatric services to both adult and adolescent patients. Also, VPH provides psychiatric assessment services, adult intensive outpatient programs, and neuromodulation procedures through electroconvulsive therapy and transcranial magnetic stimulation.

Vanderbilt University Medical Center

Notes to Consolidated Financial Statements

June 30, 2020 and 2019

- VWCH is a two-campus facility licensed for 245 beds and is a substantial provider of both inpatient and outpatient medical services in Lebanon, Tennessee. VWCH also includes an accredited chest pain center, a stroke center, and a comprehensive weight loss center.
- VMG is the practice group of physicians and advanced practice nurses employed by VUMC, most of whom have faculty appointments from the University, who perform billable professional medical services. VMG is not a separate legal entity. VMG has a board which consists of the VUMC clinical service chiefs, who also serve as clinical department chairs. Under the oversight of VUMC executive leadership, VMG sets professional practice standards, bylaws, policies, and procedures. VUMC bills for services rendered by VMG clinicians in both inpatient and outpatient locations. VMG includes nationally recognized physicians whose expertise spans the spectrum from primary care to the most specialized quaternary discipline. The entire clinical faculty is “board certified” or eligible for board certification. All staff members are re-credentialed every two years by the National Committee for Quality Assurance standards. All specialties and subspecialties currently recognized by the various national specialty boards are represented on the clinical faculty.
- VHS serves as a holding company for 16 health care related subsidiaries and joint ventures owned with various entities, including, but not limited to, VSRH and the Vanderbilt Health Affiliated Network (“VHAN”). VHS operations primarily consist of community physician practices, walk-in and retail health clinics, imaging services, outpatient surgery centers, radiation oncology centers, a home health care agency, a home infusion and respiratory service, an affiliated health network, accountable care organizations, and a rehabilitation hospital. These subsidiaries include clinics managed in multiple outpatient locations throughout middle Tennessee and southwestern Kentucky.
- Health Professional Solutions, LLC (“HPS”) is a holding company that holds interest in five VUMC subsidiaries that engage in or support various health care activities in order to improve the quality and availability of health care services in the community. These subsidiaries include businesses focused on pharmacy, supply chain, and clinically integrated support services.

The Academic Enterprise division includes all clinically-related research, research-support activities, and faculty endeavors supporting post-graduate training programs. A significant funding source for VUMC’s research has historically been the federal government. Federal funding is received from the Department of Health and Human Services, the National Institutes of Health, the Department of Defense, NASA, and other federal agencies. Sponsored research awards, including multiple-year grants and contracts from government sources, foundations, associations, and corporations signify future research commitments. Also, core activities supporting research, including advanced computing and grant administration, are included in this division.

The terms “Company,” “VUMC,” “we,” “our,” or “us” as used herein and unless otherwise stated or indicated by context refer to Vanderbilt University Medical Center and its affiliates. The terms “facilities” or “hospitals” refer to entities owned and operated by VUMC and its affiliates, and the term “employees” refers to employees of VUMC and its affiliates.

VUMC operates on a fiscal year which ends on June 30. The term “Fiscal” preceding a year refers to a particular VUMC fiscal year.

Vanderbilt University Medical Center

Notes to Consolidated Financial Statements

June 30, 2020 and 2019

2. Summary of Significant Accounting Policies

Basis of Presentation

The accompanying consolidated financial statements have been prepared on the accrual basis in accordance with accounting principles generally accepted in the U.S. ("GAAP"). Based on the existence or absence of donor-imposed restrictions, VUMC classifies resources into two categories: net assets without donor restrictions and net assets with donor restrictions. In addition, these statements follow GAAP applicable to the not-for-profit industry as described in the Financial Accounting Standards Board's ("FASB") *Accounting Standards Codification* ("ASC") Topic 958.

Principles of Consolidation

The consolidated financial statements include the accounts of VUMC and its wholly owned, majority-owned, and controlled organizations. Noncontrolling interests in less-than-wholly owned consolidated subsidiaries of VUMC are presented as a component of net assets to distinguish between the interests of VUMC and the interests of the noncontrolling owners. All material intercompany transactions and account balances among the various entities have been eliminated.

VUMC uses the equity method to account for its interests in unconsolidated partnerships, joint ventures, and limited liability entities over which it exercises significant influence. Investment carrying amounts are adjusted for VUMC's share of investee earnings or losses based on percentage of ownership. Distributions received from unconsolidated entities that represent returns on VUMC's investment (i.e., dividends) are reported as cash flows from operating activities in VUMC's statement of cash flows.

Use of Estimates

The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect amounts reported in the consolidated financial statements and accompanying notes. These estimates affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated balance sheets and the reported amounts of revenues and expenses during the reporting periods. Actual results ultimately could differ from those estimates.

Cash and Cash Equivalents

Cash and cash equivalents are liquid assets with minimal interest rate risk and maturities of three months or less when purchased. VUMC invests operating assets in a diversified manner. At times, VUMC may have cash and cash equivalents at a financial institution in excess of federally insured limits, and therefore, bears a risk of loss.

Liquidity and Availability

As of June 30, 2020, VUMC has \$2,420.1 million of financial assets available within one year of the balance sheet date to meet cash needs for general expenditures consisting of cash and cash equivalents of \$1,170.5 million, patient accounts receivable of \$470.6 million, pledges receivable of \$7.6 million, and unrestricted investments of \$771.4 million. As of June 30, 2019, VUMC had \$1,670.5 million of financial assets available within one year of the balance sheet date to meet cash needs for general expenditures consisting of cash and cash equivalents of \$574.7 million, patient accounts receivable of \$482.5 million, pledges receivable of \$6.3 million, and unrestricted investments of \$607.0 million. None of these financial assets are subject to donor or other contractual restrictions that make them unavailable for general expenditure within one year of the balance sheet date. Pledges receivable are subject to implied time restrictions but are expected to be collected within one year.

Vanderbilt University Medical Center

Notes to Consolidated Financial Statements

June 30, 2020 and 2019

VUMC has a policy to structure its financial assets to be available as its general expenditures, liabilities, and other obligations come due. In addition, as part of its liquidity management, VUMC invests cash in excess of daily requirements in various short-term investments, including certificate deposits and short-term treasury instruments.

As more fully described in Note 11 Long-Term Debt, VUMC also has committed lines of credit in the amount of \$250.0 million, with \$100.0 million drawn as of June 30, 2020, which it could draw upon in the event of an unanticipated liquidity need.

Revenue Recognition – Patient Services

VUMC recognizes revenue from patient services at the amount that reflects the consideration to which VUMC expects to be paid for providing such services. These amounts, representing transaction price, are due from patients, third-party payors (including health insurers and government programs), and others and include variable consideration for retroactive revenue adjustments due to settlements of audits, reviews, and investigations. Patient service revenue is recognized as performance obligations based on the nature of the services provided by VUMC are satisfied.

Performance obligations satisfied over time relate to admitted patients in VUMC hospitals receiving inpatient acute care services from admission to the point when services are no longer required, which is generally at the time of discharge. Revenue for performance obligations satisfied over time is recognized based on actual charges incurred in relation to total expected or actual charges. Outpatient services are performance obligations satisfied at a point in time with the related revenue being recognized when goods or services are provided.

VUMC has elected to apply the optional exemption provided in FASB (ASC) 606-10-50-14 as substantially all of its performance obligations relate to contracts with a duration of less than one year. Therefore, VUMC is not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially satisfied at the end of the reporting period. Unsatisfied or partially satisfied performance obligations are primarily related to in-house patients at the end of the reporting period. The performance obligations for these contracts are generally completed when the patients are discharged, which is typically within a week.

VUMC uses a portfolio approach consisting of major payor classes to account for categories of patient contracts as a collective group rather than recognizing revenue on an individual contract basis. Based on historical collection trends and other analysis, VUMC believes that revenue recognized by utilizing the portfolio approach approximates the revenue that would have been recognized if an individual contract approach were used.

VUMC determines the transaction price, which involves estimates and judgment, based on standard charges for goods and services provided, reduced by explicit and implicit price concessions, including contractual adjustments provided to third-party payors, discounts provided to uninsured and underinsured patients in accordance with VUMC policy, and historical collection experience. VUMC analyzes its history and identifies trends for each of its major revenue categories to estimate the appropriate price concessions. Management regularly reviews data about these major revenue categories in evaluating the reasonableness of the transaction price, taking into consideration recent experience by payor category, payor agreement rate changes, and other factors.

In addition to patient payments, VUMC earns revenue and reimbursements from certain services provided under federal healthcare programs and other contracts with third-party payors. These compensation arrangements are complex programs which extend over multiple accounting periods and are subject to the interpretation of federal and state-specific reimbursement rates, new or

Vanderbilt University Medical Center

Notes to Consolidated Financial Statements

June 30, 2020 and 2019

changing legislation, and final cost report settlements. Estimated settlements under these programs are recorded in the period the related services are performed and are subsequently adjusted, as needed, based on new information.

VUMC provides care to patients who meet the criteria for charity care under its financial assistance policy for no payment or at payment amounts less than its established charge rates. VUMC does not recognize the charges that qualify as charity care as revenue because VUMC does not pursue collection of these amounts.

Revenue Recognition – Non-Patient Services

Revenue for non-patient services is recognized at an amount that reflects the consideration VUMC expects to be entitled in exchange for providing goods or services. The amounts recognized reflect considerations due from customers, the U.S. government, and others, and is recognized as performance obligations are satisfied. Primary categories of non-patient revenue include academic and research revenue as well as other miscellaneous activities as further described in Note 8 Other Relevant Financial Information.

VUMC receives funding through grants and contracts issued by departments and agencies of the U.S. government, industry, and other foundation sponsors who restrict the use of such funds to academic and research purposes. VUMC recognizes revenue from these grants and contracts in accordance with contract terms, as defined in the agreements governing that funding. VUMC recognizes facilities and administrative (“F&A”) costs recovery as revenue when the allowable expenditure is incurred on the associated grant or contract. This activity represents reimbursement, primarily from the federal government, of F&A costs on sponsored activities.

Grants and contracts receivable include amounts due from these sponsors of externally funded research. These amounts have been billed or are billable to the sponsor and are recorded at the amount that reflects the consideration VUMC expects to receive.

Deferred Revenue

Deferred revenue is recorded for funds received in advance. The related revenue is recognized when the performance obligations have been met.

Gift Income and Pledges

VUMC recognizes unconditional promises to give cash and other assets, referred to as pledges, as gift income at fair value when the pledge is received. Conditional promises to give are recognized as pledges once the conditions are substantially met. Pledges are recognized as net assets with donor restrictions. Gifts received with donor stipulations limiting the use of the donated assets are reported as net assets with donor restrictions. Donor-restricted contributions whose restrictions are met within the same year as received are reported as gift income in the accompanying consolidated statements of operations. Gift income is recognized when a donor restriction expires, that is, when a stipulated time restriction ends or purpose restriction is accomplished. Gifts of cash or other assets that must be used to acquire long-lived assets are reported as net assets with donor restrictions until the assets are placed in service, at which point they are reclassified to net assets without donor restrictions.

Pledges receivable are reported net of allowances for uncollectible amounts based on an analysis of past collection experience and other judgmental factors. Pledges receivable are included in other current or other noncurrent assets in the consolidated balance sheets based on the expected timing of cash flows. VUMC discounts the noncurrent portion of pledges receivables at a rate commensurate with the scheduled timing of receipt. VUMC applied annual discount rates ranging from 0.5% to 1.5% to amounts outstanding as of June 30, 2020 and 2019.

Vanderbilt University Medical Center

Notes to Consolidated Financial Statements

June 30, 2020 and 2019

Concentrations of Credit Risk

VUMC grants unsecured credit to its patients, primarily residing in Nashville, Tennessee and the surrounding areas of middle Tennessee, most of whom are insured under commercial, Medicare, or TennCare agreements. Medicare, Blue Cross Blue Shield (“BCBS”), and TennCare (which includes BCBS, United, and Amerigroup) represent VUMC’s significant concentrations of credit risk from payors.

Inventories

VUMC reports inventories at the lower of cost or market, with cost being determined on the first-in, first-out method. Inventories consist primarily of medical supplies, surgical implants, and pharmaceuticals.

Restricted Cash

VUMC reports cash whose use is restricted at cost, which approximates fair value. The cash is primarily restricted for use in purchasing and constructing property, plant, and equipment.

Investments

VUMC reports investments held at fair value in the consolidated balance sheets. VUMC records purchases and sales of securities on the trade dates, and realized gains and losses are determined based on the average historical cost of the securities sold. VUMC reports net receivables and payables arising from unsettled trades as a component of investments.

Property, Plant, and Equipment, Net

VUMC records purchases of property, plant, and equipment at cost and expenses repairs and maintenance costs as incurred. VUMC capitalizes interest cost incurred on borrowed funds during the period of construction of capital assets as a component of the cost of acquiring those assets. VUMC capitalizes donated assets at fair value on the date of donation.

Capitalized software for internal use is recorded during the application development stage. These costs include fees paid to third parties for direct costs of materials and services consumed in developing or obtaining the software; payroll related costs and capitalized interest costs. Costs for training and application maintenance in the post-implementation operation stage are expensed as incurred.

VUMC computes depreciation using the straight-line method over the estimated useful life of land improvements (5 to 18 years), buildings and leasehold improvements (2 to 40 years), and equipment (1 to 20 years). Equipment costs also include capitalized internal use software costs, which are expensed over the expected useful life, which is generally 3 to 12 years. VUMC assigns useful lives in accordance with American Hospital Association guidelines.

Software for internal use is amortized on a straight-line basis over its estimated useful life. In determining the estimated useful life, management considers the effects of obsolescence, technology, competition, other economic factors, and rapid changes that may be occurring in the development of software products, operating systems, and computer hardware. Amortization begins once the software is ready for its intended use.

Vanderbilt University Medical Center

Notes to Consolidated Financial Statements

June 30, 2020 and 2019

Impairment of Long-Lived Assets

VUMC reviews long-lived assets, such as property, plant, and equipment, for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. VUMC measures the recoverability of assets to be held and used by comparing the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, VUMC recognizes an impairment charge to the extent the carrying amount of the asset exceeds its fair value.

Conditional Asset Retirement Costs and Obligations

VUMC recognizes the estimated fair value of liabilities for existing legal obligations to perform certain activities, primarily asbestos removal, in connection with the retirement, disposal, or abandonment of assets. These liabilities are included in other noncurrent liabilities on the consolidated balance sheets and total \$6.5 million and \$6.3 million as of June 30, 2020 and 2019, respectively. VUMC measures these liabilities using estimated cash flows with an inflation rate applied of 3.0% as of June 30, 2020 and 2019. VUMC discounts those cash flow estimates at a credit-adjusted, risk-free rate, which ranged from 2.9% to 4.2% as of June 30, 2020 and 2019, and adjusts these liabilities for accretion costs and revisions in estimated cash flows.

Long-Term Debt

The carrying value of VUMC's debt is the par amount adjusted for the net unamortized amount of debt issuance costs, and bond premiums and discounts.

Interest Rate Exchange Agreements

VUMC reports interest rate exchange agreements at fair value, which is determined to be the present value of future net cash settlements that reflect market yields as of the measurement date and estimated amounts that VUMC would pay, or receive, to terminate the contracts as of the report date. VUMC considers current interest rates and creditworthiness of the interest rate exchange counterparties when estimating termination settlements.

Self-Insurance Reserves

VUMC elects to self-insure a portion of its medical malpractice, professional, and general liability coverage via an irrevocable self-insurance trust. For Fiscal 2020, the maximum annual self-insurance retention was \$6.0 million per occurrence, up to \$46.0 million in the aggregate. For Fiscal 2019, the maximum annual self-insurance retention was \$5.5 million per occurrence, up to \$43.0 million in the aggregate. Actuarial firms assist management in estimating expected losses on an annual basis, at which time VUMC records medical malpractice, professional, and general liability expense within the limits of the program. These liabilities are classified as current or noncurrent based on the expected timing of cash flows and are measured at the net present value of those cash flows using a discount rate of 2.5% as of June 30, 2020 and 2019. For both Fiscal 2020 and 2019, VUMC obtained excess medical malpractice, professional, and general liability coverage from commercial insurance carriers for claims exceeding the retention limits, up to \$150.0 million. These policies would also provide coverage up to \$150.0 million if any claims in the aggregate exceeded the retention limits.

VUMC also elects to self-insure for employee health and workers' compensation expenses. Actuarial firms assist management in estimating expected losses on an annual basis. The maximum retention for workers' compensation was \$0.8 million per occurrence for both Fiscal 2020 and 2019. There is no stop loss insurance on health plan claims.

Vanderbilt University Medical Center

Notes to Consolidated Financial Statements

June 30, 2020 and 2019

Income Taxes

VUMC is a tax-exempt organization as described in Section 501(c)(3) of the Internal Revenue Code (the “Code”) and is generally exempt from federal income taxes under Section 501(a) of the Code.

Excess of Revenues Over Expenses

The consolidated statements of operations include excess of revenues over expenses as a performance indicator. Excess of revenues over expenses includes all changes in net assets without donor restrictions, except for changes in noncontrolling interest holders’ share of consolidated entities, net assets released from restrictions used for capital, and certain other items.

Statement of Cash Flows

For VUMC’s consolidated statements of cash flows, cash, cash equivalents, and restricted cash is defined as those amounts included in the cash and cash equivalents caption and restricted cash caption on the consolidated balance sheets.

Recent Accounting Pronouncements

Periodically, the FASB issues Accounting Standards Updates (“ASUs”) that may impact the recognition, measurement, and presentation of balances and activity in VUMC’s consolidated financial statements or the disclosures contained within those statements. As part of preparing consolidated financial statements, VUMC evaluates the effects of the ASUs and applies the updated guidance within the required effective dates.

Adopted

- In February 2016, the FASB issued ASU 2016-02, Leases, which requires lessees to recognize assets and liabilities for most leases. VUMC adopted this standard on July 1, 2019, using a modified retrospective approach and therefore applied the transition provisions to the most recent period presented in the consolidated financial statements, recognizing assets and offsetting obligations for current operating leases.

Not Yet Adopted

- In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement, Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement. This ASU intends to improve the effectiveness of disclosures in the notes to the financial statements by modifying disclosure requirements for fair value measurements. The ASU is effective for VUMC for annual and interim periods beginning after December 15, 2019 with early adoption permitted. VUMC is currently assessing the impact that ASU 2018-13 will have on the consolidated financial statements and will adopt the provisions upon the effective date.

3. Related Parties

On April 29, 2016, VUMC acquired the assets, liabilities, rights, and obligations of the clinical enterprise, postgraduate medical training programs, and clinically related research of the University’s owned and operated Medical Center, “the Acquisition”.

The assets acquired and liabilities assumed from the Acquisition were detailed in a Master Transfer and Separation Agreement (“MTSA”). The MTSA contains the framework for the ongoing economic relationship between VUMC and the University. The relationship is memorialized in the form of an Academic Affiliation Agreement (“AAA”), a Trademark License Agreement (“TMLA”), a Ground

Vanderbilt University Medical Center

Notes to Consolidated Financial Statements

June 30, 2020 and 2019

Lease, and a Reciprocal Master Services Agreement (“MSA”). The agreements are described below.

- The AAA outlines the ongoing academic, research, and clinical affiliation between the University and VUMC for all the University’s degree-granting, certificate, and research programs. The AAA allocates responsibility between the University and VUMC for jointly administered research and academic programs and is an exclusive agreement between VUMC and VU requiring VUMC to be organized, governed, and operated in a manner that supports VU’s academic and research mission. The agreement provides that VU will be the exclusive academic affiliate of VUMC, and VUMC will be the exclusive clinical affiliate of VU.

The AAA requires VUMC to pay VU an annual fee in equal monthly payments adjusted annually for inflation based upon the Biomedical Research and Development Price Index (“BRDPI”) in perpetuity under certain mutually agreed-upon termination or default clauses. During Fiscal 2020 and 2019, VUMC recorded operating expense totaling \$76.9 million and \$74.9 million, respectively, in connection with fees due under the AAA.

- Under the TMLA, the University grants, subject to certain consents and approvals, a perpetual license to use various University-owned licensed marks in connection with VUMC’s fundamental activities after the Acquisition date. The licensed marks, which VUMC continues to use as its primary brands, include virtually all those previously in use by VUMC. This agreement requires VUMC to pay VU a monthly royalty payment equal to 1.0% of all operating revenue of VUMC and a percentage of net income from operations (10% in Fiscal 2019 and 15% in Fiscal 2020 and beyond). During Fiscal 2020 and 2019, VUMC recorded operating expense totaling \$70.4 million and \$63.8 million, respectively, in connection with royalty fees due under the TMLA. Also, VUMC is required to pay in equal monthly installments an annual TMLA base fee, which increases 3% annually, but is also reduced by the amount of principal payments made under a subordinate note discussed in Note 11 Long-Term Debt (the “Fixed TMLA Royalty Payment”). During Fiscal 2020 and 2019, VUMC recorded operating expense totaling \$62.5 million and \$60.6 million, respectively, in connection with this base fee. VU sold its rights to future royalty payments to a third party. The TMLA is in force in perpetuity under certain mutually agreed-upon termination or default clauses.
- The Ground Lease is an agreement between VU and VUMC that allows VUMC to use the land on which VUMC’s campus and related buildings are located. The initial term of the Ground Lease ends June 30, 2115, with the option to extend the lease for two additional terms of up to 50 to 99 years each with agreement between VU and VUMC. The lease covers 1.7 million square feet or 38.75 acres of space, payable monthly and CPI adjusted annually. During Fiscal 2020 and 2019, VUMC recorded operating expense totaling \$19.4 million and \$19.0 million, respectively, in connection with fees due under the Ground Lease.
- The University and VUMC provide services to one another for agreed-upon consideration as outlined in the MSA. VU provides services to VUMC, such as information technology infrastructure support, utilities, and law enforcement staffing. VUMC provides various operational services for the University, such as a student health clinic and animal care. Additionally, the MSA encompasses an Employee Matters Agreement (“EMA”) and specific Employee Service Agreements (“ESAs”). The EMA and ESAs govern employee transactions and ongoing sharing between VU and VUMC in various capacities, such as research, teaching, clinical, and other administrative services. Services under the MSA can be terminated by either party subject to predetermined cancellation notification periods. In connection with the MSA,

Vanderbilt University Medical Center
Notes to Consolidated Financial Statements
June 30, 2020 and 2019

during Fiscal 2020 and 2019, VUMC recognized revenue totaling \$44.2 million and \$45.1 million, respectively, and recorded operating expense totaling \$123.4 million and \$122.8 million, respectively.

- Also, as part of the Acquisition, VUMC issued to VU a \$100.0 million subordinate promissory note payable, which is further described in Note 11 Long-Term Debt, with a balance of \$79.6 million as of June 30, 2020, and \$84.6 million as of June 30, 2019. VU sold its rights to future principal and interest payments on this note to a third party.

The impact of these agreements in the consolidated statements of operations during Fiscal 2020 and 2019 is as follows:

<i>(\$ in thousands)</i>	<u>2020</u>	<u>2019</u>
Academic and research revenue	\$ 13,055	\$ 14,401
Other operating revenue	31,192	30,745
Total operating revenues	<u>\$ 44,247</u>	<u>\$ 45,146</u>
Operating expenses		
Salaries, wages, and benefits	\$ 9,086	\$ 7,725
Facilities and equipment	59,516	58,872
Services and other	284,040	274,512
Interest	2,661	2,823
Total operating expenses	<u>\$ 355,303</u>	<u>\$ 343,932</u>

Other current assets include amounts receivable from VU, which totaled \$6.7 million as of June 30, 2020, and \$4.9 million as of June 30, 2019. Accounts payable and other accrued expenses include amounts payable to related parties, which totaled \$51.1 million as of June 30, 2020, and \$47.7 million as of June 30, 2019.

In the normal course of business, members of VUMC's Board of Directors or VUMC employees may be directly or indirectly associated with companies engaged in business activities with VUMC. VUMC has a written conflict of interest policy that requires, among other things, that members of the VUMC community (including trustees) may not review, approve, or administratively control contracts or business relationships when (i) the contract or business relationship is between VUMC and a business in which the individual or a family member has a material financial interest, or (ii) the individual or a family member is an employee of the business and is directly involved with activities pertaining to VUMC.

Furthermore, VUMC's conflict of interest policy extends beyond the foregoing business activities in that disclosure is required for any situation in which an applicable individual's financial, professional, or other personal activities may directly or indirectly affect, or have the appearance of affecting, an individual's professional judgment in exercising any VUMC duty or responsibility, including the conduct or reporting of research.

The policy extends to all individual members of the VUMC community (including Board of Directors, VUMC Officials, full-time, part-time, temporary faculty and staff). Each applicable person is required to certify compliance with the conflict of interest policy on an annual basis. This certification includes specifically disclosing whether VUMC conducts business with an entity in which he or she (or an immediate family member) has a material financial interest, as well as any other situation that could appear to present a conflict with VUMC's best interests.

Vanderbilt University Medical Center
Notes to Consolidated Financial Statements
June 30, 2020 and 2019

When situations exist relative to the conflict of interest policy, VUMC takes active measures to appropriately manage the actual or perceived conflict in the best interests of VUMC, including periodic reporting of measures taken to the Audit Committee of the Board of Directors.

4. Patient Service Revenue, Patient Accounts Receivable, and Estimated Third-Party Settlements

Management has determined that the nature, amount, timing, and uncertainty of revenue and cash flows are affected by the major classes of payors. The sources of patient service revenue by payor for Fiscal 2020 and 2019 are as follows:

<i>(\$ in thousands)</i>	<u>2020</u>	<u>2019</u>
Other third-party payors, primarily commercial carriers	\$ 2,553,307	\$ 2,355,860
Medicare/Managed Medicare	924,241	896,843
TennCare/Medicaid	522,606	529,785
Uninsured (self-pay)	31,566	38,383
	<u>\$ 4,031,720</u>	<u>\$ 3,820,871</u>

Patient accounts receivable comprise amounts due from the following sources as of June 30, 2020 and 2019:

<i>(\$ in thousands)</i>	<u>2020</u>	<u>2019</u>
Medicare	\$ 77,696	\$ 72,473
TennCare/Medicaid	57,741	65,903
Blue Cross	99,861	115,023
Other third-party payors, primarily commercial carriers	192,258	184,774
Patient responsibility ⁽¹⁾	42,994	44,312
Patient accounts receivable	<u>\$ 470,550</u>	<u>\$ 482,485</u>

⁽¹⁾ Includes self-pay after insurance.

Estimated third-party settlements by major payor category as of June 30, 2020 and 2019, are as follows:

<i>(\$ in thousands)</i>	<u>2020</u>	<u>2019</u>
Receivables under third-party programs		
Tricare/Champus ⁽¹⁾	\$ 4,484	\$ 8,536
Total receivables under third-party programs	<u>\$ 4,484</u>	<u>\$ 8,536</u>
Payables under third-party programs		
TennCare/Medicaid	\$ 37,781	\$ 18,896
Medicare ⁽¹⁾	9,752	14,517
Other	2,908	-
Total payables under third-party programs	<u>\$ 50,441</u>	<u>\$ 33,413</u>

⁽¹⁾ These two federal healthcare programs are combined for presentation purposes on the face of the consolidated balance sheets and are reflected as an obligation in Fiscal 2020 and Fiscal 2019.

Vanderbilt University Medical Center
Notes to Consolidated Financial Statements
June 30, 2020 and 2019

Certain contracts require pay for performance or episode of care settlements whereby VUMC receives additional payment or pays a penalty based on its ability to achieve certain clinical measures or manage the cost of care for patients within various thresholds. VUMC estimates and accrues these adjustments in the period the related services are rendered and adjusts these estimates in future periods as settlements are finalized. The aggregate liability associated with pay for performance and episode of care settlements at June 30, 2020 and 2019, was \$2.5 million and \$1.3 million, respectively, with the ultimate resolution of such financial arrangements not expected to have a material impact on the operating results of VUMC.

Medicare

Amounts received under Medicare are subject to review and final determination by program intermediaries or their agents. Final settlements have been reached for program periods ended June 30, 2015. Final settlements have not been reached for subsequent years due to audit delays experienced with the Medicare Administrative Contractor, and thus, those periods remain subject to audit by program representatives.

TennCare

TennCare is a Medicaid managed care program implemented by the state of Tennessee to provide healthcare coverage to those patients eligible for Medicaid through the Federal 1115 Waiver Program. VUMC contracts with each of the three TennCare managed care organizations (“MCOs”), which offer health maintenance organization (“HMO”) and Medicare Special Needs Products for Dual Eligible Enrollees. VUMC receives inpatient reimbursement through payments that are primarily based on the Medicare severity diagnostic related group system (“MS-DRG”) for these plans. VUMC receives outpatient payments generally based on an ambulatory payment classification system (“APC”), and/or a payor-developed fee schedule.

In accordance with the Tennessee Hospital Assessment Act, VUMC receives a payment of a portion of its unreimbursed TennCare costs based upon VUMC’s share of uninsured TennCare costs for all of the covered hospitals.

There is no assurance that this program will be continued in its current structure or will not be materially modified in the future, however, we anticipate funding will remain relatively stable over the coming year.

In Fiscal 2020 and 2019, patient service revenue includes the following supplemental amounts received in each respective period from TennCare and the associated reserves for those payments, changes in estimates effecting reserves are excluded:

<i>(\$ in thousands)</i>	2020	2019
Charity pool	\$ 24,696	\$ 12,246
Graduate medical education	14,592	14,603
Trauma fund	1,685	1,600
Virtual disproportionate share	960	-
Total supplemental TennCare revenue, net of audit provision	\$ 41,933	\$ 28,449

Vanderbilt University Medical Center
Notes to Consolidated Financial Statements
June 30, 2020 and 2019

5. Charity Care Assistance, Community Benefits, and Other Unrecovered Costs

VUMC maintains a policy which sets forth the criteria under which health care services are provided to patients who have minimal financial resources to pay for medical care. Additionally, VUMC provides other services that benefit the economically disadvantaged for which little or no payment is expected.

Charity care is determined by examining patient and family income relative to the federal poverty guidelines. VUMC provides additional discounts based on the income level of the patient household using a sliding scale for those patients with a major catastrophic medical event not qualifying for full charity assistance. Tennessee law mandates that all uninsured patients receive a discount from billed charges for medically necessary services. These amounts are classified as charity care if the patient meets charity care criteria, for which no revenue is recorded, or is included as a part of price concessions.

VUMC maintains records to identify and monitor the level of charity care provided, and these records include gross charges and patient deductibles, coinsurance and copayments foregone for services furnished under its charity care policy, and the estimated cost of those services. VUMC calculates a ratio of total costs to gross charges and then multiplies the ratio by foregone charity care charges in determining the estimated cost of charity care. The gross amount of foregone charity care revenue in Fiscal 2020 and 2019 totals \$422.7 million and \$341.5 million, respectively. The estimated cost of providing care to charity patients in Fiscal 2020 and 2019 totals \$110.1 million and \$89.9 million, respectively.

In addition to the charity care services described above, TennCare/Medicaid and state indigent programs do not cover the full cost of providing care to beneficiaries of those programs. As a result, in addition to direct charity care costs, VUMC provided services related to TennCare/Medicaid and state indigent programs and was reimbursed substantially below the cost of rendering such services. VUMC also provides public health education and training for new health professionals and provides, without charge, services to the community at large for many patients with special needs.

6. Academic and Research Revenue, and Grants and Contracts Receivable

Academic and research revenue comprises the following for Fiscal 2020 and 2019:

<i>(\$ in thousands)</i>	<u>2020</u>	<u>2019</u>
Grants and contracts revenue		
Federally funded	\$ 297,651	\$ 297,758
Non-federally funded	<u>132,557</u>	<u>113,423</u>
	430,208	411,181
Facilities and administrative costs recovery	<u>122,614</u>	<u>108,266</u>
Academic and research revenue	<u>\$ 552,822</u>	<u>\$ 519,447</u>

Vanderbilt University Medical Center
Notes to Consolidated Financial Statements
June 30, 2020 and 2019

Grants and contracts receivable comprise the following as of June 30, 2020 and 2019:

<i>(\$ in thousands)</i>	<u>2020</u>	<u>2019</u>
Federally funded	\$ 28,077	\$ 28,171
Non-federally funded	31,954	30,579
Total grants and contracts receivable	<u>\$ 60,031</u>	<u>\$ 58,750</u>

7. Pledges Receivable, Net

Pledges receivable, net of applied discounts and allowance for uncollectible pledges, as of June 30, 2020 and 2019, were as follows:

<i>(\$ in thousands)</i>	<u>2020</u>	<u>2019</u>
Amounts due		
Within one year	\$ 11,347	\$ 8,072
In one to five years	24,809	25,027
Total pledges receivable	<u>36,156</u>	<u>33,099</u>
Unamortized discount	<u>(1,112)</u>	<u>(1,296)</u>
	35,044	31,803
Allowance for uncollectible pledges	<u>(6,126)</u>	<u>(3,317)</u>
Net pledges receivable	<u>\$ 28,918</u>	<u>\$ 28,486</u>
Net pledges receivable classified as		
Current	\$ 7,552	\$ 6,327
Noncurrent	21,366	22,159
	<u>\$ 28,918</u>	<u>\$ 28,486</u>

In addition to pledges reported as pledges receivable, VUMC had cumulative bequest intentions and conditional promises to give totaling \$66.9 million as of June 30, 2020, and \$65.8 million as of June 30, 2019. Due to their conditional nature, VUMC does not recognize intentions to give as assets.

Vanderbilt University Medical Center
Notes to Consolidated Financial Statements
June 30, 2020 and 2019

8. Other Relevant Financial Information

Other current assets comprise the following as of June 30, 2020 and 2019:

<i>(\$ in thousands)</i>	<u>2020</u>	<u>2019</u>
Prepaid expenses	\$ 35,728	\$ 39,610
Other receivables	55,483	31,261
Amounts due from VU (see Note 3 Related Parties)	6,684	4,929
Current pledges receivable, net (see Note 7 Pledges Receivable, Net)	7,552	6,327
Expected recoveries from commercial insurance excess coverage	2,652	3,345
Other	10,340	3,839
Total other current assets	<u>\$ 118,439</u>	<u>\$ 89,311</u>

Other noncurrent assets comprise the following as of June 30, 2020 and 2019:

<i>(\$ in thousands)</i>	<u>2020</u>	<u>2019</u>
Equity in unconsolidated organizations	\$ 23,234	\$ 21,480
Noncurrent pledges receivable (see Note 7 Pledges Receivable, Net)	21,366	22,159
Other	8,747	4,428
Total other noncurrent assets	<u>\$ 53,347</u>	<u>\$ 48,067</u>

Other operating revenues comprise the following for Fiscal 2020 and 2019:

<i>(\$ in thousands)</i>	<u>2020</u>	<u>2019</u>
CARES funding	\$ 130,399	\$ -
Clinical contracts	46,886	40,952
Amounts recognized under MSA with VU (see Note 3 Related Parties)	31,192	30,745
VHS other revenue	28,176	23,622
Nonclinical contracts	11,898	8,442
Resident and house staff rotations	10,557	11,507
Other	42,035	41,743
Total other operating revenue	<u>\$ 301,143</u>	<u>\$ 157,011</u>

Vanderbilt University Medical Center
Notes to Consolidated Financial Statements
June 30, 2020 and 2019

9. Investments

VUMC investments are made up of current investments, restricted cash, noncurrent investments, and noncurrent investments limited as to use on the face of the consolidated balance sheets. VUMC investments include assets limited as to use related to the following specified purposes as of June 30, 2020 and 2019:

<i>(\$ in thousands)</i>	2020	2019
Self-insured malpractice program	\$ 46,223	\$ 52,069
Donor endowments	52,590	38,443
Split-interest trusts	7,124	7,383
Supplemental employee retirement program assets	7,589	5,714
	\$ 113,526	\$ 103,609

VUMC's endowment does not include gift annuities, interests in trusts held by others, contributions pending donor designation, or contributions receivable.

The Board of Directors' interpretation of its fiduciary responsibilities for donor-restricted endowments under the Uniform Prudent Management of Institutional Funds Act ("UPMIFA") requirements is to preserve intergenerational equity, barring the existence of any donor-specific provisions. Under this broad guideline, future endowment beneficiaries should receive at least the same level of real economic support as the current generation. The overarching objective is to preserve and enhance the real (inflation-adjusted) purchasing power of the endowment in perpetuity. VUMC invests assets to provide a relatively predictable and stable stream of earnings to meet spending needs and attain long-term return objectives without the assumption of undue risks.

Self-insured malpractice program – VUMC elects to self-insure a portion of its medical malpractice, professional, and general liability via an irrevocable self-insurance trust.

Donor endowments – Donor-restricted gifts where the principal amount is to be held in perpetuity. Distributions of earnings are restricted for use according to the donor's intent, as specified in a gift agreement. Donor endowments typically benefit specific programs in clinical departments of the Medical Center, for either, research, directorships, or general program support.

Split-interest trusts – Trusts established by donors where VUMC is named as beneficiary. Depending on the terms of the trust, VUMC may receive periodic distributions, and potentially a principal amount at some point in the future. Like donor endowments, split-interest trusts typically benefit specific programs as defined in the terms of the trust.

Supplemental executive retirement program assets – Assets set aside to fulfill obligations as they come due according to the terms of the retirement program.

Vanderbilt University Medical Center
Notes to Consolidated Financial Statements
June 30, 2020 and 2019

Investments were as follows as of June 30, 2020 and 2019:

<i>(\$ in thousands)</i>	<u>2020</u>	<u>2019</u>
Corporate bonds	\$ 235,249	\$ 153,940
Equity mutual funds	128,569	128,287
Cash and cash equivalents	13,147	9,436
Split-interest trusts	7,124	7,383
Hedged equity mutual funds	64,986	61,401
Fixed income mutual funds	190,054	167,079
Certificates of deposit	16,338	25,897
Asset-backed securities	26,448	29,506
Real estate mutual funds	20,680	18,969
Commercial paper	22,218	10,916
Government bonds	80,145	10,604
Hedged debt mutual funds	70,958	86,678
Commodities and managed futures mutual funds	15,902	6,895
Target date mutual funds	4,865	5,544
Total investments, at fair value	<u>\$ 896,683</u>	<u>\$ 722,535</u>

Investment returns comprise the following elements for Fiscal 2020 and 2019:

<i>(\$ in thousands)</i>	<u>2020</u>	<u>2019</u>
Interest and dividend income	\$ 19,013	\$ 19,749
Net realized gains on sales of securities	5,025	10,847
Realized investment gains, before fees	24,038	30,596
Unrealized investment gains (losses), net	3,637	(126)
Total investment returns before fees	27,675	30,470
Investment manager and trustee fees and other	(451)	(364)
Total income from investments, net	<u>\$ 27,224</u>	<u>\$ 30,106</u>

VUMC has exposure to risks, including liquidity, interest rate, counterparty, basis, regulatory, market, and credit risks, for marketable securities. Due to the level of risk exposure, it is possible that material near-term valuation changes for investment securities may occur.

VUMC manages all investments, including endowments, in various investment pools.

Vanderbilt University Medical Center
Notes to Consolidated Financial Statements
June 30, 2020 and 2019

10. Property, Plant, and Equipment, Net

Property, plant, and equipment comprise the following as of June 30, 2020 and 2019:

<i>(\$ in thousands)</i>	2020	2019
Land and land improvements	\$ 40,800	\$ 33,404
Buildings and improvements	1,189,614	1,005,364
Equipment and software	562,360	441,091
Leasehold improvements	86,869	82,322
Construction in progress	77,739	145,380
Property, plant, and equipment at cost	<u>1,957,382</u>	<u>1,707,561</u>
Accumulated depreciation and amortization	<u>(432,279)</u>	<u>(312,466)</u>
Property, plant, and equipment, net	<u>\$ 1,525,103</u>	<u>\$ 1,395,095</u>

As part of the MTSA, VUMC acquired land and land improvements and buildings and improvements which are not allowed to be repurposed without the express consent of VU.

In Fiscal 2020 and 2019, VUMC capitalized interest of \$2.9 million and \$6.0 million, respectively, related to long-term capital projects, primarily the MCJCHV expansion and the VUAH bed expansion.

Property, plant, and equipment balances above include the following amounts related to capitalized internal use software:

<i>(\$ in thousands)</i>	2020	2019
Equipment and software	\$ 167,897	\$ 158,189
Construction in progress	11,063	2,976
	<u>178,960</u>	<u>161,165</u>
Accumulated amortization	<u>(40,823)</u>	<u>(26,063)</u>
Internal use software, carrying value	<u>\$ 138,137</u>	<u>\$ 135,102</u>

Depreciation and amortization comprise the following amounts in Fiscal 2020 and 2019:

<i>(\$ in thousands)</i>	2020	2019
Depreciation of tangible assets	\$ 97,976	\$ 82,236
Amortization of finance leases, leasehold improvements, and internal use software	28,678	24,288
Total depreciation and amortization	<u>\$ 126,654</u>	<u>\$ 106,524</u>

Vanderbilt University Medical Center
Notes to Consolidated Financial Statements
June 30, 2020 and 2019

11. Long-Term Debt

Long-term debt comprises the following as of June 30, 2020 and 2019:

	<u>2020</u>	<u>2019</u>	<u>Effective</u>	<u>Fiscal</u>
(\$ in thousands)	<u>Carrying</u>	<u>Carrying</u>	<u>Interest</u>	<u>Year</u>
	<u>Amount</u>	<u>Amount</u>	<u>Rate</u> ⁽²⁾	<u>of Maturity</u>
Series debt				
Fixed-rate debt				
Series 2016A	\$ 476,930	\$ 476,930	4.1 %	2047
Series 2016B	300,000	300,000	4.1 %	2027
Series 2017A	121,270	121,270	4.1 %	2049
Series 2017	100,000	100,000	4.2 %	2038
Series 2019B	128,600	-	3.9 %	2055
Series 2020A	300,000	-	2.2 %	2022
Total fixed-rate debt	<u>1,426,800</u>	<u>998,200</u>	3.8 %	
Variable-rate debt				
Series 2016D	100,000	100,000	4.1 %	2047
Series 2016E	-	128,070	4.0 %	2047
Series 2016F	21,900	21,900	2.8 %	2025
Series 2017B	50,000	50,000	2.8 %	2047
Series 2018	53,385	53,385	1.9 %	2050
Series 2019A	35,000	-	2.0 %	2050
Total variable-rate debt	<u>260,285</u>	<u>353,355</u>	3.0 %	
Total series debt	<u>1,687,085</u>	<u>1,351,555</u>		
Other long-term debt				
Line of credit	100,000	-	1.1 %	2021
Subordinated note payable	79,583	84,583	3.2 %	2036
Product financing arrangement	29,236	31,508	4.6 %	2027
Finance leases	15,980	1,730	3.1 %	Various
Subtotal ⁽¹⁾	<u>1,911,884</u>	<u>1,469,376</u>	3.7 %	
Net unamortized premiums	56,244	58,424		
Net unamortized issuance costs	(12,517)	(12,355)		
Total long-term debt	<u>1,955,611</u>	<u>1,515,445</u>		
Line of credit	(100,000)	-		
Current portion of long-term debt	(14,321)	(8,568)		
Long-term debt, net	<u>\$ 1,841,290</u>	<u>\$ 1,506,877</u>		

(1) The effective interest rate of 3.7% as of June 30, 2020, is presented exclusive of interest rate exchange agreements discussed in Note 12 Interest Rate Exchange Agreements. Inclusive of these agreements, the overall portfolio effective interest rate was 4.0%.

(2) The effective interest rate for each debt instrument is calculated by dividing each instrument's interest expense by the weighted average debt outstanding, and where applicable, interest expense is reduced by premium amortization and increased by original issue discount amortization. Interest rates per the agreements are detailed in the accompanying notes.

Vanderbilt University Medical Center

Notes to Consolidated Financial Statements

June 30, 2020 and 2019

On April 29, 2016, VUMC issued the Series 2016 A, B, D, E, and F bonds (“2016 Series Debt”) and notes aggregating \$1.3 billion of proceeds for the purpose of financing the Medical Center Acquisition and paying a portion of the costs of issuance associated with the 2016 Series Debt.

The bonds and notes comprising the 2016 Series Debt were issued by the Health and Educational Facilities Board of The Metropolitan Government of Nashville and Davidson County, Tennessee (“HEFB”). As a conduit issuer, the HEFB loaned the debt proceeds to VUMC. VUMC’s debt service requirements under these loan agreements coincide with required debt service of the actual HEFB bonds.

- The Series 2016A tax-exempt fixed-rate revenue bonds were issued in the par amount of \$476.9 million and include an original issue premium of \$59.6 million. The Series 2016A bonds have a final maturity date of July 1, 2046, and can be optionally redeemed at par on or after July 1, 2026. The 2016A bonds were structured as serial bonds with maturities from Fiscal 2030 through 2032, as well as three term bonds maturing Fiscal 2036 through 2047, which are subject to mandatory sinking fund redemption in lots. The Series 2016A bonds bear interest at 5% per annum and pay interest semiannually on July 1 and January 1.
- The Series 2016B taxable fixed-rate revenue bonds were issued in the par amount of \$300.0 million, bearing interest at 4.1% per annum. Interest is paid semiannually on July 1 and January 1, and has a bullet maturity of July 1, 2026. VUMC is entitled, at its option, to redeem all or a portion of the Series 2016B bonds before April 1, 2026, at a make-whole redemption price, which equals the greater of (i) 100% of the remaining outstanding principal and (ii) the net present value of the remaining scheduled principal and interest payments to the original maturity date, using a discount rate of 35 basis points above rates for U.S. Treasury securities with comparable maturities.
- The Series 2016D taxable variable-rate revenue notes (“floating rate notes”) were issued in the par amount of \$100.0 million and bear interest initially at a fixed spread to one-month LIBOR of 2.5% through the initial mandatory tender date of July 1, 2021, and a final maturity of July 1, 2046. Beginning six months prior to the mandatory tender date of July 1, 2021, the bonds have an optional redemption feature. If the Series 2016D bonds are successfully remarketed at the mandatory tender date, they are subject to mandatory redemption in lots commencing on July 1, 2021, and each July thereafter until final maturity.
- The Series 2016E taxable term loan revenue notes were issued in the par amount of \$128.1 million and were placed privately with a bank. The notes bear interest in a variable-rate mode at a fixed spread to one-month LIBOR of 2.4% through the initial mandatory tender date of July 1, 2022, and a final maturity of July 1, 2046. During Fiscal 2018, VUMC renegotiated the interest to a variable-rate mode at a fixed spread to one-month LIBOR of 1.8%. In addition to optional redemption of all or a portion of the notes at any time, subject to notice, the Series 2016E notes are subject to principal amortization commencing on July 1, 2022, as defined in the Series 2016E loan agreement between VUMC and the lender. During Fiscal 2020, the Series 2016E bonds were extinguished using proceeds from the 2019B taxable fixed private placement notes, discussed further below.
- The Series 2016F taxable variable-rate revenue bonds were issued in the par amount of \$75.0 million and were placed privately with a bank. The bonds bear interest in a variable-rate mode at a fixed spread to one-month LIBOR of 2.5% through the initial mandatory tender date of July 1, 2022. During Fiscal 2018, \$53.1 million of the Series 2016F bonds were extinguished using proceeds from the 2018 tax-exempt fixed-rate revenue bonds, discussed further below. The renegotiated interest rate on the remaining \$21.9 million of principal outstanding is a

Vanderbilt University Medical Center

Notes to Consolidated Financial Statements

June 30, 2020 and 2019

variable-rate mode at a fixed spread to one-month LIBOR of 1.2%. The remaining principal has a mandatory tender date of July 1, 2024. Prior to that, VUMC must pay \$2.1 million of principal on July 1, 2022, and \$2.2 million of principal on July 1, 2023. The remaining \$17.6 million of principal is due on July 1, 2024.

On July 26, 2017, the Series 2017A Tax-Exempt and Series 2017 Taxable Corporate Bonds were issued, and on August 1, 2017, the Series 2017B Taxable Revenue Bonds were issued ("2017 Series Debt"), aggregating \$271.3 million of proceeds for the purpose of refinancing existing debt, funding capital projects related to the MCJCHV expansion and the VUAH bed expansion/clinical relocation, which is a phased project, and paying a portion of the costs of issuance associated with the 2017 Series Debt.

The Series 2017A Tax-Exempt Revenue Bonds and the Series 2017B Taxable Term Loan Revenue Note were issued by the HEFB. The Series 2017 Taxable Bonds were a corporate issue with VUMC as the issuer.

- The Series 2017A tax-exempt fixed-rate revenue bonds were issued in the par amount of \$121.3 million and include an original issue premium of \$5.1 million. The final maturity date is July 1, 2048, and optional redemption at par can occur on or after July 1, 2027. The Series 2017A bonds bear interest at 4.4% per annum and pay interest semiannually on July 1 and January 1.
- The Series 2017 taxable fixed-rate corporate bonds were issued in the par amount of \$100.0 million, bearing interest at 4.2% per annum. Interest is paid semiannually on July 1 and January 1, and the bonds have a final maturity date of July 1, 2037. There is a bullet payable beginning July 1, 2026, that allows VUMC to call the debt.
- The Series 2017B taxable variable-rate term loan notes were issued in the par amount of \$50 million and placed privately with a bank. The notes bear interest initially at a fixed-spread to one-month LIBOR of 1.2%. The notes have a final maturity date of July 1, 2046, a tender date of August 1, 2024, and may be redeemed at any time. Proceeds from the issuance of the Series 2017B notes were used to extinguish the Series 2016C R-FLOATs, initially issued on April 29, 2016.

On April 20, 2018, the Series 2018 Tax-Exempt Revenue Bonds ("2018 Series Debt") aggregating \$53.4 million of proceeds were issued for the purpose of refinancing existing debt and paying a portion of the costs of issuance associated with the 2018 Series Debt. The Series 2018 Tax-Exempt Revenue Bonds were issued by the HEFB, were placed privately with a bank, and bear interest at a fixed spread to 81% of one-month LIBOR of 0.6%. The bonds have a final maturity date of July 1, 2049 and can be optionally redeemed on or after July 1, 2025. Proceeds from the issuance of the Series 2018 bonds were used to extinguish a portion of the Series 2016F taxable variable-rate bonds.

On July 30, 2019, VUMC entered into a term loan agreement (2019A Term Loan) with a lender for \$35 million to pay for the acquisition of Tennova – Lebanon (now Vanderbilt Wilson County Hospital) hospital facilities, near term capital expenditures, and costs of issuance. The term loan bears interest at a variable rate plus a fixed spread to one-month LIBOR of 0.50% through the maturity date of August 1, 2029. VUMC has the option to redeem prepay all or a portion of the loan at any time, subject to notice. The 2019 loan is subject to principal amortization commencing on July 1, 2024 and ending July 1, 2049, as defined in the 2019 loan agreement between VUMC and the lender.

Vanderbilt University Medical Center

Notes to Consolidated Financial Statements

June 30, 2020 and 2019

On October 22, 2019, the Series 2019B Taxable Fixed Private Placement Notes (“Series 2019B Notes”) aggregating \$128.6 million of proceeds were issued for the purpose of refinancing existing debt and paying a portion of the costs of issuance associated with the Series 2019B Notes. The lender for the Series 2019B Notes was New York Life. The Series 2019B Notes were placed privately with a bank, and bear interest at a fixed rate of 3.9% per annum. The notes have a final maturity date of July 1, 2054. Proceeds from the issuance of the Series 2019B Notes were used to extinguish the Series 2016E Taxable Term Loan Revenue Notes.

On April 9, 2020, the Series 2020A Taxable Fixed Term Loan (“Series 2020A Loan”) aggregating \$300 million was issued to provide additional liquidity during the COVID-19 pandemic. The lender for the Series 2020A Loan was JPMorgan Chase Bank. The debt bears interest at a fixed rate of 2.1% per annum, has an optional redemption after one year, and has a final maturity date of April 1, 2022. As of June 30, 2020, these funds have not been used and are held in cash and investments on the consolidated balance sheet.

Each of the bonds and notes comprising the 2016, 2017, 2018, 2019, and 2020 Series Debt represent separate obligations under a Master Trust Indenture (“MTI”) structure. The MTI provides the flexibility for multiple parties to participate in debt issuances as part of an obligated group; presently, VUMC has no other third-party members participating in the obligated group. All debt issued under the MTI is a general obligation of the obligated group. Under the provisions of the Leasehold Deed of Trust, Security Agreement, Assignment of Rents and Leases, and Fixture Filing (the “Security Agreement”) within the MTI, gross receivables of the obligated group are pledged as collateral. Additionally, the Security Agreement established a mortgage lien on (i) the leasehold interest of the land subject to the Ground Lease; (ii) the buildings, structures, improvements, and fixtures now or hereafter located on the land subject to the Ground Lease; and (iii) certain other collateral.

Trust indentures for certain bond issues contain covenants and restrictions, the most material of which include limitations on the issuance of additional debt, maintenance of a specified debt service coverage ratio, and a minimum amount of days cash on hand. VUMC complied with such covenants and restrictions as of June 30, 2020 and 2019.

On April 29, 2016, VUMC delivered a secured subordinated promissory note in the amount of \$100.0 million to the University to finance the Acquisition (the “subordinated note”). In July of 2018, VU sold its rights to future principal and interest payments on this note to a third party. The note was issued at a fixed rate of 3.25% with monthly principal payments totaling \$5.0 million annually commencing on May 31, 2016, for a period of 20 years ending on April 30, 2036. VUMC may, at any time and from time to time, without premium or penalty, prepay all or any portion of the unpaid principal amount of the subordinated note. This note is secured by the gross receivables and mortgaged property described in the Security Agreement subject to the requirements of the 2016 Series Debt and the MTI.

As part of the Acquisition, VUMC assumed a 10-year, unsecured, noninterest-bearing product financing arrangement with a vendor for the purchase and implementation of internal use software. As part of this agreement, VUMC committed to an annual payment of \$0.5 million payable in monthly installments through November 2019. These payments were considered imputed interest. During Fiscal 2020, the annual payment increased to \$5.3 million payable in monthly installments. These payments are considered principal and imputed interest and continue through Fiscal 2027. The balance due under the Product Financing Arrangement is \$29.2 million and \$31.5 million as of June 30, 2020 and 2019, respectively. At June 30, 2020 and 2019, \$4.1 million and \$1.9 million was included in the current portion of long-term debt caption, with the remaining balance in long-term debt, net of current portion.

Vanderbilt University Medical Center
Notes to Consolidated Financial Statements
June 30, 2020 and 2019

In Fiscal 2020 and 2019, noncash investing and financing activities totaled \$19.1 million and \$2.4 million, respectively, related to finance leases.

VUMC has an agreement with a bank to provide a general use line of credit with a maximum available commitment totaling \$100.0 million. On March 18, 2020, VUMC drew down the available \$100 million, which bears interest at a fixed spread to one-month LIBOR of 0.7% and has no maturity date if the line of credit is renewed annually. The outstanding balance on the line of credit is \$100.0 million and \$0.0 million as of June 30, 2020 and 2019, respectively. The line of credit accrues a commitment fee of 0.15% per annum on any unused portion of the line of credit.

VUMC established three additional lines of credit with banks in Fiscal 2020:

- \$50 million line of credit with Truist, bearing interest at a fixed spread to one-month LIBOR of 1.0%, maturing in FY 2022 with a commitment fee of 0.25% on any unused portion of the line of credit.
- \$50 million line of credit with Truist, bearing interest at a fixed spread to one-month LIBOR of 0.85%, maturing in FY 2021 with a commitment fee of 0.25% on any unused portion of the line of credit.
- \$50 million line of credit with Bank of New York Mellon, bearing interest at a fixed spread to one-month LIBOR of 1.4%, maturing in FY 2021 with a commitment fee of 0.25% on any unused portion of the line of credit.

As of June 30, 2020, VUMC has not drawn on any of these three new lines of credit. Commitment fees for the lines of credit totaled \$0.2 million in Fiscal 2020.

Interest paid on all obligations, net of amounts capitalized, was \$62.7 million and \$59.7 million in Fiscal 2020 and 2019, respectively.

Principal retirements and scheduled sinking fund requirements based on nominal maturity schedules for long-term debt due in subsequent fiscal years ending June 30 are as follows:

(\$ in thousands)

2021	\$ 114,321
2022	412,963
2023	14,763
2024	14,528
2025	79,658
Thereafter	1,275,651
	<u>\$ 1,911,884</u>

Vanderbilt University Medical Center
Notes to Consolidated Financial Statements
June 30, 2020 and 2019

12. Interest Rate Exchange Agreements

On April 29, 2016, the University transferred an interest rate exchange agreement to VUMC with a total notional amount of \$150.0 million and an original termination date of May 1, 2040. VUMC split the transferred notional amount into two agreements, with key features summarized below:

<u>Notional Amount</u>	<u>Pay Fixed Rate</u>	<u>Receive Variable Rate</u>	<u>Mandatory Termination Date</u>
\$75.0 million	4.12%	68% of one-month LIBOR	April 29, 2021 ⁽¹⁾
\$75.0 million	4.18%	68% of one-month LIBOR	April 29, 2023

⁽¹⁾ As of June 30, 2020, we were negotiating to extend the mandatory termination date for this agreement. Subsequent to the balance sheet date, we executed this agreement which extended the mandatory termination date to April 2026. Under these new terms, the fixed rate increases to 4.28% starting May 3, 2021.

VUMC incorporated these interest rate exchange agreements into its debt portfolio management strategy. Collateral pledging requirements were removed from the novated agreements, and the agreements were modified to either be negotiated, extended, or terminated automatically on April 29, 2021 and 2023, at which point the exchange agreements will be settled at fair value.

VUMC recorded the following activity related to the interest rate exchange agreements during Fiscal 2020 and 2019:

<i>(\$ in thousands)</i>	<u>2020</u>	<u>2019</u>
Mark-to-market adjustments	\$ (32,441)	\$ (13,695)
Cash settlements	<u>(4,711)</u>	<u>(3,785)</u>
Unrealized loss on interest rate exchange agreements, net of cash settlements	<u>\$ (37,152)</u>	<u>\$ (17,480)</u>

13. Leases

VUMC has operating and finance leases for real estate, personal property and equipment. VUMC determines if an arrangement is a lease at the inception of a contract. Leases with an initial term of twelve months or less are not recorded on the consolidated balance sheets.

VUMC has lease agreements which require payments for lease and non-lease components and has elected to account for these as a single lease component. For leases that commenced before the effective date of ASU 2016-02, VUMC elected the permitted practical expedients to not reassess the following: (i) whether any expired or existing contracts contain leases; (ii) the lease classification for any expired or existing leases; and (iii) initial direct costs for any existing leases.

Right-of-use assets represent VUMC's right to use an underlying asset during the lease term, and lease liabilities represent VUMC's obligation to make lease payments arising from the lease. Right-of-use assets and liabilities are recognized at the commencement date, based on the net present value of fixed lease payments over the lease term. VUMC's lease terms include options to extend or terminate the lease when it is reasonably certain that the options will be exercised. As most of

Vanderbilt University Medical Center
Notes to Consolidated Financial Statements
June 30, 2020 and 2019

VUMC's operating leases do not provide an implicit rate, VUMC uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. VUMC considers recent debt issuances, as well as publicly available data for instruments with similar characteristics when calculating its incremental borrowing rates. Finance lease agreements generally include an interest rate that is used to determine the present value of future lease payments. Operating fixed lease expense and finance lease depreciation expense are recognized on a straight-line basis over the lease term. Variable lease costs consist primarily of common area maintenance.

Operating and finance lease right-of-use assets and lease liabilities as of June 30, 2020 is as follows:

<i>(\$ in thousands)</i>	Balance Sheet Classification	2020
Assets:		
Operating leases	Operating leases	\$ 846,695
Finance leases	Property, plant, and equipment, net	16,712
Total lease assets		<u>\$ 863,407</u>
Liabilities:		
Current:		
Operating leases	Current portion of operating lease liabilities	\$ 70,062
Finance leases	Current portion of long-term debt	5,206
Noncurrent:		
Operating leases	Noncurrent portion of operating lease liabilities	797,811
Finance leases	Long-term debt, net of current portion	10,774
Total lease liabilities		<u>\$ 883,853</u>
Weighted-average remaining term:		
Operating leases		57.3 years
Finance leases		3.8 years
Weighted-average discount rate:		
Operating leases		3.7%
Finance leases		2.4%

Included in the tables above is the Ground Lease with VU expiring in 2115 discussed below. Excluding this lease, the weighted average remaining lease term for VUMC's operating leases is 8.7. The land lease comprises \$489.7 million of the operating lease asset and \$492.5 million of the operating lease liability detailed below.

Vanderbilt University Medical Center
Notes to Consolidated Financial Statements
June 30, 2020 and 2019

Lease expense for finance and operating leases for the year ended June 30, 2020, are as follows:

<i>(\$ in thousands)</i>	2020
Finance lease expense:	
Amortization of leased assets	\$ 4,433
Interest on lease liabilities	273
Operating lease expense ⁽¹⁾	107,358
Short-term lease expense ⁽¹⁾	3,787
Variable lease expense ⁽¹⁾	13,321
	<u>\$ 129,172</u>

⁽¹⁾ Expense is included in "Facilities and equipment" in the consolidated statements of operations.

The following table presents supplemental cash flow information for the year ended June 30, 2020:

<i>(\$ in thousands)</i>	2020
Cash paid for amounts included in the measurement of lease liabilities:	
Operating cash flows for operating leases	\$ 103,166
Operating cash flows for finance leases	273
Financing cash flows for finance leases	4,334

The following table reconciles the undiscounted minimum lease payments to the operating and financing lease liabilities recorded on the consolidated balance sheet at June 30, 2020:

<i>(\$ in thousands)</i>	Operating Leases	Finance Leases
2021	\$ 98,655	\$ 5,396
2022	79,773	3,832
2023	69,309	3,231
2024	62,709	2,692
2025	59,110	1,253
Thereafter	1,888,989	-
Total minimum lease payments	<u>2,258,545</u>	<u>16,404</u>
Less: amount of lease payments representing interest	(1,390,672)	(424)
Present value of future minimum lease payments	867,873	15,980
Less: current lease obligations	(70,062)	(5,206)
Long-term lease obligations	<u>\$ 797,811</u>	<u>\$ 10,774</u>

In Fiscal 2019, rent expense was \$124.8 million.

Vanderbilt University Medical Center
Notes to Consolidated Financial Statements
June 30, 2020 and 2019

Essential provisions of leases considered by management to be material are as follows:

- On April 29, 2016, VUMC entered into a Ground Lease with VU for approximately 1.7 million square feet of land for an initial term ending June 30, 2115, and an option to extend for up to two additional terms of 50 to 99 years each upon agreement by VU and VUMC. The initial annual base rent of \$19.4 million is payable monthly, and is CPI adjusted annually. The Ground Lease allows VUMC to use the land on which its campus and related buildings are located. Included in the table above are \$1.8 billion in ground lease payments representing future minimum rentals based on current payments.
- In July 2007, VU entered into an agreement to lease approximately 50% of the space in the 850,000 square foot One Hundred Oaks shopping center located approximately five miles from the main campus ("100 Oaks Lease"). VU redeveloped this leased space primarily for medical and office uses. This operating lease commenced during Fiscal 2009 with an initial lease term of 12 years. In October 2014, VU agreed to an amendment which extends the original lease term by an additional 15 years, with an option to renew the lease further for four additional 10-year periods. As part of the lease agreement, the lessee also has first rights on leasing additional space in the shopping center and first rights on purchasing if the landlord desires to sell. On April 29, 2016, the 100 Oaks Lease was assigned to VUMC. As a condition of the assignment, amendments to the 100 Oaks Lease were added which required VUMC to provide the landlord a \$25.0 million irrevocable standby letter of credit, pay a \$13.2 million refinancing penalty payable to the landlord, and pay \$7.8 million of the landlord's closing costs, financing fees, and prepayment penalties associated with a refinancing of the landlord's debt. The prepayment penalty and closing costs were recorded as part of the Acquisition. The irrevocable standby letter of credit must remain in place through April 29, 2026. The amounts related to this standby letter of credit are recorded as facilities and equipment expense and totaled \$0.2 million in both Fiscal 2020 and 2019. VUMC included minimum property rental payments totaling \$118.6 million related to this space in the above minimum lease payments table.
- On April 29, 2016, VU assigned to VUMC a lease for approximately 231,000 square feet of office space at 2525 West End Avenue with expiration dates ranging from 2026 through 2030, with options to renew for two additional five-year periods. VUMC included minimum lease payments totaling \$67.8 million related to this space in the above minimum lease payments table.
- On April 29, 2016, VUMC and VU entered into certain lease agreements for the use of space in buildings owned by both entities. As of June 30, 2020, VUMC's estimated future minimum lease payments to VU totaled \$22.1 million. Estimated future lease receipts from VU for the fiscal year ended June 30, 2021, are \$7.4 million, subject to annual renewal.

Vanderbilt University Medical Center
Notes to Consolidated Financial Statements
June 30, 2020 and 2019

14. Net Assets

Net asset restrictions relate to the following purposes as of June 30, 2020 and 2019:

<i>(\$ in thousands)</i>	2020	2019
Donor-restricted - time or purpose		
Property, plant, and equipment	\$ 10,920	\$ 11,023
Research and education	106,167	88,084
Operations	4,661	3,841
Total donor-restricted - time or purpose	\$ 121,748	\$ 102,948
Donor restricted - perpetuity		
Research and education	\$ 64,807	\$ 52,949

Net assets without donor restrictions are free of donor-imposed restrictions. This classification includes all revenues, gains, and losses not restricted by donors. VUMC reports all expenditures in net assets without donor restrictions since the use of restricted contributions in accordance with donors' stipulations results in the release of the restriction.

Donor restricted – time or purpose contain donor-imposed stipulations that expire with the passage of time or that can be satisfied by the action of VUMC. These net assets may include unconditional pledges, split-interest agreements, interests in trusts held by others, and accumulated appreciation on donor-restricted endowments not yet appropriated by the Board of Directors for distribution. Donor gifts that are restricted for funding capital projects are considered released from restriction once related capital expenditures have been made and the asset is placed in service.

Donor restricted – perpetuity contains amounts held in perpetuity as requested by donors. These net assets may include unconditional pledges, donor-restricted endowments, split-interest agreements, and interests in trusts held by others. Generally, the donors of these assets permit VUMC to use a portion of the income earned on related investments for specific purposes.

UPMIFA specifies that unless stated otherwise in a gift instrument, donor-restricted assets in an endowment fund are restricted assets until appropriated for expenditure. Barring the existence of specific instructions in gift agreements for donor-restricted endowments, VUMC reports the historical value of such endowments as donor restricted – perpetuity and the net accumulated appreciation as donor restricted – time or purpose. In this context, the historical value represents the original value of initial contributions restricted as permanent endowments plus the original value of subsequent contributions and, if applicable, the value of accumulations made in accordance with the direction of specific donor gift agreements.

Vanderbilt University Medical Center
Notes to Consolidated Financial Statements
June 30, 2020 and 2019

15. Fair Value Measurements

Fair value measurements represent the amount at which the instrument could be exchanged in an orderly transaction between market participants at the measurement date. VUMC utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three levels:

- Level 1 Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets that VUMC has the ability to access.

- Level 2 Inputs to the valuation methodology include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in inactive markets, inputs other than quoted prices that are observable for the assets or liabilities, and inputs that are derived principally from or corroborated by observable market data by correlation or other means.

- Level 3 Inputs to the valuation methodology are unobservable and significant to the fair value measurement. Unobservable inputs reflect VUMC's assumptions about the inputs market participants would use in pricing the asset or liability, including assumptions about risk. Unobservable inputs are developed based on the best information available in the circumstances and may include VUMC's own data.

VUMC's principal assets and liabilities are cash and cash equivalents, investments, patient accounts receivable, estimated receivables and payables under third-party programs, grants and contracts receivable, pledges receivable, accounts payable and other accrued expenses, self-insurance reserves, long-term debt, and interest rate exchange agreements. Except for long-term debt, the carrying amount of these assets and liabilities approximates fair value.

As of June 30, 2020, the carrying value and estimated fair value of total long-term debt totaled \$2.0 billion and \$2.0 billion, respectively. As of June 30, 2019, the carrying value and estimated fair value of total long-term debt totaled \$1.5 billion and \$1.6 billion, respectively. VUMC bases estimated fair value of long-term debt on market conditions prevailing at fiscal year-end reporting dates. Besides potentially volatile market conditions, fair value estimates typically reflect limited secondary market trading. The fair values of the fixed-rate Series Debt, as defined in Note 11 Long-Term Debt, were based on a Level 2 computation using quoted prices for similar liabilities in active markets as of June 30, 2020 and 2019, as applicable. The carrying amounts related to VUMC's variable-rate Series Debt and other long-term debt obligations approximate their fair values as of June 30, 2020 and 2019. As of June 30, 2020 and 2019, the fair values of the subordinated note payable and the product financing arrangement were based on a Level 2 discounted cash flow approach applying a risk-adjusted spread for issuers of similar credit quality to U.S. Treasury yields for securities with comparable maturities.

Vanderbilt University Medical Center
Notes to Consolidated Financial Statements
June 30, 2020 and 2019

For financial instruments measured at fair value on a recurring basis, the following tables summarize valuation hierarchy levels as of June 30, 2020 and 2019, determined by the nature of the financial instrument and the least observable input significant to the fair value measurement:

(\$ in thousands)	Fair Value Measurements as of June 30, 2020			Total Carrying Amount
	Level 1	Level 2	Level 3	
Assets				
Corporate bonds	\$ 15,805	\$ 219,444	\$ -	\$ 235,249
Equity mutual funds	34,589	93,980	-	128,569
Cash and cash equivalents	13,147	-	-	13,147
Beneficial interests in split-interest trusts	-	7,124	-	7,124
Hedged equity mutual funds	-	64,986	-	64,986
Fixed-income mutual funds	120,658	69,396	-	190,054
Certificates of deposit	-	16,338	-	16,338
Asset-backed securities	-	26,448	-	26,448
Real estate mutual funds	-	20,680	-	20,680
Commercial paper	-	22,218	-	22,218
Government bonds	10,665	69,480	-	80,145
Hedged debt mutual funds	-	70,958	-	70,958
Commodities and managed futures mutual funds	9,121	6,781	-	15,902
Target date mutual funds	-	4,865	-	4,865
Total assets reported at fair value	<u>\$ 203,985</u>	<u>\$ 692,698</u>	<u>\$ -</u>	<u>\$ 896,683</u>
Liabilities				
Interest rate exchange agreements	\$ -	\$ 100,342	\$ -	\$ 100,342
Total liabilities reported at fair value	<u>\$ -</u>	<u>\$ 100,342</u>	<u>\$ -</u>	<u>\$ 100,342</u>

Vanderbilt University Medical Center
Notes to Consolidated Financial Statements
June 30, 2020 and 2019

(\$ in thousands)	Fair Value Measurements as of June 30, 2019			
	Level 1	Level 2	Level 3	Total Carrying Amount
Assets				
Corporate bonds	\$ 2,657	\$ 151,283	\$ -	\$ 153,940
Equity mutual funds	31,873	96,414	-	128,287
Cash and cash equivalents	9,436	-	-	9,436
Beneficial interests in split-interest trusts	-	7,383	-	7,383
Hedged equity mutual funds	-	61,401	-	61,401
Fixed-income mutual funds	46,146	120,933	-	167,079
Certificates of deposit	-	25,897	-	25,897
Asset-backed securities	-	29,506	-	29,506
Real estate mutual funds	-	18,969	-	18,969
Commercial paper	-	10,916	-	10,916
Government bonds	-	10,604	-	10,604
Hedged debt mutual funds	-	86,678	-	86,678
Commodities and managed futures mutual funds	-	6,895	-	6,895
Target date mutual funds	-	5,544	-	5,544
Total assets reported at fair value	\$ 90,112	\$ 632,423	\$ -	\$ 722,535
Liabilities				
Interest rate exchange agreements	\$ -	\$ 67,901	\$ -	\$ 67,901
Total liabilities reported at fair value	\$ -	\$ 67,901	\$ -	\$ 67,901

VUMC employs derivatives, primarily interest rate exchange agreements, to help manage interest rate risks associated with variable-rate debt. In addition to the credit risk of the counterparty owing a balance, VUMC calculates the fair value of interest rate exchange agreements based on the present value of future net cash settlements that reflect market yields as of the measurement date.

Parties to interest rate exchange agreements are subject to risk for changes in interest rates, as well as the risk of credit loss in the event of nonperformance by the counterparty. VUMC deals only with high-quality counterparties that meet rating criteria for financial stability and credit-worthiness.

16. Retirement Plan

VUMC's full-time employees participate in a 403(b) defined contribution retirement plan administered by a third party. For eligible employees with one year of continuous service, this plan requires employer matching of employee contributions up to 5% of eligible compensation. The employee immediately vests in these contributions.

VUMC funds the obligations under this plan through monthly transfers to the respective retirement plan administrator with the corresponding expense recognized in the year incurred. During Fiscal 2020 and 2019, VUMC recognized \$69.8 million and \$64.1 million, respectively, of expense in connection with this plan.

Vanderbilt University Medical Center
Notes to Consolidated Financial Statements
June 30, 2020 and 2019

17. Functional Expense

VUMC provides general health care services primarily to residents within its geographic location and supports research and education programs. Total operating expense by nature and function for Fiscal 2020 and 2019 were as follows:

(\$ in thousands)

	For the year ended June 30, 2020			
	Healthcare Services	Academic Research and Education	Administrative and Other	Total
Salaries, wages, and benefits	\$ 1,773,506	\$ 542,728	\$ 179,561	\$ 2,495,795
Supplies and drugs	980,544	46,640	19,214	1,046,398
Facilities and equipment	160,705	40,556	72,144	273,405
Services and other	549,059	98,291	92,905	740,255
Depreciation and amortization	103,734	1,521	21,399	126,654
Interest	47,172	13,585	14	60,771
Total operating expense	<u>\$ 3,614,720</u>	<u>\$ 743,321</u>	<u>\$ 385,237</u>	<u>\$ 4,743,278</u>

(\$ in thousands)

	For the year ended June 30, 2019			
	Healthcare Services	Academic Research and Education	Administrative and Other	Total
Salaries, wages, and benefits	\$ 1,613,439	\$ 490,280	\$ 187,191	\$ 2,290,910
Supplies and drugs	831,059	47,418	13,734	892,211
Facilities and equipment	156,210	38,257	74,507	268,974
Services and other	517,935	95,339	87,805	701,079
Depreciation and amortization	83,922	992	21,610	106,524
Interest	43,082	12,241	1,206	56,529
Total operating expense	<u>\$ 3,245,647</u>	<u>\$ 684,527</u>	<u>\$ 386,053</u>	<u>\$ 4,316,227</u>

Certain expense categories are attributable to more than one function. Therefore, these expenses require an allocation on a reasonable basis that is consistently applied. The expenses that are allocated include salaries, wages, and benefits, and services and other.

Vanderbilt University Medical Center

Notes to Consolidated Financial Statements

June 30, 2020 and 2019

18. Commitments and Contingencies

Management has policies, procedures, and an organizational structure to enforce and monitor compliance with government statutes and regulations. VUMC's compliance with such laws and regulations is subject to future government review and interpretations, as well as regulatory actions unknown or unasserted at this time.

- Litigation. VUMC is a defendant in certain lawsuits alleging medical malpractice and civil action.

On August 16, 2016, VUMC received written notice from VU of a third-party claim which could, if determined adversely to VU, require indemnification by VUMC pursuant to the provisions of the MTSA, dated as of April 29, 2016. The third-party claim was prompted by a lawsuit (Cassell v. Vanderbilt University, et al., No. 3:16-cv-02086 (U.S.D.C. M.D. TN)) brought by current and former employees of VU which alleged claims relating to administration of the Vanderbilt University Retirement Plan and New Faculty Plan. A settlement in the matter was reached and was approved by the United States District Court for the Middle District of Tennessee in late October 2019, under which Plaintiffs dismissed their lawsuit in exchange for payment by VU of \$14.5 million. VUMC had established a liability reserve reflecting its estimated liability under the settlement, net of proceeds of applicable policies of insurance. Settlement funds were deposited with the settlement administrator and were distributed to Plan participants beginning in April 2020, and the litigation is now resolved.

In late Fiscal 2018, VUMC identified that standing orders used in certain VUMC clinical departments may not have been documented and entered appropriately. Upon further review, VUMC determined that medical record documentation required to support the medical necessity for the services rendered pursuant to certain of such orders was insufficient and that certain reimbursement amounts received for the services so ordered must consequently be repaid. Repayments totaling approximately \$2.7 million were made to governmental and commercial payors during the period from December 2019 through March 2020.

In December 2019, VUMC was notified by the Internal Revenue Service ("IRS") of its intention to conduct an examination of the VUMC 403b Retirement Plan for the year ending December 31, 2017. During that examination, VUMC identified certain concerns relating to the calculation of the employer match provided under the Plan, which was implemented by VUMC in April 2016. VUMC is evaluating options to resolve these concerns; if they are not resolved favorably, correction of the concerns could be required by the IRS. VUMC has established a liability reserve relating to the potential cost to correct such issues.

Through the operation of its compliance program, VUMC from time to time initiates the review of billing for clinical services provided by VUMC and its affiliated providers. VUMC has established a liability reserve relating to certain matters under review as of June 30, 2020, which is not material to VUMC's overall financial position.

- Regulations. VUMC's compliance with regulations and laws is subject to future government reviews and interpretations, as well as regulatory actions unknown at this time. VUMC believes that the liability, if any, from such reviews will not have a significant effect on VUMC's consolidated financial position.

Vanderbilt University Medical Center
Notes to Consolidated Financial Statements
June 30, 2020 and 2019

- **Medical Malpractice Self-Insurance.** The consolidated balance sheets include reserves for medical malpractice, professional, and general liability coverage totaling \$60.3 million as of June 30, 2020, and \$56.3 million as of June 30, 2019. These liabilities are measured at the net present value of those cash flows using a discount rate of 2.5% at both dates and are classified as current or noncurrent based on the expected timing of cash flows. Other current assets include expected recoveries from commercial insurance carriers under excess coverage arrangements totaling \$2.7 million as of June 30, 2020, and \$3.3 million as of June 30, 2019. During Fiscal 2020 and 2019, VUMC recorded expenses for medical malpractice self-insurance of \$26.0 million and \$23.5 million, respectively.
- **Employee Health and Workers' Compensation Insurance.** Accrued compensation and benefits included actuarially determined liabilities for employee health and workers' compensation claims totaling \$16.9 million and \$6.1 million, respectively, as of June 30, 2020, and \$17.3 million and \$6.6 million, respectively, as of June 30, 2019. During Fiscal 2020 and 2019, VUMC recorded expenses for self-insured employee health benefit plans, net of employee premiums, totaling \$181.5 million and \$177.2 million, respectively. During Fiscal 2020 and 2019, VUMC recorded expenses for self-insured workers' compensation plans of \$2.9 million and \$2.8 million, respectively.
- **Federal and State Contracts and Other Requirements.** Expenditures related to federal and state grants and contracts are subject to adjustment based upon review by the granting agencies. Amounts of expenditures that granting agencies might disallow cannot be determined at this time. These amounts affect government grants and contracts revenue, as well as facilities and administrative costs recovery. VUMC does not expect these costs to impact the consolidated financial position by material amounts.
- **Health Care Services.** In Fiscal 2020 and 2019, 83% and 85%, respectively, of VUMC's operating revenue was generated by providing health care services, where revenue is affected by reimbursement arrangements with federal and state healthcare programs, commercial insurance, and other managed care payors. If reimbursement rates from third-party payors decrease or if contract terms become less favorable in future periods, VUMC's operating revenues may decline. See Note 4 Patient Service Revenue, Patient Accounts Receivable, and Estimated Third-Party Settlements, for further information regarding healthcare revenues and related receivables.
- **HIPAA Compliance.** Under the Health Insurance Portability and Accountability Act of 1996 ("HIPAA"), the federal government has authority to complete fraud and abuse investigations. HIPAA has established substantial fines and penalties for offenders. VUMC maintains policies, procedures, and organizational structures to enforce and monitor compliance with HIPAA, as well as other applicable local, state, and federal statutes and regulations.
- **Construction.** VUMC had contractual commitments under major construction and equipment contracts totaling \$90.2 million and \$113.7 million as of June 30, 2020 and 2019, respectively.
- **Letter of Credit.** As a requirement of the assignment of the 100 Oaks Lease described in Note 13 Leases, VUMC provided an irrevocable standby letter of credit of \$25.0 million to the landlord of the property dated June 10, 2016.

Vanderbilt University Medical Center

Notes to Consolidated Financial Statements

June 30, 2020 and 2019

19. Other Events

COVID-19

In January of Fiscal 2020, the Secretary of the U.S. Department of Health and Human Services (“HHS”) declared a national public emergency due to a novel strain of coronavirus. During March of this fiscal year, the World Health Organization designated the outbreak of this coronavirus, known as COVID-19, as a global pandemic. This global health crisis has impacted many facets of our business. Patient volumes and the related revenue for most services were significantly lower in the fourth quarter of Fiscal 2020 as various policies were implemented by federal, state and local governments in response, including stay-at-home orders issued by the Governor of Tennessee and Mayor of Nashville resulting in business closures, social distancing and suspension of elective and nonemergent procedures. Potential changes in payor mix were evaluated to determine impact on collectability estimates and ultimately the recognition of revenue. VUMC experienced supply chain disruptions, including price increases in medical supplies, particularly personal protective equipment. The pandemic also created significant volatility in the U.S. and global financial markets that impacted VUMC’s investment portfolios. Through June 30, 2020, volumes rebounded from the mid-March through mid-May periods with many metrics approaching pre-COVID-19 levels, as certain of these policies, such as stay-at-home orders and suspension of elective and nonemergent procedures were lifted. Due to the evolving nature of the COVID-19 pandemic, despite these positive indicators, the ultimate impact to VUMC and its financial condition is presently unknown.

Sources of pandemic relief include the federal stimulus package known as The Coronavirus Aid, Relief, and Economic Security (“CARES”) Act, which was signed into law on March 27, 2020. The Act provides an estimated \$2.2 trillion to fight the COVID-19 pandemic, stimulate the U.S. economy and provide emergency assistance to affected individuals and businesses, including hospitals and other healthcare providers. The CARES Act includes a number of provisions important to our industry, including \$100.0 billion under the Public Health and Social Services Emergency Fund (“Provider Relief Fund”) to reimburse eligible health care providers for health care-related expenses or lost revenues not otherwise reimbursed that are directly attributable to COVID-19. These provider relief funds included \$50 billion distributed to providers based on their share of the Medicare fee-for-service reimbursement (“General Distributions”). Also included was funding for certain targeted distributions (“Targeted Distributions”) to qualifying providers (primarily rural and high impact areas). As of June 30, 2020, VUMC has recognized approximately \$83.3 million in General Distributions and \$35.7 million in Targeted Distributions, for a total of \$119.0 million, under the Provider Relief Fund of the CARES Act. These amounts are presented in Other operating revenue in our consolidated statement of operations.

In addition, the CARES Act provides for an expansion of the Medicare Accelerated and Advance Payment Program whereby inpatient acute care hospitals and other eligible providers may request accelerated payment of up to 100% of their Medicare payment amount for a six-month period to be repaid through withholding of future Medicare fee-for-service payments beginning 120 days after receipt. During Fiscal 2020, VUMC received advance payments from Medicare of \$222.4 million, which has been recorded as a current liability on our consolidated balance sheet.

On October 1, 2020, a continuing resolution for the Medicare Accelerated and Advance Payment Program was signed (the Resolution), updating key provisions of the program. Under the revised terms of the program, health care providers will have one year before the Centers for Medicare and Medicaid Services (CMS) begins to recoup these advance payments by offsetting them against newly submitted claims. Additionally, once the recoupment period begins, for the first 11 months,

Vanderbilt University Medical Center

Notes to Consolidated Financial Statements

June 30, 2020 and 2019

only 25% of the claims amount will be withheld, and for the following 6 months, only 50% of the claims amount will be withheld. In total, a provider will have 29 months from the first payment to repay these advances. After the repayment period expires, the remaining balance will be subject to interest. The interest rate, which was previously 10.25%, has been reduced to 4%. VUMC is still assessing the impact the Resolution will have on the consolidated financial statements, if any.

The CARES Act also allows for deferred payment of the employer portion of certain payroll taxes between March 27, 2020 and December 31, 2020, with 50% due December 31, 2021 and the remaining 50% due December 31, 2022. VUMC began deferring these payroll tax payments during the fourth quarter of Fiscal 2020. As of June 30, 2020, VUMC had deferred payroll tax payments of approximately \$27.6 million, which are included in Other noncurrent liabilities in the consolidated balance sheet.

Through the Paycheck Protection Program and Health Care Enhancement Act (the "PPHCE Act"), which was enacted on April 24, 2020, we recognized an additional \$11.4 million as a payroll retention credit in Other operating revenue.

To provide more liquidity during the global health crisis, we drew on our \$100.0 million existing line of credit and executed the \$300.0 million Series 2020A Loan. We also executed three additional lines of credit totaling \$150.0 million out of an abundance of caution. As of June 30, 2020, no amounts have been drawn on the new lines of credit. These agreements were discussed further in Note 11 Long-Term Debt.

Subsequent to June 30, 2020 and through the date this report was issued, VUMC has received an additional \$9.5 million in Targeted Distributions.

Acquisition of VWCH

Effective August 1, 2019, VUMC acquired a two-campus hospital facility licensed for 245 beds from Community Health Systems, Inc. ("CHS"): Tennova Healthcare – Lebanon, now known as Vanderbilt Wilson County Hospital ("VWCH") for total consideration of \$19.3 million. VUMC's acquisition included not only the two-campus hospital facilities, but also related physician clinic operations and outpatient services that now bear the Vanderbilt name including: Vanderbilt Surgery Center, Vanderbilt Sleep Disorders Center, Vanderbilt Primary Care, Vanderbilt Primary Care Walk-In, and Vanderbilt Gastroenterology. VWCH is staffed by more than 200 community physicians and employs approximately 600 administrators, nurses, and support personnel. After the acquisition, VUMC retained substantially all employees of the hospital's previous owner.

The following table summarizes the fair value of net assets acquired:

(\$ in thousands)

Inventories	\$ 2,966
Other current assets	865
Property, plant, and equipment, net	15,780
Accounts payable and other accrued expenses	(359)
Total invested capital	<u>\$ 19,252</u>

Vanderbilt University Medical Center
Notes to Consolidated Financial Statements
June 30, 2020 and 2019

20. Subsequent Events

On September 19, 2020, the Department of Health and Human Services (HHS) released additional reporting requirements for health care entities that have received either (or both) General and Targeted Distributions from the Provider Relief Fund (PRF). The Post-Payment Notice of Reporting Requirements (the Notice) changes previous reporting requirement guidance issued on July 20, 2020 and amended on August 14, 2020 and could have an impact on how health care entities account for and record PRF payments. HHS intends to issue Frequently Asked Questions to aid in the reporting process. VUMC is still assessing the impact the Notice will have on the consolidated financial statements, if any.

On September 30, 2020, VUMC announced plans to purchase two hospitals from subsidiaries of CHS. The two hospitals (Tennova Healthcare-Shelbyville and Tennova Healthcare-Harton) have a total of 195 beds. A definitive agreement has been executed for the sale of the facilities and related businesses, including physician clinic operations and other outpatient services. VUMC also announced plans to acquire a minority ownership interest in CHS's Tennova Healthcare-Clarksville hospital, a 270-bed facility, from CHS's existing minority partner, GHS Holdings, LLC, a wholly-owned subsidiary of Clarksville Volunteer Health, Inc., a non-profit corporation based in Clarksville, TN. The definitive agreement provides for VUMC to acquire GHS Holdings' 20% ownership interest in Tennova Healthcare-Clarksville and related physician practices.

Management evaluated events after June 30, 2020 through October 13, 2020, the date on which the consolidated financial statements were issued. During this period, other than discussed previously, there were no subsequent events requiring recognition or disclosure in the consolidated financial statements that have not been recorded or disclosed.

Supplementary Information

Vanderbilt University Medical Center
Schedule of Expenditures of Federal Awards and State Financial Assistance
Fiscal Period 7/1/2019 – 6/30/2020

<i>Federal Awarding Agency/Program Title</i>	<i>Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
DEPARTMENT OF AGRICULTURE									
AGRICULTURAL RESEARCH_BASIC AND APPLIED RESEARCH	10.001	59-0210-6-004	US CIVILIAN RESEARCH AND DEVELOPMENT FOUNDATION	59-0210-6-004		\$27,498	\$85,948	RESEARCH AND DEVELOPMENT	\$357,858,137
AGRICULTURAL RESEARCH_BASIC AND APPLIED RESEARCH	10.001	59-0210-6-004	US CIVILIAN RESEARCH AND DEVELOPMENT FOUNDATION	59-0210-6-004		\$6,779	\$85,948	RESEARCH AND DEVELOPMENT	\$357,858,137
AGRICULTURAL RESEARCH_BASIC AND APPLIED RESEARCH	10.001	59-0210-6-004	US CIVILIAN RESEARCH AND DEVELOPMENT FOUNDATION	59-0210-6-004		\$3,195	\$85,948	RESEARCH AND DEVELOPMENT	\$357,858,137
AGRICULTURAL RESEARCH_BASIC AND APPLIED RESEARCH	10.001	59-0210-8-184	US CIVILIAN RESEARCH AND DEVELOPMENT FOUNDATION	59-0210-8-184		\$47,457	\$85,948	RESEARCH AND DEVELOPMENT	\$357,858,137
AGRICULTURAL RESEARCH_BASIC AND APPLIED RESEARCH	10.001	59-0210-8-184	US CIVILIAN RESEARCH AND DEVELOPMENT FOUNDATION	59-0210-8-184		\$1,019	\$85,948	RESEARCH AND DEVELOPMENT	\$357,858,137
AGRICULTURE AND FOOD RESEARCH INITIATIVE (AFRI)	10.310	2017-68001-26352			\$155,673	\$400,612	\$400,612	RESEARCH AND DEVELOPMENT	\$357,858,137
TOTAL DEPARTMENT OF AGRICULTURE					\$155,673	\$486,560			
DEPARTMENT OF DEFENSE									
COLLABORATIVE RESEARCH AND DEVELOPMENT	12.114	W912HQ-16-C-0033	UNIVERSITY OF PITTSBURGH	W912HQ-16-C-0033		\$169,154	\$169,154	RESEARCH AND DEVELOPMENT	\$357,858,137
BASIC SCIENTIFIC RESEARCH - COMBATING WEAPONS OF MASS DESTRUCTION	12.351	HDTRA1-13-1-0034			-\$837	\$0	\$0	RESEARCH AND DEVELOPMENT	\$357,858,137
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-10-2-0133			\$93,908	\$106,037	\$8,431,018	RESEARCH AND DEVELOPMENT	\$357,858,137
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-12-1-0159			\$34,093	\$34,093	\$8,431,018	RESEARCH AND DEVELOPMENT	\$357,858,137
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-15-1-0259			\$132,992	\$136,520	\$8,431,018	RESEARCH AND DEVELOPMENT	\$357,858,137
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-15-1-0328			\$29,639	\$8,431,018	\$8,431,018	RESEARCH AND DEVELOPMENT	\$357,858,137
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-15-1-0559				\$9,053	\$8,431,018	RESEARCH AND DEVELOPMENT	\$357,858,137
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-15-1-0622				\$347	\$8,431,018	RESEARCH AND DEVELOPMENT	\$357,858,137
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-16-1-0605			\$20,367	\$220,270	\$8,431,018	RESEARCH AND DEVELOPMENT	\$357,858,137
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-16-1-0622				\$215,798	\$8,431,018	RESEARCH AND DEVELOPMENT	\$357,858,137
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-16-2-0061			\$78,091	\$128,918	\$8,431,018	RESEARCH AND DEVELOPMENT	\$357,858,137
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-17-1-0257				\$171,965	\$8,431,018	RESEARCH AND DEVELOPMENT	\$357,858,137
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-17-1-0304				\$194,198	\$8,431,018	RESEARCH AND DEVELOPMENT	\$357,858,137
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-17-1-0308				\$171,892	\$8,431,018	RESEARCH AND DEVELOPMENT	\$357,858,137
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-17-1-0309				\$102,203	\$8,431,018	RESEARCH AND DEVELOPMENT	\$357,858,137
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-17-1-0328			-\$73	\$24,871	\$8,431,018	RESEARCH AND DEVELOPMENT	\$357,858,137
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-17-1-0345				\$33,096	\$8,431,018	RESEARCH AND DEVELOPMENT	\$357,858,137
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-17-1-0442				\$418,404	\$8,431,018	RESEARCH AND DEVELOPMENT	\$357,858,137
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-17-1-0503				\$468,875	\$8,431,018	RESEARCH AND DEVELOPMENT	\$357,858,137
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-17-2-0003			\$41,569	\$249,098	\$8,431,018	RESEARCH AND DEVELOPMENT	\$357,858,137
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-17-2-0055			\$79,617	\$494,298	\$8,431,018	RESEARCH AND DEVELOPMENT	\$357,858,137
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-18-1-0029				\$325,406	\$8,431,018	RESEARCH AND DEVELOPMENT	\$357,858,137
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-18-1-0149				\$648,555	\$8,431,018	RESEARCH AND DEVELOPMENT	\$357,858,137
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-18-1-0301			\$18,180	\$262,465	\$8,431,018	RESEARCH AND DEVELOPMENT	\$357,858,137
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-18-1-0536			\$18,806	\$150,926	\$8,431,018	RESEARCH AND DEVELOPMENT	\$357,858,137
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-18-1-0683				\$258,387	\$8,431,018	RESEARCH AND DEVELOPMENT	\$357,858,137
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-18-1-0719				-\$21	\$8,431,018	RESEARCH AND DEVELOPMENT	\$357,858,137
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-18-1-0810			\$203,823	\$410,817	\$8,431,018	RESEARCH AND DEVELOPMENT	\$357,858,137
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-18-1-0814			\$25,422	\$248,091	\$8,431,018	RESEARCH AND DEVELOPMENT	\$357,858,137
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-19-1-0090				\$97,992	\$8,431,018	RESEARCH AND DEVELOPMENT	\$357,858,137
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-19-1-0415				\$182,053	\$8,431,018	RESEARCH AND DEVELOPMENT	\$357,858,137
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-19-1-0446				\$145,897	\$8,431,018	RESEARCH AND DEVELOPMENT	\$357,858,137
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-19-1-0580				\$70,532	\$8,431,018	RESEARCH AND DEVELOPMENT	\$357,858,137
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-19-1-0640			\$58,898	\$112,332	\$8,431,018	RESEARCH AND DEVELOPMENT	\$357,858,137
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-19-1-0782				\$97,400	\$8,431,018	RESEARCH AND DEVELOPMENT	\$357,858,137
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-19-1-0812				\$193,725	\$8,431,018	RESEARCH AND DEVELOPMENT	\$357,858,137
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-20-1-0269				\$19,945	\$8,431,018	RESEARCH AND DEVELOPMENT	\$357,858,137
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-10-2-0090	JOHNS HOPKINS UNIVERSITY	W81XWH-10-2-0090	\$25,290	\$8,431,018	\$8,431,018	RESEARCH AND DEVELOPMENT	\$357,858,137
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-15-1-0023	UNIVERSITY OF TENNESSEE	W81XWH-15-1-0023	\$46,612	\$8,431,018	\$8,431,018	RESEARCH AND DEVELOPMENT	\$357,858,137
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-15-2-0046	DUKE UNIVERSITY	W81XWH-15-2-0046	\$9,619	\$8,431,018	\$8,431,018	RESEARCH AND DEVELOPMENT	\$357,858,137
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-15-2-0068	VANDERBILT UNIVERSITY	W81XWH-15-2-0068	\$36,958	\$8,431,018	\$8,431,018	RESEARCH AND DEVELOPMENT	\$357,858,137

Vanderbilt University Medical Center
Schedule of Expenditures of Federal Awards and State Financial Assistance
Fiscal Period 7/1/2019 – 6/30/2020

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-15-2-0068	VANDERBILT UNIVERSITY	W81XWH-15-2-0068		\$24,732	\$8,431,018	RESEARCH AND DEVELOPMENT	\$357,858,137
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-15-2-0074	JOHNS HOPKINS UNIVERSITY	W81XWH-15-2-0074		\$79	\$8,431,018	RESEARCH AND DEVELOPMENT	\$357,858,137
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-16-1-0063	VANDERBILT UNIVERSITY	W81XWH-16-1-0063		-\$400	\$8,431,018	RESEARCH AND DEVELOPMENT	\$357,858,137
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-16-1-0559	VANDERBILT UNIVERSITY	W81XWH-16-1-0559		\$3,334	\$8,431,018	RESEARCH AND DEVELOPMENT	\$357,858,137
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-16-2-0003	FLORIDA STATE	W81XWH-16-2-0003		\$196,871	\$8,431,018	RESEARCH AND DEVELOPMENT	\$357,858,137
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-16-2-0052	VANDERBILT UNIVERSITY	W81XWH-16-2-0052		\$12,385	\$8,431,018	RESEARCH AND DEVELOPMENT	\$357,858,137
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-16-2-0060	JOHNS HOPKINS UNIVERSITY	W81XWH-16-2-0060		\$359,682	\$8,431,018	RESEARCH AND DEVELOPMENT	\$357,858,137
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-16-D-0024	UNIVERSITY OF PITTSBURGH	W81XWH-16-D-0024		\$73,295	\$8,431,018	RESEARCH AND DEVELOPMENT	\$357,858,137
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-16-D-0024	UNIVERSITY OF PITTSBURGH	W81XWH-16-D-0024		\$39,023	\$8,431,018	RESEARCH AND DEVELOPMENT	\$357,858,137
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-17-1-0597	UNIVERSITY OF COLORADO	W81XWH-17-1-0597		\$9,904	\$8,431,018	RESEARCH AND DEVELOPMENT	\$357,858,137
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-17-1-0610	UNIVERSITY OF PITTSBURGH	W81XWH-17-1-0610		\$415,058	\$8,431,018	RESEARCH AND DEVELOPMENT	\$357,858,137
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-17-1-0631	UNIVERSITY OF CALIFORNIA AT SAN FRANCISCO	W81XWH-17-1-0631		\$190,851	\$8,431,018	RESEARCH AND DEVELOPMENT	\$357,858,137
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-17-1-0702	UNIVERSITY OF MARYLAND	W81XWH-17-1-0702		\$26,146	\$8,431,018	RESEARCH AND DEVELOPMENT	\$357,858,137
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-18-1-0234	VANDERBILT UNIVERSITY	W81XWH-18-1-0234		\$53,921	\$8,431,018	RESEARCH AND DEVELOPMENT	\$357,858,137
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-18-1-0412	VANDERBILT UNIVERSITY	W81XWH-18-1-0412		\$13,804	\$8,431,018	RESEARCH AND DEVELOPMENT	\$357,858,137
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-18-1-0719	NATIONAL JEWISH HEALTH	W81XWH-18-1-0719		\$9,039	\$8,431,018	RESEARCH AND DEVELOPMENT	\$357,858,137
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-18-1-0790	UNIVERSITY OF ROCHESTER	W81XWH-18-1-0790		\$113,226	\$8,431,018	RESEARCH AND DEVELOPMENT	\$357,858,137
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-18-1-0790	UNIVERSITY OF ROCHESTER	W81XWH-18-1-0790		\$325,907	\$8,431,018	RESEARCH AND DEVELOPMENT	\$357,858,137
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-19-1-0405	IDBIOLOGICS, LLC	W81XWH-19-1-0405		\$11,781	\$8,431,018	RESEARCH AND DEVELOPMENT	\$357,858,137
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-12-1-0159				-\$176	\$8,431,018	RESEARCH AND DEVELOPMENT	\$357,858,137
BASIC SCIENTIFIC RESEARCH	12.431	W911NF-14-2-0022	VANDERBILT UNIVERSITY	W911NF-14-2-0022		\$191,985	\$191,985	RESEARCH AND DEVELOPMENT	\$357,858,137
UNIFORMED SERVICES UNIVERSITY MEDICAL RESEARCH PROJECTS	12.750	HU0001-17-2-0023	HENRY M. JACKSON FOUNDATION	HU0001-17-2-0023		\$8,783	\$8,783	RESEARCH AND DEVELOPMENT	\$357,858,137
AIR FORCE DEFENSE RESEARCH SCIENCES PROGRAM	12.800	FA8650-16-2-6G02	UNIVERSITY OF CINCINNATI	FA8650-16-2-6G02		\$41,494	\$41,494	RESEARCH AND DEVELOPMENT	\$357,858,137
RESEARCH AND TECHNOLOGY DEVELOPMENT	12.910	HR0011-18-2-0001			\$2,051,080	\$2,819,491	\$4,172,645	RESEARCH AND DEVELOPMENT	\$357,858,137
RESEARCH AND TECHNOLOGY DEVELOPMENT	12.910	D17AP00023	UNIVERSITY OF TENNESSEE	D17AP00023		\$2,812	\$4,172,645	RESEARCH AND DEVELOPMENT	\$357,858,137
RESEARCH AND TECHNOLOGY DEVELOPMENT	12.910	HR0011-17-2-0023	INSTITUT PASTEUR	HR0011-17-2-0023		\$2,608	\$4,172,645	RESEARCH AND DEVELOPMENT	\$357,858,137
COVID-19 RESEARCH AND TECHNOLOGY DEVELOPMENT	12.910	COVID-19 HR0011-18-2-0001				\$1,347,734	\$4,172,645	RESEARCH AND DEVELOPMENT	\$357,858,137
W81XWH-17-C-0252	12.RD	W81XWH-17-C-0252			\$236,369	\$525,452	\$525,452	RESEARCH AND DEVELOPMENT	\$357,858,137
TOTAL DEPARTMENT OF DEFENSE					\$3,092,305	\$13,540,531			
DEPARTMENT OF JUSTICE									
CRIME VICTIM ASSISTANCE	16.575	63811:ST TN	TN DEPARTMENT OF CHILDREN'S SERVICES	63811:ST TN		\$169,371	\$169,371	RESEARCH AND DEVELOPMENT	\$357,858,137
HAROLD ROGERS PRESCRIPTION DRUG MONITORING PROGRAM	16.754	64793:ST TN	TN DEPARTMENT OF HEALTH	64793:ST TN		\$55,697	\$55,697	RESEARCH AND DEVELOPMENT	\$357,858,137
COMPREHENSIVE OPIOID ABUSE SITE-BASED PROGRAM	16.838	65987:ST TN	TN DEPARTMENT OF MENTAL HEALTH AND DEVELOPMENTAL DISABILITIES	65987:ST TN		\$3,170	\$5,398	RESEARCH AND DEVELOPMENT	\$357,858,137
COMPREHENSIVE OPIOID ABUSE SITE-BASED PROGRAM	16.838	66183:ST TN	TN DEPARTMENT OF MENTAL HEALTH AND DEVELOPMENTAL DISABILITIES	66183:ST TN		\$2,228	\$5,398	RESEARCH AND DEVELOPMENT	\$357,858,137
15JC1V19P00000597	16.RD	15JC1V19P00000597				\$165,984	\$165,984	RESEARCH AND DEVELOPMENT	\$357,858,137
TOTAL DEPARTMENT OF JUSTICE						\$396,450			
DEPARTMENT OF TREASURY									
COVID-19 CORONAVIRUS RELIEF FUND	21.019	COVID-19 TN COMMUNITY CARES PROGRAM	UNITED WAY OF GREATER NASHVILLE	TN COMMUNITY CARES PROGRAM		\$483,312	\$483,312	N/A	\$0
TOTAL DEPARTMENT OF TREASURY						\$483,312			
NATIONAL AERONAUTICS & SPACE ADMINISTRATION									
EXPLORATION	43.003	80NCCS19M0161	NATIONAL COUNCIL ON RADIATION PROTECTION AND MEASUREMENTS	80NCCS19M0161		\$87,284	\$87,284	RESEARCH AND DEVELOPMENT	\$357,858,137
TOTAL NATIONAL AERONAUTICS & SPACE ADMINISTRATION						\$87,284			

Vanderbilt University Medical Center
Schedule of Expenditures of Federal Awards and State Financial Assistance
Fiscal Period 7/1/2019 – 6/30/2020

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
INSTITUTE OF MUSEUM AND LIBRARY SERVICES OR NATIONAL ENDOWMENT FOR THE ARTS OR NATIONAL ENDOWMENT FOR THE HUMANITIES									
PROMOTION OF THE ARTS_ GRANTS TO ORGANIZATIONS AND INDIVIDUALS	45.024	1884433-38-C-18				\$62,225	\$62,225	RESEARCH AND DEVELOPMENT	\$357,858,137
						\$62,225			
NATIONAL SCIENCE FOUNDATION									
ENGINEERING	47.041	IIP-1912903				\$5,267	\$8,899	RESEARCH AND DEVELOPMENT	\$357,858,137
ENGINEERING	47.041	CBET-1605200	VANDERBILT UNIVERSITY	CBET-1605200		\$1,084	\$8,899	RESEARCH AND DEVELOPMENT	\$357,858,137
ENGINEERING	47.041	CBET-1705714	VANDERBILT UNIVERSITY	CBET-1705714		\$2,548	\$8,899	RESEARCH AND DEVELOPMENT	\$357,858,137
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	NSF CNS-1757644				\$19,021	\$85,499	RESEARCH AND DEVELOPMENT	\$357,858,137
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	NSF IIS-1418504				\$66,478	\$85,499	RESEARCH AND DEVELOPMENT	\$357,858,137
BIOLOGICAL SCIENCES	47.074	NSF IOS-1557634				\$89,427	\$205,854	RESEARCH AND DEVELOPMENT	\$357,858,137
BIOLOGICAL SCIENCES	47.074	1814520	UNIVERSITY OF TENNESSEE	1814520		\$107,573	\$205,854	RESEARCH AND DEVELOPMENT	\$357,858,137
BIOLOGICAL SCIENCES	47.074	1845634	UNIVERSITY OF MASSACHUSETTS	1845634		\$8,854	\$205,854	RESEARCH AND DEVELOPMENT	\$357,858,137
SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	47.075	1840896	VANDERBILT UNIVERSITY	1840896		\$19,245	\$19,245	RESEARCH AND DEVELOPMENT	\$357,858,137
EDUCATION AND HUMAN RESOURCES	47.076	NSF DUE-1926794				\$38,293	\$38,293	RESEARCH AND DEVELOPMENT	\$357,858,137
OFFICE OF INTERNATIONAL SCIENCE AND ENGINEERING	47.079	OISE-19-66185-1	US CIVILIAN RESEARCH AND DEVELOPMENT FOUNDATION	OISE-19-66185-1		\$3,059	\$29,053	RESEARCH AND DEVELOPMENT	\$357,858,137
OFFICE OF INTERNATIONAL SCIENCE AND ENGINEERING	47.079	OISE-9531011	US CIVILIAN RESEARCH AND DEVELOPMENT FOUNDATION	OISE-9531011		\$25,994	\$29,053	RESEARCH AND DEVELOPMENT	\$357,858,137
INTEGRATIVE ACTIVITIES	47.083	1936970	VANDERBILT UNIVERSITY	1936970		\$89,879	\$89,879	RESEARCH AND DEVELOPMENT	\$357,858,137
						\$476,722			
ENVIRONMENTAL PROTECTION AGENCY									
SCIENCE TO ACHIEVE RESULTS (STAR) RESEARCH PROGRAM	66.509	RD-83950101-0				\$39,465	\$188,454	RESEARCH AND DEVELOPMENT	\$357,858,137
SCIENCE TO ACHIEVE RESULTS (STAR) RESEARCH PROGRAM	66.509	83573601	VANDERBILT UNIVERSITY	83573601		\$31,483	\$245,648	RESEARCH AND DEVELOPMENT	\$357,858,137
SCIENCE TO ACHIEVE RESULTS (STAR) RESEARCH PROGRAM	66.509	83927501	MEHARRY MEDICAL COLLEGE	83927501		\$16,964	\$245,648	RESEARCH AND DEVELOPMENT	\$357,858,137
SCIENCE TO ACHIEVE RESULTS (STAR) RESEARCH PROGRAM	66.509	83927501	MEHARRY MEDICAL COLLEGE	83927501		\$8,747	\$245,648	RESEARCH AND DEVELOPMENT	\$357,858,137
						\$39,465	\$245,648		
DEPARTMENT OF ENERGY									
EPIDEMIOLOGY AND OTHER HEALTH STUDIES FINANCIAL ASSISTANCE PROGRAM	81.108	DE-AU000042	NATIONAL COUNCIL ON RADIATION PROTECTION AND MEASUREMENTS	DE-AU000042		\$1,177	\$1,177	RESEARCH AND DEVELOPMENT	\$357,858,137
NUCLEAR ENERGY RESEARCH, DEVELOPMENT AND DEMONSTRATION	81.121	DE-NE0008664	VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY	DE-NE0008664		\$168,398	\$168,398	RESEARCH AND DEVELOPMENT	\$357,858,137
						\$169,575			
DEPARTMENT OF EDUCATION									
SPECIAL EDUCATION_ GRANTS TO STATES	84.027	33136-00718	VANDERBILT UNIVERSITY	33136-00718		\$4,545	\$2,963,001	SPECIAL EDUCATION CLUSTER (IDEA)	\$3,171,870
SPECIAL EDUCATION_ GRANTS TO STATES	84.027	45026:ST TN	TN DEPARTMENT OF EDUCATION	45026:ST TN		\$331,754	\$2,963,001	SPECIAL EDUCATION CLUSTER (IDEA)	\$3,171,870
SPECIAL EDUCATION_ GRANTS TO STATES	84.027	45237:ST TN	TN DEPARTMENT OF EDUCATION	45237:ST TN	\$111,266	\$2,568,587	\$2,963,001	SPECIAL EDUCATION CLUSTER (IDEA)	\$3,171,870
SPECIAL EDUCATION_ GRANTS TO STATES	84.027	H027A140052-14A	VANDERBILT UNIVERSITY	H027A140052-14A		\$58,115	\$2,963,001	SPECIAL EDUCATION CLUSTER (IDEA)	\$3,171,870
REHABILITATION SERVICES_ VOCATIONAL REHABILITATION GRANTS TO STATES	84.126	34570-91018	VANDERBILT UNIVERSITY	34570-91018		\$36,040	\$36,040	N/A	\$0
SPECIAL EDUCATION_ PRESCHOOL GRANTS	84.173	49454:ST TN	TN DEPARTMENT OF EDUCATION	49454:ST TN		\$3,906	\$208,869	SPECIAL EDUCATION CLUSTER (IDEA)	\$3,171,870
SPECIAL EDUCATION_ PRESCHOOL GRANTS	84.173	49454:ST TN	TN DEPARTMENT OF EDUCATION	49454:ST TN		\$204,963	\$208,869	SPECIAL EDUCATION CLUSTER (IDEA)	\$3,171,870
SPECIAL EDUCATION-GRANTS FOR INFANTS AND FAMILIES	84.181	49965:ST TN	TN DEPARTMENT OF EDUCATION	49965:ST TN		\$11	\$954,789	N/A	\$0
SPECIAL EDUCATION-GRANTS FOR INFANTS AND FAMILIES	84.181	54078:ST TN	TN DEPARTMENT OF EDUCATION	54078:ST TN		-\$430	\$954,789	N/A	\$0
SPECIAL EDUCATION-GRANTS FOR INFANTS AND FAMILIES	84.181	62363:ST TN	TN DEPARTMENT OF EDUCATION	62363:ST TN		\$955,208	\$954,789	N/A	\$0
RESEARCH IN SPECIAL EDUCATION	84.324	R324 A160300				\$46,500	\$315,508	RESEARCH AND DEVELOPMENT	\$357,858,137
RESEARCH IN SPECIAL EDUCATION	84.324	R324 A180171-19	VANDERBILT UNIVERSITY	R324 A180171-19		\$100,723	\$416,231	RESEARCH AND DEVELOPMENT	\$357,858,137
SPECIAL EDUCATION - PERSONNEL DEVELOPMENT TO IMPROVE SERVICES AND RESULTS FOR CHILDREN WITH DISABILITIES	84.325	H325 K160371				\$7,120	\$389,993	N/A	\$0

Vanderbilt University Medical Center
Schedule of Expenditures of Federal Awards and State Financial Assistance
Fiscal Period 7/1/2019 – 6/30/2020

<i>Federal Awarding Agency/Program Title</i>	<i>Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
SPECIAL EDUCATION - PERSONNEL DEVELOPMENT TO IMPROVE SERVICES AND RESULTS FOR CHILDREN WITH DISABILITIES	84.325	H325 K190046				\$118,590	\$389,993	N/A	\$0
SPECIAL EDUCATION - PERSONNEL DEVELOPMENT TO IMPROVE SERVICES AND RESULTS FOR CHILDREN WITH DISABILITIES	84.325	H325 K190064				\$140,211	\$389,993	N/A	\$0
SPECIAL EDUCATION - PERSONNEL DEVELOPMENT TO IMPROVE SERVICES AND RESULTS FOR CHILDREN WITH DISABILITIES	84.325	H325 K190068				\$124,072	\$389,993	N/A	\$0
SPECIAL EDUCATION _TECHNICAL ASSISTANCE AND DISSEMINATION TO IMPROVE SERVICES AND RESULTS FOR CHILDREN WITH DISABILITIES	84.326	H326 T150002				-\$12,863	\$224,867	N/A	\$0
SPECIAL EDUCATION _TECHNICAL ASSISTANCE AND DISSEMINATION TO IMPROVE SERVICES AND RESULTS FOR CHILDREN WITH DISABILITIES	84.326	H326 T180048				\$237,730	\$224,867	N/A	\$0
TRANSITION PROGRAMS FOR STUDENTS WITH INTELLECTUAL DISABILITIES INTO HIGHER EDUCATION	84.407	P407A150058-19	VANDERBILT UNIVERSITY	P407A150058-19		\$21,911	\$21,911	RESEARCH AND DEVELOPMENT	\$357,858,137
TOTAL DEPARTMENT OF EDUCATION						\$157,766	\$5,215,701		
DEPARTMENT OF HEALTH AND HUMAN SERVICES									
GLOBAL AIDS	93.067	5 NU2 GGH001943-04-00			\$225,786	\$13,934,651	\$23,253,711	N/A	\$0
COVID-19 GLOBAL AIDS	93.067	COVID-19 5 NU2 GGH001943-04-00				\$1,562	\$23,253,711	N/A	\$0
GLOBAL AIDS	93.067	6 NU2 GGH001943-03-10			\$305,774	\$9,317,498	\$23,253,711	N/A	\$0
BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES - PREVENTION AND SURVEILLANCE	93.073	5 NU53 DD000001-03-03				\$1,740	\$1,740	N/A	\$0
HOSPITAL PREPAREDNESS PROGRAM (HPP) AND PUBLIC HEALTH EMERGENCY PREPAREDNESS (PHEP) ALIGNED COOPERATIVE AGREEMENTS	93.074	54788-ST TN	TN DEPARTMENT OF HEALTH	54788-ST TN		\$246,516	\$246,516	N/A	\$0
BLOOD DISORDER PROGRAM: PREVENTION, SURVEILLANCE, AND RESEARCH	93.080	1 NU58 DD000010-01-00	UNIVERSITY OF TENNESSEE	1 NU58 DD000010-01-00		\$8,779	\$29,184	RESEARCH AND DEVELOPMENT	\$357,858,137
BLOOD DISORDER PROGRAM: PREVENTION, SURVEILLANCE, AND RESEARCH	93.080	6 NU27 DD001155-04-02	UNIVERSITY OF NORTH CAROLINA	6 NU27 DD001155-04-02		\$5,190	\$29,184	RESEARCH AND DEVELOPMENT	\$357,858,137
BLOOD DISORDER PROGRAM: PREVENTION, SURVEILLANCE, AND RESEARCH	93.080	6 NU27 DD001155-05-02	UNIVERSITY OF NORTH CAROLINA	6 NU27 DD001155-05-02		\$15,215	\$29,184	RESEARCH AND DEVELOPMENT	\$357,858,137
PREVENTION OF DISEASE, DISABILITY, AND DEATH THROUGH IMMUNIZATION AND CONTROL OF RESPIRATORY AND RELATED DISEASES	93.083	5 U01 IP000979-05			\$6,437	\$30,100	\$775,833	RESEARCH AND DEVELOPMENT	\$357,858,137
PREVENTION OF DISEASE, DISABILITY, AND DEATH THROUGH IMMUNIZATION AND CONTROL OF RESPIRATORY AND RELATED DISEASES	93.083	5 U01 IP000979-06			\$44,132	\$742,397	\$775,833	RESEARCH AND DEVELOPMENT	\$357,858,137
COVID-19 PREVENTION OF DISEASE, DISABILITY, AND DEATH THROUGH IMMUNIZATION AND CONTROL OF RESPIRATORY AND RELATED DISEASES	93.083	COVID-19 5 U01 IP000979-06				\$3,336	\$775,833	RESEARCH AND DEVELOPMENT	\$357,858,137
PREVENTION OF DISEASE, DISABILITY, AND DEATH BY INFECTIOUS DISEASES	93.084	1 U01 CK000512-01	UNIVERSITY OF TEXAS	1 U01 CK000512-01		\$8,492	\$8,492	RESEARCH AND DEVELOPMENT	\$357,858,137
FOOD AND DRUG ADMINISTRATION _RESEARCH	93.103	1 R01 FD006649-01			\$24,263	\$145,751	\$1,024,091	RESEARCH AND DEVELOPMENT	\$357,858,137
FOOD AND DRUG ADMINISTRATION _RESEARCH	93.103	5 R01 FD004778-04			\$46,732	\$46,732	\$1,024,091	RESEARCH AND DEVELOPMENT	\$357,858,137
FOOD AND DRUG ADMINISTRATION _RESEARCH	93.103	5 R01 FD004778-05				\$219,770	\$1,024,091	RESEARCH AND DEVELOPMENT	\$357,858,137
FOOD AND DRUG ADMINISTRATION _RESEARCH	93.103	7 R01 FD004117-05			-\$3,470	-\$3,470	\$1,024,091	RESEARCH AND DEVELOPMENT	\$357,858,137
FOOD AND DRUG ADMINISTRATION _RESEARCH	93.103	5 U01 FD006292-02	DUKE UNIVERSITY	5 U01 FD006292-02		\$12,391	\$1,024,091	RESEARCH AND DEVELOPMENT	\$357,858,137
FOOD AND DRUG ADMINISTRATION _RESEARCH	93.103	5 U01 FD006292-03	DUKE UNIVERSITY	5 U01 FD006292-03		\$55,468	\$1,024,091	RESEARCH AND DEVELOPMENT	\$357,858,137
FOOD AND DRUG ADMINISTRATION _RESEARCH	93.103	5 U01 FD006292-03	MEDICAL DEVICE INNOVATION CONSORTIUM	5 U01 FD006292-03	\$108,511	\$204,333	\$1,024,091	RESEARCH AND DEVELOPMENT	\$357,858,137
FOOD AND DRUG ADMINISTRATION _RESEARCH	93.103	5 U01 FD006292-03	MEDICAL DEVICE INNOVATION CONSORTIUM	5 U01 FD006292-03		\$133,839	\$1,024,091	RESEARCH AND DEVELOPMENT	\$357,858,137
FOOD AND DRUG ADMINISTRATION _RESEARCH	93.103	5 U01 FD006292-03	WAKE FOREST UNIVERSITY	5 U01 FD006292-03		\$2,967	\$1,024,091	RESEARCH AND DEVELOPMENT	\$357,858,137
FOOD AND DRUG ADMINISTRATION _RESEARCH	93.103	5 U02 FD006292-03	MEDICAL DEVICE INNOVATION CONSORTIUM	5 U02 FD006292-03		\$71,915	\$1,024,091	RESEARCH AND DEVELOPMENT	\$357,858,137
FOOD AND DRUG ADMINISTRATION _RESEARCH	93.103	HHSF223201400020I	HARVARD PILGRIM HEALTH CARE	HHSF223201400020I		\$16,393	\$1,024,091	RESEARCH AND DEVELOPMENT	\$357,858,137
FOOD AND DRUG ADMINISTRATION _RESEARCH	93.103	HHSF223201400030I	HARVARD PILGRIM HEALTH CARE	HHSF223201400030I		\$49,022	\$1,024,091	RESEARCH AND DEVELOPMENT	\$357,858,137
FOOD AND DRUG ADMINISTRATION _RESEARCH	93.103	HHSF223201400030I	HARVARD PILGRIM HEALTH CARE	HHSF223201400030I		\$2,384	\$1,024,091	RESEARCH AND DEVELOPMENT	\$357,858,137
FOOD AND DRUG ADMINISTRATION _RESEARCH	93.103	HHSF223201400030I	HARVARD PILGRIM HEALTH CARE	HHSF223201400030I		\$1,058	\$1,024,091	RESEARCH AND DEVELOPMENT	\$357,858,137
FOOD AND DRUG ADMINISTRATION _RESEARCH	93.103	HHSF223201400042I	HARVARD PILGRIM HEALTH CARE	HHSF223201400042I		\$44,832	\$1,024,091	RESEARCH AND DEVELOPMENT	\$357,858,137
FOOD AND DRUG ADMINISTRATION _RESEARCH	93.103	HHSF223201400042I	HARVARD PILGRIM HEALTH CARE	HHSF223201400042I		\$5,726	\$1,024,091	RESEARCH AND DEVELOPMENT	\$357,858,137
FOOD AND DRUG ADMINISTRATION _RESEARCH	93.103	HHSF223201610046C	UNIVERSITY OF COLORADO	HHSF223201610046C		\$231	\$1,024,091	RESEARCH AND DEVELOPMENT	\$357,858,137
FOOD AND DRUG ADMINISTRATION _RESEARCH	93.103	HHSF223201710132C	HARVARD PILGRIM HEALTH CARE	HHSF223201710132C		\$48,023	\$1,024,091	RESEARCH AND DEVELOPMENT	\$357,858,137
FOOD AND DRUG ADMINISTRATION _RESEARCH	93.103	5 R01 FD004778-04				-\$33,274	\$1,024,091	RESEARCH AND DEVELOPMENT	\$357,858,137

Vanderbilt University Medical Center
Schedule of Expenditures of Federal Awards and State Financial Assistance
Fiscal Period 7/1/2019 – 6/30/2020

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total	
COMPREHENSIVE COMMUNITY MENTAL HEALTH SERVICES FOR CHILDREN WITH SERIOUS EMOTIONAL DISTURBANCES (SED)	93.104	60896:ST TN	TN DEPARTMENT OF MENTAL HEALTH AND DEVELOPMENTAL DISABILITIES	60896:ST TN		\$44,020	\$197,591	N/A	\$0	
COMPREHENSIVE COMMUNITY MENTAL HEALTH SERVICES FOR CHILDREN WITH SERIOUS EMOTIONAL DISTURBANCES (SED)	93.104	60896:ST TN	TN DEPARTMENT OF MENTAL HEALTH AND DEVELOPMENTAL DISABILITIES	60896:ST TN		\$153,571	\$197,591	N/A	\$0	
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110	5 H30 MC24046-04-00	HEMPHILIA OF GEORGIA, INC.	5 H30 MC24046-04-00		\$3,307,105	\$4,395,942	RESEARCH AND DEVELOPMENT	\$357,858,137	
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110	5 H30 MC24046-08-00	HEMPHILIA OF GEORGIA, INC.	5 H30 MC24046-08-00		\$15,049	\$4,395,942	RESEARCH AND DEVELOPMENT	\$357,858,137	
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110	5 UA3 MC11054-11-00	MASSACHUSETTS GENERAL HOSPITAL	5 UA3 MC11054-11-00		\$73,973	\$4,395,942	RESEARCH AND DEVELOPMENT	\$357,858,137	
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110	6 UA3 MC11054-10-00	MASSACHUSETTS GENERAL HOSPITAL	6 UA3 MC11054-10-00		\$5,262	\$4,395,942	RESEARCH AND DEVELOPMENT	\$357,858,137	
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110	6 UA3 MC11054-10-00	MASSACHUSETTS GENERAL HOSPITAL	6 UA3 MC11054-10-00		\$37,961	\$4,395,942	RESEARCH AND DEVELOPMENT	\$357,858,137	
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110	6 UA3 MC11054-11-00	MASSACHUSETTS GENERAL HOSPITAL	6 UA3 MC11054-11-00		\$19,649	\$4,395,942	RESEARCH AND DEVELOPMENT	\$357,858,137	
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110	1 H6M MC03236-01-00				\$145,628	\$4,395,942	RESEARCH AND DEVELOPMENT	\$357,858,137	
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110	5 T73 MC030767-04-00			\$211,462	\$783,215	\$4,395,942	RESEARCH AND DEVELOPMENT	\$357,858,137	
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110	7 T73 MC030767-03-01				\$8,100	\$4,395,942	RESEARCH AND DEVELOPMENT	\$357,858,137	
ENVIRONMENTAL HEALTH	93.113	1 R01 ES031401-01			\$20,170	\$92,777	\$344,023	RESEARCH AND DEVELOPMENT	\$357,858,137	
ENVIRONMENTAL HEALTH	93.113	2 R01 ES010563-17	PURDUE UNIVERSITY	2 R01 ES010563-17		\$59,121	\$344,023	RESEARCH AND DEVELOPMENT	\$357,858,137	
			ALBERT EINSTEIN COLLEGE OF MEDICINE							
ENVIRONMENTAL HEALTH	93.113	5 R01 ES007331-24	OF YESHIVA UNIVERSITY	5 R01 ES007331-24		-\$3,210	\$344,023	RESEARCH AND DEVELOPMENT	\$357,858,137	
ENVIRONMENTAL HEALTH	93.113	5 R01 ES007331-25	PURDUE UNIVERSITY	5 R01 ES007331-25		\$126,572	\$344,023	RESEARCH AND DEVELOPMENT	\$357,858,137	
ENVIRONMENTAL HEALTH	93.113	5 R01 ES027845-03	COLUMBIA UNIVERSITY	5 R01 ES027845-03		\$21,348	\$344,023	RESEARCH AND DEVELOPMENT	\$357,858,137	
ENVIRONMENTAL HEALTH	93.113	7 R01 ES016931-12	PURDUE UNIVERSITY	7 R01 ES016931-12		\$47,415	\$344,023	RESEARCH AND DEVELOPMENT	\$357,858,137	
ORAL DISEASES AND DISORDERS RESEARCH	93.121	1 R01 DE027749-01			\$93,599	\$620,516	\$929,993	RESEARCH AND DEVELOPMENT	\$357,858,137	
ORAL DISEASES AND DISORDERS RESEARCH	93.121	1 R01 DE029650-01				\$14,537	\$929,993	RESEARCH AND DEVELOPMENT	\$357,858,137	
ORAL DISEASES AND DISORDERS RESEARCH	93.121	1 R21 DE029002-01				\$154,093	\$929,993	RESEARCH AND DEVELOPMENT	\$357,858,137	
ORAL DISEASES AND DISORDERS RESEARCH	93.121	5 K23 DE028010-02				\$124,850	\$929,993	RESEARCH AND DEVELOPMENT	\$357,858,137	
			UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON							
ORAL DISEASES AND DISORDERS RESEARCH	93.121	1 R03 DE027494-01		1 R03 DE027494-01		\$15,997	\$929,993	RESEARCH AND DEVELOPMENT	\$357,858,137	
EMERGENCY MEDICAL SERVICES FOR CHILDREN	93.127	5 H33 MC31540-03-00				\$104,939	\$135,580	N/A	\$0	
EMERGENCY MEDICAL SERVICES FOR CHILDREN	93.127	5 H33 MC31540-04-00				\$30,641	\$135,580	N/A	\$0	
INJURY PREVENTION AND CONTROL RESEARCH AND STATE AND COMMUNITY BASED PROGRAMS	93.136	1 R01 CE003009-01-00	UNIVERSITY OF NORTH CAROLINA	1 R01 CE003009-01-00		\$20,068	\$110,301	RESEARCH AND DEVELOPMENT	\$357,858,137	
INJURY PREVENTION AND CONTROL RESEARCH AND STATE AND COMMUNITY BASED PROGRAMS	93.136	34301-29420:ST TN	TN DEPARTMENT OF HEALTH	34301-29420:ST TN		\$90,233	\$110,301	RESEARCH AND DEVELOPMENT	\$357,858,137	
COMMUNITY PROGRAMS TO IMPROVE MINORITY HEALTH GRANT PROGRAM	93.137	5 CPI MP171157 03 00	MEHARRY MEDICAL COLLEGE	5 CPI MP171157 03 00		\$8,019	\$21,044	RESEARCH AND DEVELOPMENT	\$357,858,137	
COMMUNITY PROGRAMS TO IMPROVE MINORITY HEALTH GRANT PROGRAM	93.137	5 CPI MP171157 03 00	MEHARRY MEDICAL COLLEGE	5 CPI MP171157 03 00		\$13,025	\$21,044	RESEARCH AND DEVELOPMENT	\$357,858,137	
AIDS EDUCATION AND TRAINING CENTERS	93.145	5 U10 HA30535-03-00				\$768,763	\$797,590	\$4,114,443	RESEARCH AND DEVELOPMENT	\$357,858,137
AIDS EDUCATION AND TRAINING CENTERS	93.145	6 U10 HA030535-04-07				\$2,266,188	\$3,313,647	\$4,114,443	RESEARCH AND DEVELOPMENT	\$357,858,137
			RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY							
AIDS EDUCATION AND TRAINING CENTERS	93.145	5 U10 HA028686-04-00		5 U10 HA028686-04-00		\$3,206	\$4,114,443	RESEARCH AND DEVELOPMENT	\$357,858,137	
COVID-19 COORDINATED SERVICES AND ACCESS TO RESEARCH FOR WOMEN, INFANTS, CHILDREN, AND YOUTH	93.153	COVID-19 1 H1X HA37046-01-00				\$5,718	\$452,863	N/A	\$0	
COORDINATED SERVICES AND ACCESS TO RESEARCH FOR WOMEN, INFANTS, CHILDREN, AND YOUTH	93.153	5 H12 HA030750-03				\$41,179	\$452,863	N/A	\$0	
COORDINATED SERVICES AND ACCESS TO RESEARCH FOR WOMEN, INFANTS, CHILDREN, AND YOUTH	93.153	5 H12 HA030750-04-00				\$405,966	\$452,863	N/A	\$0	
HUMAN GENOME RESEARCH	93.172	1 K99 HG010904-01				\$25,938	\$7,666,830	RESEARCH AND DEVELOPMENT	\$357,858,137	
HUMAN GENOME RESEARCH	93.172	1 R01 HG010863-01				\$303,296	\$7,666,830	RESEARCH AND DEVELOPMENT	\$357,858,137	
HUMAN GENOME RESEARCH	93.172	1 R21 HG010652-01				\$150,422	\$7,666,830	RESEARCH AND DEVELOPMENT	\$357,858,137	
HUMAN GENOME RESEARCH	93.172	1 R35 HG010718-01				\$273,037	\$7,666,830	RESEARCH AND DEVELOPMENT	\$357,858,137	
HUMAN GENOME RESEARCH	93.172	1 U01 HG010232-01			\$73,266	\$88,841	\$7,666,830	RESEARCH AND DEVELOPMENT	\$357,858,137	
HUMAN GENOME RESEARCH	93.172	1 U01 HG011166-01				\$24,156	\$7,666,830	RESEARCH AND DEVELOPMENT	\$357,858,137	
HUMAN GENOME RESEARCH	93.172	3 R01 HG009694-02S1				-\$450	\$7,666,830	RESEARCH AND DEVELOPMENT	\$357,858,137	
HUMAN GENOME RESEARCH	93.172	3 R01 HG009694-03S1			\$128,019	\$175,199	\$7,666,830	RESEARCH AND DEVELOPMENT	\$357,858,137	
HUMAN GENOME RESEARCH	93.172	3 U01 HG010232-02S1				\$116,091	\$7,666,830	RESEARCH AND DEVELOPMENT	\$357,858,137	
HUMAN GENOME RESEARCH	93.172	5 R01 HG006844-09			\$202,291	\$684,122	\$7,666,830	RESEARCH AND DEVELOPMENT	\$357,858,137	
HUMAN GENOME RESEARCH	93.172	5 R01 HG009694-03			\$485,417	\$738,194	\$7,666,830	RESEARCH AND DEVELOPMENT	\$357,858,137	
HUMAN GENOME RESEARCH	93.172	5 RM1 HG009034-03			\$4,162	\$4,162	\$7,666,830	RESEARCH AND DEVELOPMENT	\$357,858,137	
HUMAN GENOME RESEARCH	93.172	5 RM1 HG009034-04			\$346,319	\$996,063	\$7,666,830	RESEARCH AND DEVELOPMENT	\$357,858,137	

Vanderbilt University Medical Center
Schedule of Expenditures of Federal Awards and State Financial Assistance
Fiscal Period 7/1/2019 – 6/30/2020

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total	
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	5 R01 DC013767-04	VANDERBILT UNIVERSITY	5 R01 DC013767-04		\$1,014	\$6,241,892	RESEARCH AND DEVELOPMENT	\$357,858,137	
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	5 R01 DC013767-04	VANDERBILT UNIVERSITY	5 R01 DC013767-04		\$3,551	\$6,241,892	RESEARCH AND DEVELOPMENT	\$357,858,137	
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	5 R01 DC013767-05	VANDERBILT UNIVERSITY	5 R01 DC013767-05		\$4,313	\$6,241,892	RESEARCH AND DEVELOPMENT	\$357,858,137	
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	5 R01 DC014037-05	VANDERBILT UNIVERSITY	5 R01 DC014037-05		\$68,599	\$6,241,892	RESEARCH AND DEVELOPMENT	\$357,858,137	
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	5 R01 DC014462-03	VANDERBILT UNIVERSITY	5 R01 DC014462-03		\$185,748	\$6,241,892	RESEARCH AND DEVELOPMENT	\$357,858,137	
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	5 R01 DC015780-03	NATHAN S. KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH (NKI)	5 R01 DC015780-03	\$9,016	\$22,851	\$6,241,892	RESEARCH AND DEVELOPMENT	\$357,858,137	
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	5 R01 DC015780-04	NATHAN S. KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH (NKI)	5 R01 DC015780-04		\$21,068	\$6,241,892	RESEARCH AND DEVELOPMENT	\$357,858,137	
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	5 R01 DC016643-03	BOYS TOWN NATIONAL RESEARCH HOSPITAL	5 R01 DC016643-03		\$76,881	\$6,241,892	RESEARCH AND DEVELOPMENT	\$357,858,137	
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	5 R01 DC017078-02	MASSACHUSETTS EYE AND EAR INFIRMARY	5 R01 DC017078-02		\$32,729	\$6,241,892	RESEARCH AND DEVELOPMENT	\$357,858,137	
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	5 R03 DC015329-02	WAYNE STATE UNIVERSITY	5 R03 DC015329-02		\$1,537	\$6,241,892	RESEARCH AND DEVELOPMENT	\$357,858,137	
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	5 R44 DC015920-02	INTELLIGENT HEARING SYSTEMS, INC.	5 R44 DC015920-02		\$103,972	\$6,241,892	RESEARCH AND DEVELOPMENT	\$357,858,137	
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	5 U01 DC014706-02	UNIVERSITY OF UTAH	5 U01 DC014706-02		\$3,555	\$6,241,892	RESEARCH AND DEVELOPMENT	\$357,858,137	
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	7 R01 DC015405-04	UNIVERSITY OF PITTSBURGH	7 R01 DC015405-04		\$32,364	\$6,241,892	RESEARCH AND DEVELOPMENT	\$357,858,137	
IMMUNIZATION RESEARCH, DEMONSTRATION, PUBLIC INFORMATION AND EDUCATION_TRAINING AND CLINICAL SKILLS IMPROVEMENT PROJECTS	93.185	5 U01 IP001063-03				\$169,633	\$1,906,052	RESEARCH AND DEVELOPMENT	\$357,858,137	
IMMUNIZATION RESEARCH, DEMONSTRATION, PUBLIC INFORMATION AND EDUCATION_TRAINING AND CLINICAL SKILLS IMPROVEMENT PROJECTS	93.185	5 U01 IP001063-04				\$1,036,193	\$1,906,052	RESEARCH AND DEVELOPMENT	\$357,858,137	
IMMUNIZATION RESEARCH, DEMONSTRATION, PUBLIC INFORMATION AND EDUCATION_TRAINING AND CLINICAL SKILLS IMPROVEMENT PROJECTS	93.185	5 U01 IP001083-02				\$77,134	\$1,906,052	RESEARCH AND DEVELOPMENT	\$357,858,137	
IMMUNIZATION RESEARCH, DEMONSTRATION, PUBLIC INFORMATION AND EDUCATION_TRAINING AND CLINICAL SKILLS IMPROVEMENT PROJECTS	93.185	5 U01 IP001083-03				\$486,850	\$1,906,052	RESEARCH AND DEVELOPMENT	\$357,858,137	
IMMUNIZATION RESEARCH, DEMONSTRATION, PUBLIC INFORMATION AND EDUCATION_TRAINING AND CLINICAL SKILLS IMPROVEMENT PROJECTS	93.185	6 U01 IP001116-01-01	JOHNS HOPKINS UNIVERSITY	6 U01 IP001116-01-01		\$41,706	\$1,906,052	RESEARCH AND DEVELOPMENT	\$357,858,137	
COVID-19 IMMUNIZATION RESEARCH, DEMONSTRATION, PUBLIC INFORMATION AND EDUCATION_TRAINING AND CLINICAL SKILLS IMPROVEMENT PROJECTS	93.185	COVID-19 5 U01 IP001083-03				\$94,536	\$1,906,052	RESEARCH AND DEVELOPMENT	\$357,858,137	
RESEARCH AND TRAINING IN COMPLEMENTARY AND INTEGRATIVE HEALTH	93.213	5 R01 AT004821-10				\$948	\$254,794	RESEARCH AND DEVELOPMENT	\$357,858,137	
RESEARCH AND TRAINING IN COMPLEMENTARY AND INTEGRATIVE HEALTH	93.213	1 R01 AT009680-01A1	RUSH UNIVERSITY MEDICAL CENTER	1 R01 AT009680-01A1		\$234,208	\$254,794	RESEARCH AND DEVELOPMENT	\$357,858,137	
RESEARCH AND TRAINING IN COMPLEMENTARY AND INTEGRATIVE HEALTH	93.213	3 U54 AT007748-05S1	DUKE UNIVERSITY	3 U54 AT007748-05S1		\$17,497	\$254,794	RESEARCH AND DEVELOPMENT	\$357,858,137	
RESEARCH AND TRAINING IN COMPLEMENTARY AND INTEGRATIVE HEALTH	93.213	5 UH3 AT009145-04	BROWN UNIVERSITY	5 UH3 AT009145-04		\$2,141	\$254,794	RESEARCH AND DEVELOPMENT	\$357,858,137	
NATIONAL RESEARCH SERVICE AWARDS_HEALTH SERVICES RESEARCH TRAINING	93.225	1 T32 HS026122-01				\$36,879	\$39,656	\$451,932	RESEARCH AND DEVELOPMENT	\$357,858,137
NATIONAL RESEARCH SERVICE AWARDS_HEALTH SERVICES RESEARCH TRAINING	93.225	5 T32 HS026122-02				\$23,573	\$412,276	\$451,932	RESEARCH AND DEVELOPMENT	\$357,858,137
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	1 K12 HS026395-01				\$98,080	\$2,655,572	RESEARCH AND DEVELOPMENT	\$357,858,137	
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	1 R01 HS025976-01A1				\$18,861	\$2,655,572	RESEARCH AND DEVELOPMENT	\$357,858,137	
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	1 R18 HS025910-01A1				\$5,863	\$261,536	\$2,655,572	RESEARCH AND DEVELOPMENT	\$357,858,137
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	1 R18 HS025931-01A1				\$151,899	\$227,696	\$2,655,572	RESEARCH AND DEVELOPMENT	\$357,858,137
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	1 R18 HS026158-01				\$32,635	\$55,144	\$2,655,572	RESEARCH AND DEVELOPMENT	\$357,858,137
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	1 R18 HS026616-01				\$28,190	\$184,281	\$2,655,572	RESEARCH AND DEVELOPMENT	\$357,858,137
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	5 K12 HS022990-05				\$72,885	\$207,140	\$2,655,572	RESEARCH AND DEVELOPMENT	\$357,858,137
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	5 K12 HS026395-02				\$401,758	\$2,655,572	RESEARCH AND DEVELOPMENT	\$357,858,137	
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	5 R01 HS025976-02				\$60,508	\$363,768	\$2,655,572	RESEARCH AND DEVELOPMENT	\$357,858,137
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	5 R03 HS026069-01					\$5,348	\$2,655,572	RESEARCH AND DEVELOPMENT	\$357,858,137
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	5 R03 HS026069-02					\$45,791	\$2,655,572	RESEARCH AND DEVELOPMENT	\$357,858,137
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	5 R18 HS025931-02					\$30,350	\$2,655,572	RESEARCH AND DEVELOPMENT	\$357,858,137
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	5 R18 HS026158-02				\$80,150	\$246,720	\$2,655,572	RESEARCH AND DEVELOPMENT	\$357,858,137
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	5 R18 HS026616-02				\$84,085	\$428,637	\$2,655,572	RESEARCH AND DEVELOPMENT	\$357,858,137
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	6 R01 HS021496-04					\$13,705	\$2,655,572	RESEARCH AND DEVELOPMENT	\$357,858,137
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	1 R01 HS025979-01A1	ATRIUM HEALTH	1 R01 HS025979-01A1		\$13,602	\$2,655,572	RESEARCH AND DEVELOPMENT	\$357,858,137	
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	1 R01 HS025979-02	ATRIUM HEALTH	1 R01 HS025979-02		\$19,696	\$2,655,572	RESEARCH AND DEVELOPMENT	\$357,858,137	
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	1 R01 HS026742-01A1	WASHINGTON UNIVERSITY IN ST. LOUIS	1 R01 HS026742-01A1		\$1,763	\$2,655,572	RESEARCH AND DEVELOPMENT	\$357,858,137	
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	1 R18 HS223757-01A1	BRIGHAM AND WOMEN'S HOSPITAL	1 R18 HS223757-01A1		\$1,104	\$2,655,572	RESEARCH AND DEVELOPMENT	\$357,858,137	

Vanderbilt University Medical Center
Schedule of Expenditures of Federal Awards and State Financial Assistance
Fiscal Period 7/1/2019 – 6/30/2020

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total	
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	5 R01 HS023306-04	INDIANA UNIVERSITY	5 R01 HS023306-04		\$1,847	\$2,655,572	RESEARCH AND DEVELOPMENT	\$357,858,137	
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	5 R01 HS025411-02	INDIANA UNIVERSITY	5 R01 HS025411-02		\$18	\$2,655,572	RESEARCH AND DEVELOPMENT	\$357,858,137	
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	5 U18 HS025291-03	SEATTLE CHILDREN'S HOSPITAL	5 U18 HS025291-03		\$18,219	\$2,655,572	RESEARCH AND DEVELOPMENT	\$357,858,137	
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	7 U18 HS025291-04	KAISER FOUNDATION	7 U18 HS025291-04		\$21,204	\$2,655,572	RESEARCH AND DEVELOPMENT	\$357,858,137	
MENTAL HEALTH RESEARCH GRANTS	93.242	1 R01 MH116058-01A1.02			\$340,486	\$723,936	\$9,268,917	RESEARCH AND DEVELOPMENT	\$357,858,137	
MENTAL HEALTH RESEARCH GRANTS	93.242	1 R01 MH119817-01A1				\$354,795	\$9,268,917	RESEARCH AND DEVELOPMENT	\$357,858,137	
MENTAL HEALTH RESEARCH GRANTS	93.242	1 R01 MH120736-01				\$292,663	\$9,268,917	RESEARCH AND DEVELOPMENT	\$357,858,137	
MENTAL HEALTH RESEARCH GRANTS	93.242	1 R01 MH121455-01			\$24,487	\$199,562	\$9,268,917	RESEARCH AND DEVELOPMENT	\$357,858,137	
MENTAL HEALTH RESEARCH GRANTS	93.242	1 R01 MH121620-01				\$118,430	\$9,268,917	RESEARCH AND DEVELOPMENT	\$357,858,137	
MENTAL HEALTH RESEARCH GRANTS	93.242	1 R21 MH118539-02				\$168,885	\$9,268,917	RESEARCH AND DEVELOPMENT	\$357,858,137	
MENTAL HEALTH RESEARCH GRANTS	93.242	1 R33 MH120149-01A1				\$14,091	\$9,268,917	RESEARCH AND DEVELOPMENT	\$357,858,137	
MENTAL HEALTH RESEARCH GRANTS	93.242	1 R61 MH123029-01				\$136,485	\$9,268,917	RESEARCH AND DEVELOPMENT	\$357,858,137	
MENTAL HEALTH RESEARCH GRANTS	93.242	2 R01 MH102272-06				\$356,604	\$9,268,917	RESEARCH AND DEVELOPMENT	\$357,858,137	
MENTAL HEALTH RESEARCH GRANTS	93.242	5 F32 MH112263-02				\$4,079	\$9,268,917	RESEARCH AND DEVELOPMENT	\$357,858,137	
MENTAL HEALTH RESEARCH GRANTS	93.242	5 K01 MH107255-04				\$34,478	\$9,268,917	RESEARCH AND DEVELOPMENT	\$357,858,137	
MENTAL HEALTH RESEARCH GRANTS	93.242	5 K23 MH116339-04			\$360	\$176,938	\$9,268,917	RESEARCH AND DEVELOPMENT	\$357,858,137	
MENTAL HEALTH RESEARCH GRANTS	93.242	5 K24 MH110598-03				\$149,519	\$9,268,917	RESEARCH AND DEVELOPMENT	\$357,858,137	
MENTAL HEALTH RESEARCH GRANTS	93.242	5 R01 MH100096-07				\$538	\$9,268,917	RESEARCH AND DEVELOPMENT	\$357,858,137	
MENTAL HEALTH RESEARCH GRANTS	93.242	5 R01 MH102246-06			\$91,472	\$585,377	\$9,268,917	RESEARCH AND DEVELOPMENT	\$357,858,137	
MENTAL HEALTH RESEARCH GRANTS	93.242	5 R01 MH102266-05			\$53,372	\$240,839	\$9,268,917	RESEARCH AND DEVELOPMENT	\$357,858,137	
MENTAL HEALTH RESEARCH GRANTS	93.242	5 R01 MH102272-05				\$9,898	\$86,271	\$9,268,917	RESEARCH AND DEVELOPMENT	\$357,858,137
MENTAL HEALTH RESEARCH GRANTS	93.242	5 R01 MH107435-05			\$1,051	\$459,029	\$9,268,917	RESEARCH AND DEVELOPMENT	\$357,858,137	
MENTAL HEALTH RESEARCH GRANTS	93.242	5 R01 MH111599-04				\$520,406	\$9,268,917	RESEARCH AND DEVELOPMENT	\$357,858,137	
MENTAL HEALTH RESEARCH GRANTS	93.242	5 R01 MH111776-04			\$61,222	\$297,399	\$9,268,917	RESEARCH AND DEVELOPMENT	\$357,858,137	
MENTAL HEALTH RESEARCH GRANTS	93.242	5 R01 MH111877-04			\$57,874	\$360,761	\$9,268,917	RESEARCH AND DEVELOPMENT	\$357,858,137	
MENTAL HEALTH RESEARCH GRANTS	93.242	5 R01 MH113362-04			\$98,635	\$710,617	\$9,268,917	RESEARCH AND DEVELOPMENT	\$357,858,137	
MENTAL HEALTH RESEARCH GRANTS	93.242	5 R01 MH113438-03			\$98,746	\$258,928	\$9,268,917	RESEARCH AND DEVELOPMENT	\$357,858,137	
MENTAL HEALTH RESEARCH GRANTS	93.242	5 R01 MH113478-04			\$81,021	\$463,170	\$9,268,917	RESEARCH AND DEVELOPMENT	\$357,858,137	
MENTAL HEALTH RESEARCH GRANTS	93.242	5 R01 MH113576-02			\$5,304	\$8,637	\$9,268,917	RESEARCH AND DEVELOPMENT	\$357,858,137	
MENTAL HEALTH RESEARCH GRANTS	93.242	5 R01 MH114906-03			\$396,614	\$682,594	\$9,268,917	RESEARCH AND DEVELOPMENT	\$357,858,137	
MENTAL HEALTH RESEARCH GRANTS	93.242	5 R01 MH115000-03			\$155,529	\$356,070	\$9,268,917	RESEARCH AND DEVELOPMENT	\$357,858,137	
MENTAL HEALTH RESEARCH GRANTS	93.242	5 R01 MH116269-02				\$113,796	\$9,268,917	RESEARCH AND DEVELOPMENT	\$357,858,137	
MENTAL HEALTH RESEARCH GRANTS	93.242	5 R03 MH112783-02			\$14,272	\$24,567	\$9,268,917	RESEARCH AND DEVELOPMENT	\$357,858,137	
MENTAL HEALTH RESEARCH GRANTS	93.242	5 R21 MH111567-02			\$230,209	\$250,593	\$9,268,917	RESEARCH AND DEVELOPMENT	\$357,858,137	
MENTAL HEALTH RESEARCH GRANTS	93.242	5 R21 MH113262-03				\$1	\$9,268,917	RESEARCH AND DEVELOPMENT	\$357,858,137	
MENTAL HEALTH RESEARCH GRANTS	93.242	5 R24 MH109105-04			-\$22,527	\$288,354	\$9,268,917	RESEARCH AND DEVELOPMENT	\$357,858,137	
MENTAL HEALTH RESEARCH GRANTS	93.242	6 R34 MH104428-03				\$1,462	\$9,268,917	RESEARCH AND DEVELOPMENT	\$357,858,137	
MENTAL HEALTH RESEARCH GRANTS	93.242	7 R01 MH106511-03			\$13,740	\$13,740	\$9,268,917	RESEARCH AND DEVELOPMENT	\$357,858,137	
MENTAL HEALTH RESEARCH GRANTS	93.242	1 R01 MH112913-01A1	UNIVERSITY OF WISCONSIN	1 R01 MH112913-01A1		-\$3,780	\$9,268,917	RESEARCH AND DEVELOPMENT	\$357,858,137	
MENTAL HEALTH RESEARCH GRANTS	93.242	1 R01 MH118223-01	MASSACHUSETTS GENERAL HOSPITAL	1 R01 MH118223-01		\$92,538	\$9,268,917	RESEARCH AND DEVELOPMENT	\$357,858,137	
MENTAL HEALTH RESEARCH GRANTS	93.242	1 R01 MH118273-01A1	VANDERBILT UNIVERSITY	1 R01 MH118273-01A1		\$83,717	\$9,268,917	RESEARCH AND DEVELOPMENT	\$357,858,137	
MENTAL HEALTH RESEARCH GRANTS	93.242	1 R01 MH120122-01	UNIVERSITY OF COLORADO	1 R01 MH120122-01		\$65,270	\$9,268,917	RESEARCH AND DEVELOPMENT	\$357,858,137	
MENTAL HEALTH RESEARCH GRANTS	93.242	1 R01 MH121407-01	PORTLAND STATE UNIVERSITY	1 R01 MH121407-01		\$9,620	\$9,268,917	RESEARCH AND DEVELOPMENT	\$357,858,137	
MENTAL HEALTH RESEARCH GRANTS	93.242	1 R21 MH121165-01	CASE WESTERN RESERVE UNIVERSITY	1 R21 MH121165-01		\$9,912	\$9,268,917	RESEARCH AND DEVELOPMENT	\$357,858,137	
MENTAL HEALTH RESEARCH GRANTS	93.242	1 UG3 MH120102-01	CALIFORNIA INSTITUTE OF TECHNOLOGY (CALTECH)	1 UG3 MH120102-01		\$60,522	\$9,268,917	RESEARCH AND DEVELOPMENT	\$357,858,137	
MENTAL HEALTH RESEARCH GRANTS	93.242	2 R44 MH115528-02	ADAPTIVE TECHNOLOGY CONSULTING, LLC	2 R44 MH115528-02		\$9,016	\$9,268,917	RESEARCH AND DEVELOPMENT	\$357,858,137	
MENTAL HEALTH RESEARCH GRANTS	93.242	3 U01 MH109539-04S2	MASSACHUSETTS GENERAL HOSPITAL	3 U01 MH109539-04S2		\$15,387	\$9,268,917	RESEARCH AND DEVELOPMENT	\$357,858,137	
MENTAL HEALTH RESEARCH GRANTS	93.242	5 R01 MH098260-05	UNIVERSITY OF PENNSYLVANIA	5 R01 MH098260-05		\$867	\$9,268,917	RESEARCH AND DEVELOPMENT	\$357,858,137	
MENTAL HEALTH RESEARCH GRANTS	93.242	5 R01 MH107467-04	UNIVERSITY OF CALIFORNIA AT SAN FRANCISCO	5 R01 MH107467-04		\$63,845	\$9,268,917	RESEARCH AND DEVELOPMENT	\$357,858,137	
MENTAL HEALTH RESEARCH GRANTS	93.242	5 R01 MH107467-05	UNIVERSITY OF CALIFORNIA AT SAN FRANCISCO	5 R01 MH107467-05		\$13,509	\$9,268,917	RESEARCH AND DEVELOPMENT	\$357,858,137	
MENTAL HEALTH RESEARCH GRANTS	93.242	5 R01 MH118233-02	MASSACHUSETTS GENERAL HOSPITAL	5 R01 MH118233-02		\$97,053	\$9,268,917	RESEARCH AND DEVELOPMENT	\$357,858,137	
MENTAL HEALTH RESEARCH GRANTS	93.242	5 U01 MH110925-03	UNIVERSITY OF NORTH CAROLINA	5 U01 MH110925-03		\$417	\$9,268,917	RESEARCH AND DEVELOPMENT	\$357,858,137	
MENTAL HEALTH RESEARCH GRANTS	93.242	5 U01 MH110925-03	UNIVERSITY OF NORTH CAROLINA	5 U01 MH110925-03		\$7,998	\$9,268,917	RESEARCH AND DEVELOPMENT	\$357,858,137	

Vanderbilt University Medical Center
Schedule of Expenditures of Federal Awards and State Financial Assistance
Fiscal Period 7/1/2019 – 6/30/2020

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
MENTAL HEALTH RESEARCH GRANTS	93.242	5 U01 MH110925-04	UNIVERSITY OF NORTH CAROLINA	5 U01 MH110925-04		\$4,645	\$9,268,917	RESEARCH AND DEVELOPMENT	\$357,858,137
MENTAL HEALTH RESEARCH GRANTS	93.242	5 U01 MH110925-04	UNIVERSITY OF NORTH CAROLINA	5 U01 MH110925-04		\$32,474	\$9,268,917	RESEARCH AND DEVELOPMENT	\$357,858,137
MENTAL HEALTH RESEARCH GRANTS	93.242	5 U01 MH112913-02	UNIVERSITY OF WISCONSIN	5 U01 MH112913-02		\$198,165	\$9,268,917	RESEARCH AND DEVELOPMENT	\$357,858,137
MENTAL HEALTH RESEARCH GRANTS	93.242	5 U01 MH112913-03	UNIVERSITY OF WISCONSIN	5 U01 MH112913-03		\$809	\$9,268,917	RESEARCH AND DEVELOPMENT	\$357,858,137
MENTAL HEALTH RESEARCH GRANTS	93.242	5 U19 MH113136-03	JOHNS HOPKINS UNIVERSITY	5 U19 MH113136-03		\$56,886	\$9,268,917	RESEARCH AND DEVELOPMENT	\$357,858,137
MENTAL HEALTH RESEARCH GRANTS	93.242	5 R01 MH100096-07				-\$538	\$9,268,917	RESEARCH AND DEVELOPMENT	\$357,858,137
MENTAL HEALTH RESEARCH GRANTS	93.242	7 R01 MH106511-03				-\$3,029	\$9,268,917	RESEARCH AND DEVELOPMENT	\$357,858,137
ADVANCED NURSING EDUCATION GRANT PROGRAM	93.247	1 T14 HP33119-01-00	VANDERBILT UNIVERSITY	1 T14 HP33119-01-00		\$18,359	\$18,359	RESEARCH AND DEVELOPMENT	\$357,858,137
EARLY HEARING DETECTION AND INTERVENTION	93.251	34347-75420-ST TN	TN DEPARTMENT OF HEALTH	34347-75420-ST TN		\$15,213	\$15,213	RESEARCH AND DEVELOPMENT	\$357,858,137
COVID-19 POISON CENTER SUPPORT AND ENHANCEMENT GRANT	93.253	COVID-19 1 H4C HS37367-01-00				\$24,426	\$426,182	N/A	\$0
POISON CENTER SUPPORT AND ENHANCEMENT GRANT	93.253	2 H4B HS030752-04-00				\$339,925	\$426,182	N/A	\$0
POISON CENTER SUPPORT AND ENHANCEMENT GRANT	93.253	5 H4B HS030752-03-00				\$61,831	\$426,182	N/A	\$0
OCCUPATIONAL SAFETY AND HEALTH PROGRAM	93.262	1 R21 OH011452-01-00	UNIVERSITY OF CALIFORNIA AT SAN FRANCISCO	1 R21 OH011452-01-00		\$5,605	\$32,533	RESEARCH AND DEVELOPMENT	\$357,858,137
OCCUPATIONAL SAFETY AND HEALTH PROGRAM	93.262	5 R21 OH011452-02-00	UNIVERSITY OF CALIFORNIA AT SAN FRANCISCO	5 R21 OH011452-02-00		\$26,928	\$32,533	RESEARCH AND DEVELOPMENT	\$357,858,137
IMMUNIZATION COOPERATIVE AGREEMENTS	93.268	200-2012-50430				\$27,999	\$28,406	RESEARCH AND DEVELOPMENT	\$357,858,137
IMMUNIZATION COOPERATIVE AGREEMENTS	93.268	200-2013-F-57544	ABT ASSOCIATES, INC.	200-2013-F-57544		\$407	\$28,406	RESEARCH AND DEVELOPMENT	\$357,858,137
ALCOHOL RESEARCH PROGRAMS	93.273	1 R21 AA025385-02			\$14,899	\$56,744	\$1,342,265	RESEARCH AND DEVELOPMENT	\$357,858,137
ALCOHOL RESEARCH PROGRAMS	93.273	5 R01 AA026186-04			\$18,709	\$328,293	\$1,342,265	RESEARCH AND DEVELOPMENT	\$357,858,137
ALCOHOL RESEARCH PROGRAMS	93.273	5 U01 AA026222-02			\$195,298	\$211,009	\$1,342,265	RESEARCH AND DEVELOPMENT	\$357,858,137
ALCOHOL RESEARCH PROGRAMS	93.273	5 U01 AA026222-03			\$342,684	\$499,156	\$1,342,265	RESEARCH AND DEVELOPMENT	\$357,858,137
ALCOHOL RESEARCH PROGRAMS	93.273	1 R01 AA025859-02	BOSTON MEDICAL CENTER	1 R01 AA025859-02		-\$5,385	\$1,342,265	RESEARCH AND DEVELOPMENT	\$357,858,137
ALCOHOL RESEARCH PROGRAMS	93.273	1 R01 AA027654-01A1	UNIVERSITY OF IOWA	1 R01 AA027654-01A1		\$10,567	\$1,342,265	RESEARCH AND DEVELOPMENT	\$357,858,137
ALCOHOL RESEARCH PROGRAMS	93.273	5 R01 AA025859-03	BOSTON MEDICAL CENTER	5 R01 AA025859-03		\$26,050	\$1,342,265	RESEARCH AND DEVELOPMENT	\$357,858,137
ALCOHOL RESEARCH PROGRAMS	93.273	5 R01 AA025947-02	RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC.	5 R01 AA025947-02		\$28,628	\$1,342,265	RESEARCH AND DEVELOPMENT	\$357,858,137
ALCOHOL RESEARCH PROGRAMS	93.273	5 U01 AA020780-08	BOSTON MEDICAL CENTER	5 U01 AA020780-08		\$15,140	\$1,342,265	RESEARCH AND DEVELOPMENT	\$357,858,137
ALCOHOL RESEARCH PROGRAMS	93.273	5 U01 AA020780-09	BOSTON MEDICAL CENTER	5 U01 AA020780-09		\$80,595	\$1,342,265	RESEARCH AND DEVELOPMENT	\$357,858,137
ALCOHOL RESEARCH PROGRAMS	93.273	5 U01 AA026224-02	YALE UNIVERSITY	5 U01 AA026224-02		\$6,194	\$1,342,265	RESEARCH AND DEVELOPMENT	\$357,858,137
ALCOHOL RESEARCH PROGRAMS	93.273	5 U01 AA026224-03	YALE UNIVERSITY	5 U01 AA026224-03		\$34,809	\$1,342,265	RESEARCH AND DEVELOPMENT	\$357,858,137
ALCOHOL RESEARCH PROGRAMS	93.273	7 R03 AA026099-03	OCHSNER CLINIC FOUNDATION	7 R03 AA026099-03		\$39,695	\$1,342,265	RESEARCH AND DEVELOPMENT	\$357,858,137
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	1 K01 DA050740-01				\$1,762	\$2,108,140	RESEARCH AND DEVELOPMENT	\$357,858,137
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	1 K23 DA047476-01A1			\$20,611	\$163,446	\$2,108,140	RESEARCH AND DEVELOPMENT	\$357,858,137
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	1 R01 DA045729-03			\$6,173	\$416,396	\$2,108,140	RESEARCH AND DEVELOPMENT	\$357,858,137
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	5 K23 DA038720-05				\$106,605	\$2,108,140	RESEARCH AND DEVELOPMENT	\$357,858,137
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	5 R01 DA037891-05			\$391,177	\$554,326	\$2,108,140	RESEARCH AND DEVELOPMENT	\$357,858,137
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	5 R01 DA040630-05				\$409,675	\$2,108,140	RESEARCH AND DEVELOPMENT	\$357,858,137
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	1 R21 DA043960-01A1	UNIVERSITY OF ALABAMA AT BIRMINGHAM	1 R21 DA043960-01A1		\$13,000	\$2,108,140	RESEARCH AND DEVELOPMENT	\$357,858,137
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	3 UG1 DA015831-18S9	THE MCLLEAN HOSPITAL CORPORATION	3 UG1 DA015831-18S9		\$70,003	\$2,108,140	RESEARCH AND DEVELOPMENT	\$357,858,137
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	3 UG1 DA040317-05S2	DUKE UNIVERSITY	3 UG1 DA040317-05S2	\$7,422	\$264,892	\$2,108,140	RESEARCH AND DEVELOPMENT	\$357,858,137
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	5 R01 DA034629-05	UNIVERSITY OF PITTSBURGH	5 R01 DA034629-05		-\$4	\$2,108,140	RESEARCH AND DEVELOPMENT	\$357,858,137
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	5 R01 DA039522-04	RUSH MEDICAL CENTER	5 R01 DA039522-04		\$29,730	\$2,108,140	RESEARCH AND DEVELOPMENT	\$357,858,137
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	5 R21 DA043960-02	UNIVERSITY OF ALABAMA AT BIRMINGHAM	5 R21 DA043960-02		\$61,712	\$2,108,140	RESEARCH AND DEVELOPMENT	\$357,858,137
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	5 UG1 DA040317-04	DUKE UNIVERSITY	5 UG1 DA040317-04		-\$4	\$2,108,140	RESEARCH AND DEVELOPMENT	\$357,858,137
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	5 UG1 DA040317-05	DUKE UNIVERSITY	5 UG1 DA040317-05		\$16,601	\$2,108,140	RESEARCH AND DEVELOPMENT	\$357,858,137
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	1 R03 EB029078-01				\$4,162	\$2,752,042	RESEARCH AND DEVELOPMENT	\$357,858,137
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	1 R21 EB029639-01				\$15,186	\$2,752,042	RESEARCH AND DEVELOPMENT	\$357,858,137
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	1 U18 EB029351-01				\$359,282	\$2,752,042	RESEARCH AND DEVELOPMENT	\$357,858,137
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	5 R01 EB017767-05				\$2,677	\$2,752,042	RESEARCH AND DEVELOPMENT	\$357,858,137

Vanderbilt University Medical Center
Schedule of Expenditures of Federal Awards and State Financial Assistance
Fiscal Period 7/1/2019 – 6/30/2020

<i>Federal Awarding Agency/Program Title</i>	<i>Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	5 R01 EB018992-04			\$289,895	\$417,848	\$2,752,042	RESEARCH AND DEVELOPMENT	\$357,858,137
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	5 R01 EB020666-04				\$51,940	\$2,752,042	RESEARCH AND DEVELOPMENT	\$357,858,137
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	5 R01 EB024525-03				\$457,252	\$2,752,042	RESEARCH AND DEVELOPMENT	\$357,858,137
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	5 R01 EB026991-02			\$120,227	\$260,872	\$2,752,042	RESEARCH AND DEVELOPMENT	\$357,858,137
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	5 R21 EB021012-02			\$30,055	\$95,720	\$2,752,042	RESEARCH AND DEVELOPMENT	\$357,858,137
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	5 R21 EB025258-03			\$15,660	\$131,621	\$2,752,042	RESEARCH AND DEVELOPMENT	\$357,858,137
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	5 T32 EB001628-17				\$345,109	\$2,752,042	RESEARCH AND DEVELOPMENT	\$357,858,137
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	1 R01 EB024864-01	VANDERBILT UNIVERSITY	1 R01 EB024864-01		\$10,409	\$2,752,042	RESEARCH AND DEVELOPMENT	\$357,858,137
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	1 R01 EB026901-01A1	VANDERBILT UNIVERSITY	1 R01 EB026901-01A1		\$81,814	\$2,752,042	RESEARCH AND DEVELOPMENT	\$357,858,137
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	1 R01 EB027498-01A1	VANDERBILT UNIVERSITY	1 R01 EB027498-01A1		\$9,208	\$2,752,042	RESEARCH AND DEVELOPMENT	\$357,858,137
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	1 R01 EB028615-01	VANDERBILT UNIVERSITY	1 R01 EB028615-01		\$13,727	\$2,752,042	RESEARCH AND DEVELOPMENT	\$357,858,137
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	2 R01 EB016695-05	VANDERBILT UNIVERSITY	2 R01 EB016695-05		-\$1	\$2,752,042	RESEARCH AND DEVELOPMENT	\$357,858,137
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	5 R01 EB014308-04	VANDERBILT UNIVERSITY	5 R01 EB014308-04		\$155,183	\$2,752,042	RESEARCH AND DEVELOPMENT	\$357,858,137
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	5 R01 EB016695-06	VANDERBILT UNIVERSITY	5 R01 EB016695-06		\$111,103	\$2,752,042	RESEARCH AND DEVELOPMENT	\$357,858,137
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	5 R01 EB016695-07	VANDERBILT UNIVERSITY	5 R01 EB016695-07		\$58,287	\$2,752,042	RESEARCH AND DEVELOPMENT	\$357,858,137
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	5 R01 EB017230-04	VANDERBILT UNIVERSITY	5 R01 EB017230-04		\$3,273	\$2,752,042	RESEARCH AND DEVELOPMENT	\$357,858,137
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	5 R01 EB019980-04	VANDERBILT UNIVERSITY	5 R01 EB019980-04		\$16,189	\$2,752,042	RESEARCH AND DEVELOPMENT	\$357,858,137
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	5 R01 EB023717-02	VANDERBILT UNIVERSITY	5 R01 EB023717-02		\$92,939	\$2,752,042	RESEARCH AND DEVELOPMENT	\$357,858,137
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	5 U01 EB021214-04	UNIVERSITY OF CALIFORNIA AT SAN FRANCISCO	5 U01 EB021214-04		\$58,242	\$2,752,042	RESEARCH AND DEVELOPMENT	\$357,858,137
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307	5 U54 MD010722-04			\$1,286,539	\$2,185,728	\$2,620,426	RESEARCH AND DEVELOPMENT	\$357,858,137
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307	5 U54 MD010722-05				\$256,153	\$2,620,426	RESEARCH AND DEVELOPMENT	\$357,858,137
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307	1 U54 MD012397-01A1	SAN DIEGO STATE UNIVERSITY	1 U54 MD012397-01A1		\$4,503	\$2,620,426	RESEARCH AND DEVELOPMENT	\$357,858,137
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307	5 R01 MD013493-02	DUKE UNIVERSITY	5 R01 MD013493-02		\$45,454	\$2,620,426	RESEARCH AND DEVELOPMENT	\$357,858,137
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307	5 R01 MD013493-03	DUKE UNIVERSITY	5 R01 MD013493-03		\$9,233	\$2,620,426	RESEARCH AND DEVELOPMENT	\$357,858,137
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307	5 U54 MD007586-33	MEHARRY MEDICAL COLLEGE	5 U54 MD007586-33		\$25,917	\$2,620,426	RESEARCH AND DEVELOPMENT	\$357,858,137
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307	5 U54 MD007586-33	MEHARRY MEDICAL COLLEGE	5 U54 MD007586-33		\$12,016	\$2,620,426	RESEARCH AND DEVELOPMENT	\$357,858,137
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307	5 U54 MD007586-33	MEHARRY MEDICAL COLLEGE	5 U54 MD007586-33		\$18,487	\$2,620,426	RESEARCH AND DEVELOPMENT	\$357,858,137
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307	5 U54 MD007593-10	MEHARRY MEDICAL COLLEGE	5 U54 MD007593-10		\$44,507	\$2,620,426	RESEARCH AND DEVELOPMENT	\$357,858,137
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307	5 U54 MD012397-02	SAN DIEGO STATE UNIVERSITY	5 U54 MD012397-02		\$18,428	\$2,620,426	RESEARCH AND DEVELOPMENT	\$357,858,137
TRANS-NIH RESEARCH SUPPORT	93.310	1 DP2 HD098859-01			\$16,988	\$521,659	\$29,803,867	RESEARCH AND DEVELOPMENT	\$357,858,137
TRANS-NIH RESEARCH SUPPORT	93.310	2 U01 HG007674-06			\$56,924	\$75,192	\$29,803,867	RESEARCH AND DEVELOPMENT	\$357,858,137
TRANS-NIH RESEARCH SUPPORT	93.310	3 OT2 OD023850-01			\$71,856	\$241,941	\$29,803,867	RESEARCH AND DEVELOPMENT	\$357,858,137
TRANS-NIH RESEARCH SUPPORT	93.310	3 U01 HG007674-07S1				\$77,586	\$29,803,867	RESEARCH AND DEVELOPMENT	\$357,858,137
TRANS-NIH RESEARCH SUPPORT	93.310	5 U01 HG007674-07			\$52,545	\$1,094,006	\$29,803,867	RESEARCH AND DEVELOPMENT	\$357,858,137
TRANS-NIH RESEARCH SUPPORT	93.310	5 U2C OD023196-03			\$2,259,470	\$9,809,647	\$29,803,867	RESEARCH AND DEVELOPMENT	\$357,858,137
TRANS-NIH RESEARCH SUPPORT	93.310	5 U2C OD23196-02			\$6,885,169	\$15,080,279	\$29,803,867	RESEARCH AND DEVELOPMENT	\$357,858,137
TRANS-NIH RESEARCH SUPPORT	93.310	1 U01 GM132769-01	ALABAMA STATE UNIVERSITY	1 U01 GM132769-01		\$61,501	\$29,803,867	RESEARCH AND DEVELOPMENT	\$357,858,137
TRANS-NIH RESEARCH SUPPORT	93.310	1 U24 GM132217-01	UNIVERSITY OF NORTH TEXAS	1 U24 GM132217-01		\$494,558	\$29,803,867	RESEARCH AND DEVELOPMENT	\$357,858,137

Vanderbilt University Medical Center
Schedule of Expenditures of Federal Awards and State Financial Assistance
Fiscal Period 7/1/2019 – 6/30/2020

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
TRANS-NIH RESEARCH SUPPORT	93.310	1 U24 OD023319-03	NORTHWESTERN UNIVERSITY	1 U24 OD023319-03		\$39,378	\$29,803,867	RESEARCH AND DEVELOPMENT	\$357,858,137
TRANS-NIH RESEARCH SUPPORT	93.310	1 U54 DK120058-01	VANDERBILT UNIVERSITY	1 U54 DK120058-01		-\$1,257	\$29,803,867	RESEARCH AND DEVELOPMENT	\$357,858,137
TRANS-NIH RESEARCH SUPPORT	93.310	4 U24 OD023319-04	NORTHWESTERN UNIVERSITY	4 U24 OD023319-04		\$30,850	\$29,803,867	RESEARCH AND DEVELOPMENT	\$357,858,137
TRANS-NIH RESEARCH SUPPORT	93.310	4 UH3 OD023271-03	UNIVERSITY OF WASHINGTON	4 UH3 OD023271-03		\$18,191	\$29,803,867	RESEARCH AND DEVELOPMENT	\$357,858,137
TRANS-NIH RESEARCH SUPPORT	93.310	4 UH3 OD023271-04	UNIVERSITY OF WASHINGTON	4 UH3 OD023271-04		\$115,459	\$29,803,867	RESEARCH AND DEVELOPMENT	\$357,858,137
TRANS-NIH RESEARCH SUPPORT	93.310	4 UH3 OD023282-03	UNIVERSITY OF WISCONSIN	4 UH3 OD023282-03		\$332,731	\$29,803,867	RESEARCH AND DEVELOPMENT	\$357,858,137
ALBERT EINSTEIN COLLEGE OF MEDICINE									
TRANS-NIH RESEARCH SUPPORT	93.310	4 UH3 OD023320-03	OF YESHIVA UNIVERSITY	4 UH3 OD023320-03		\$39,518	\$29,803,867	RESEARCH AND DEVELOPMENT	\$357,858,137
TRANS-NIH RESEARCH SUPPORT	93.310	5 U2C OD023375-03	DUKE UNIVERSITY	5 U2C OD023375-03		\$45,198	\$29,803,867	RESEARCH AND DEVELOPMENT	\$357,858,137
TRANS-NIH RESEARCH SUPPORT	93.310	5 U54 DK120058-02	VANDERBILT UNIVERSITY	5 U54 DK120058-02		\$154,418	\$29,803,867	RESEARCH AND DEVELOPMENT	\$357,858,137
TRANS-NIH RESEARCH SUPPORT	93.310	5 U54 GM119023-05	BOSTON COLLEGE	5 U54 GM119023-05		\$2,172	\$29,803,867	RESEARCH AND DEVELOPMENT	\$357,858,137
TRANS-NIH RESEARCH SUPPORT	93.310	5 UH3 OD023282-04	UNIVERSITY OF WISCONSIN	5 UH3 OD023282-04		\$1,370,188	\$29,803,867	RESEARCH AND DEVELOPMENT	\$357,858,137
ALBERT EINSTEIN COLLEGE OF MEDICINE									
TRANS-NIH RESEARCH SUPPORT	93.310	5 UH3 OD023320-05	OF YESHIVA UNIVERSITY	5 UH3 OD023320-05		\$200,847	\$29,803,867	RESEARCH AND DEVELOPMENT	\$357,858,137
TRANS-NIH RESEARCH SUPPORT	93.310	8 U54 GM119023-03	FISK UNIVERSITY	8 U54 GM119023-03		-\$195	\$29,803,867	RESEARCH AND DEVELOPMENT	\$357,858,137
RARE DISORDERS: RESEARCH, SURVEILLANCE, HEALTH PROMOTION, AND EDUCATION	93.315	1 U01 DD001234-01-00				\$17,217	\$74,780	RESEARCH AND DEVELOPMENT	\$357,858,137
RARE DISORDERS: RESEARCH, SURVEILLANCE, HEALTH PROMOTION, AND EDUCATION	93.315	1 U01 DD001235-01-00				\$31,382	\$74,780	RESEARCH AND DEVELOPMENT	\$357,858,137
RARE DISORDERS: RESEARCH, SURVEILLANCE, HEALTH PROMOTION, AND EDUCATION	93.315	5 U01 DD001073-06				\$22,399	\$74,780	RESEARCH AND DEVELOPMENT	\$357,858,137
RARE DISORDERS: RESEARCH, SURVEILLANCE, HEALTH PROMOTION, AND EDUCATION	93.315	5 U01 DD001075-06				\$3,782	\$74,780	RESEARCH AND DEVELOPMENT	\$357,858,137
EMERGING INFECTIONS PROGRAMS	93.317	59293:ST TN	TN DEPARTMENT OF HEALTH	59293:ST TN		\$2,624,870	\$2,886,847	RESEARCH AND DEVELOPMENT	\$357,858,137
COVID-19 EMERGING INFECTIONS PROGRAMS	93.317	COVID-19 59293:ST TN	TN DEPARTMENT OF HEALTH	59293:ST TN		\$261,977	\$2,886,847	RESEARCH AND DEVELOPMENT	\$357,858,137
EPIDEMIOLOGY AND LABORATORY CAPACITY FOR INFECTIOUS DISEASES (ELC)	93.323	61814:ST TN	TN DEPARTMENT OF HEALTH	61814:ST TN		\$205,175	\$223,549	RESEARCH AND DEVELOPMENT	\$357,858,137
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	5 KL2 TR002245-02				-\$6,006	\$0	RESEARCH AND DEVELOPMENT	\$357,858,137
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	5 KL2 TR002245-03				\$90,089	\$544,050	RESEARCH AND DEVELOPMENT	\$357,858,137
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	5 KL2 TR002245-04				\$245,944	\$17,692,747	RESEARCH AND DEVELOPMENT	\$357,858,137
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	5 R21 TR001723-02				\$80,412	\$17,692,747	RESEARCH AND DEVELOPMENT	\$357,858,137
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	5 TL1 TR002244-03				\$243,054	\$17,692,747	RESEARCH AND DEVELOPMENT	\$357,858,137
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	5 TL1 TR002244-04				\$76,581	\$17,692,747	RESEARCH AND DEVELOPMENT	\$357,858,137
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	5 U01 TR002398-02				\$177,764	\$895,746	RESEARCH AND DEVELOPMENT	\$357,858,137
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	5 U24 TR001579-03				\$106,092	\$129,304	RESEARCH AND DEVELOPMENT	\$357,858,137
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	5 U24 TR001579-04				\$175,094	\$3,379,907	RESEARCH AND DEVELOPMENT	\$357,858,137
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	5 U1L TR002243-03				\$537,661	\$7,090,651	RESEARCH AND DEVELOPMENT	\$357,858,137
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	5 U1L TR002243-04				\$2,144,080	\$17,692,747	RESEARCH AND DEVELOPMENT	\$357,858,137
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	1 U01 TR002383-01	VANDERBILT UNIVERSITY	1 U01 TR002383-01		\$6,284	\$17,692,747	RESEARCH AND DEVELOPMENT	\$357,858,137
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	1 U01 TR003206-01	ROCKEFELLER UNIVERSITY	1 U01 TR003206-01		\$2,069	\$17,692,747	RESEARCH AND DEVELOPMENT	\$357,858,137
UNIVERSITY OF CALIFORNIA AT LOS ANGELES									
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	3 U1L TR001881-0352	ANGELES	3 U1L TR001881-0352		-\$10,737	\$17,692,747	RESEARCH AND DEVELOPMENT	\$357,858,137
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	3 U1L TR002553-0251	DUKE UNIVERSITY	3 U1L TR002553-0251		\$21,511	\$17,692,747	RESEARCH AND DEVELOPMENT	\$357,858,137
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	4 UH3 TR002097-03	VANDERBILT UNIVERSITY	4 UH3 TR002097-03		\$283,745	\$17,692,747	RESEARCH AND DEVELOPMENT	\$357,858,137
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	5 U01 TR001803-02	DUKE UNIVERSITY	5 U01 TR001803-02		\$40,509	\$17,692,747	RESEARCH AND DEVELOPMENT	\$357,858,137
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	5 U01 TR001803-04	DUKE UNIVERSITY	5 U01 TR001803-04		\$161,352	\$17,692,747	RESEARCH AND DEVELOPMENT	\$357,858,137
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	5 U01 TR001812-03	UNIVERSITY OF MASSACHUSETTS	5 U01 TR001812-03		\$1,971	\$39,803	RESEARCH AND DEVELOPMENT	\$357,858,137
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	5 U01 TR001812-04	UNIVERSITY OF MASSACHUSETTS	5 U01 TR001812-04		\$189,161	\$17,692,747	RESEARCH AND DEVELOPMENT	\$357,858,137
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	5 U01 TR002383-02	VANDERBILT UNIVERSITY	5 U01 TR002383-02		\$89,829	\$17,692,747	RESEARCH AND DEVELOPMENT	\$357,858,137
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	5 U24 TR001608-04	DUKE UNIVERSITY	5 U24 TR001608-04		\$1,524,935	\$17,692,747	RESEARCH AND DEVELOPMENT	\$357,858,137
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	5 U24 TR001608-04	DUKE UNIVERSITY	5 U24 TR001608-04		\$1,562	\$17,692,747	RESEARCH AND DEVELOPMENT	\$357,858,137
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	5 U24 TR001608-04S1	DUKE UNIVERSITY	5 U24 TR001608-04S1		\$116,896	\$17,692,747	RESEARCH AND DEVELOPMENT	\$357,858,137
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	5 UG3 TR002097-02	VANDERBILT UNIVERSITY	5 UG3 TR002097-02		\$4,983	\$17,692,747	RESEARCH AND DEVELOPMENT	\$357,858,137
UNIVERSITY OF CALIFORNIA AT LOS ANGELES									
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	5 U1L TR001881-04	ANGELES	5 U1L TR001881-04		\$390,463	\$17,692,747	RESEARCH AND DEVELOPMENT	\$357,858,137
COVID-19 NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	COVID-19 5 U1L TR002243-04				\$653	\$17,692,747	RESEARCH AND DEVELOPMENT	\$357,858,137
21ST CENTURY CURES ACT - BEAU BIDEN CANCER MOONSHOT	93.353	1 U2C CA233291-01				\$239,737	\$1,480,863	RESEARCH AND DEVELOPMENT	\$357,858,137

Vanderbilt University Medical Center
Schedule of Expenditures of Federal Awards and State Financial Assistance
Fiscal Period 7/1/2019 – 6/30/2020

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
CANCER TREATMENT RESEARCH	93.395	1 R01 CA213201-01A1			\$95,473	\$318,202	\$2,780,047	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER TREATMENT RESEARCH	93.395	1 U01 CA253560-01				\$8,976	\$2,780,047	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER TREATMENT RESEARCH	93.395	5 R00 CA181491-04				\$2,401	\$2,780,047	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER TREATMENT RESEARCH	93.395	5 R01 CA166492-06				\$3,657	\$2,780,047	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER TREATMENT RESEARCH	93.395	5 R01 CA227481-02			\$8,758	\$489,415	\$2,780,047	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER TREATMENT RESEARCH	93.395	5 R21 CA208631-02				\$20	\$2,780,047	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER TREATMENT RESEARCH	93.395	5 R21 CA226562-02				\$99,912	\$2,780,047	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER TREATMENT RESEARCH	93.395	5 UG1 CA233270-01				\$336,503	\$2,780,047	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER TREATMENT RESEARCH	93.395	5 UG1 CA233270-02				\$136,229	\$2,780,047	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER TREATMENT RESEARCH	93.395	1 R01 CA224241-01A1	VANDERBILT UNIVERSITY	1 R01 CA224241-01A1		\$256,135	\$2,780,047	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER TREATMENT RESEARCH	93.395	1 R01 CA238553-01	VANDERBILT UNIVERSITY	1 R01 CA238553-01		\$3,606	\$2,780,047	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER TREATMENT RESEARCH	93.395	1 R01 CA243326-01A1	VANDERBILT UNIVERSITY	1 R01 CA243326-01A1		\$16,057	\$2,780,047	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER TREATMENT RESEARCH	93.395	1 R37 CA223770-01	VANDERBILT UNIVERSITY	1 R37 CA223770-01		\$2,525	\$2,780,047	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER TREATMENT RESEARCH	93.395	1 U01 CA236229-01	FRED HUTCHINSON CANCER RESEARCH CENTER	1 U01 CA236229-01		\$3,150	\$2,780,047	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER TREATMENT RESEARCH	93.395	1 UG1 CA189955-01	CHILDRENS HOSPITAL OF PHILADELPHIA	1 UG1 CA189955-01		-\$3,252	\$2,780,047	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER TREATMENT RESEARCH	93.395	1 UG1 CA233259-01	EMORY UNIVERSITY	1 UG1 CA233259-01		\$64,832	\$2,780,047	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER TREATMENT RESEARCH	93.395	2 P01 CA129243-11	MEMORIAL SLOAN-KETTERING CANCER CENTER	2 P01 CA129243-11		\$16,987	\$2,780,047	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER TREATMENT RESEARCH	93.395	2 U10 CA180820-06	EASTERN COOPERATIVE ONCOLOGY GROUP	2 U10 CA180820-06		\$13,336	\$2,780,047	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER TREATMENT RESEARCH	93.395	2 U10 CA180820-06	EASTERN COOPERATIVE ONCOLOGY GROUP	2 U10 CA180820-06		\$18,421	\$2,780,047	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER TREATMENT RESEARCH	93.395	2 U10 CA180820-07	EASTERN COOPERATIVE ONCOLOGY GROUP	2 U10 CA180820-07		\$6,299	\$2,780,047	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER TREATMENT RESEARCH	93.395	2 U10 CA180868-06	NRG ONCOLOGY FOUNDATION	2 U10 CA180868-06		\$7,477	\$2,780,047	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER TREATMENT RESEARCH	93.395	2 U10 CA180886-06	CHILDRENS HOSPITAL OF PHILADELPHIA	2 U10 CA180886-06		\$37,308	\$2,780,047	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER TREATMENT RESEARCH	93.395	2 U10 CA180886-06	CHILDRENS HOSPITAL OF PHILADELPHIA	2 U10 CA180886-06		\$48,938	\$2,780,047	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER TREATMENT RESEARCH	93.395	2 U10 CA180886-06	CHILDRENS HOSPITAL OF PHILADELPHIA	2 U10 CA180886-06		\$12,934	\$2,780,047	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER TREATMENT RESEARCH	93.395	2 U10 CA180886-06	CHILDRENS HOSPITAL OF PHILADELPHIA	2 U10 CA180886-06		\$10,653	\$2,780,047	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER TREATMENT RESEARCH	93.395	2 U10 CA180886-07	EASTERN COOPERATIVE ONCOLOGY GROUP	2 U10 CA180886-07		\$5,664	\$2,780,047	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER TREATMENT RESEARCH	93.395	2 U10 CA180888-06	SOUTHWEST ONCOLOGY GROUP	2 U10 CA180888-06		\$15,351	\$2,780,047	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER TREATMENT RESEARCH	93.395	4 R00 CA218892-02	UNIVERSITY OF HAWAII	4 R00 CA218892-02		\$101,041	\$2,780,047	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER TREATMENT RESEARCH	93.395	4 R42 CA171552-02	AADI, LLC	4 R42 CA171552-02		-\$409	\$2,780,047	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER TREATMENT RESEARCH	93.395	5 P01 CA129243-12	MEMORIAL SLOAN-KETTERING CANCER CENTER	5 P01 CA129243-12		\$125,928	\$2,780,047	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER TREATMENT RESEARCH	93.395	5 R01 CA116021-14	VANDERBILT UNIVERSITY	5 R01 CA116021-14		\$17,416	\$2,780,047	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER TREATMENT RESEARCH	93.395	5 R01 CA116021-15	VANDERBILT UNIVERSITY	5 R01 CA116021-15		\$20,506	\$2,780,047	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER TREATMENT RESEARCH	93.395	5 R01 CA181050-02	CHILDREN'S HOSPITAL LOS ANGELES	5 R01 CA181050-02		\$8,631	\$2,780,047	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER TREATMENT RESEARCH	93.395	5 R01 CA189163-04	JOHN WAYNE CANCER INSTITUTE	5 R01 CA189163-04		\$148	\$2,780,047	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER TREATMENT RESEARCH	93.395	5 R01 CA196854-04	CHILDRENS HOSPITAL OF PHILADELPHIA	5 R01 CA196854-04		-\$1,560	\$2,780,047	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER TREATMENT RESEARCH	93.395	5 R01 CA214043-03	VANDERBILT UNIVERSITY	5 R01 CA214043-03		\$62,731	\$2,780,047	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER TREATMENT RESEARCH	93.395	5 U10 CA018082-05	EASTERN COOPERATIVE ONCOLOGY GROUP	5 U10 CA018082-05		-\$1,514	\$2,780,047	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER TREATMENT RESEARCH	93.395	5 U10 CA180820-05	EASTERN COOPERATIVE ONCOLOGY GROUP	5 U10 CA180820-05		-\$2,160	\$2,780,047	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER TREATMENT RESEARCH	93.395	5 U10 CA180820-05	EASTERN COOPERATIVE ONCOLOGY GROUP	5 U10 CA180820-05		\$2,331	\$2,780,047	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER TREATMENT RESEARCH	93.395	5 U10 CA180820-05	EASTERN COOPERATIVE ONCOLOGY GROUP	5 U10 CA180820-05		\$3,070	\$2,780,047	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER TREATMENT RESEARCH	93.395	5 U10 CA180820-05	EASTERN COOPERATIVE ONCOLOGY GROUP	5 U10 CA180820-05		\$19,475	\$2,780,047	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER TREATMENT RESEARCH	93.395	5 U10 CA180820-05	EASTERN COOPERATIVE ONCOLOGY GROUP	5 U10 CA180820-05		\$13,863	\$2,780,047	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER TREATMENT RESEARCH	93.395	5 U10 CA180820-05	EASTERN COOPERATIVE ONCOLOGY GROUP	5 U10 CA180820-05		\$7,291	\$2,780,047	RESEARCH AND DEVELOPMENT	\$357,858,137

Vanderbilt University Medical Center
Schedule of Expenditures of Federal Awards and State Financial Assistance
Fiscal Period 7/1/2019 – 6/30/2020

<i>Federal Awarding Agency/Program Title</i>	<i>Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
CANCER TREATMENT RESEARCH	93.395	5 U10 CA180820-05	EASTERN COOPERATIVE ONCOLOGY GROUP	5 U10 CA180820-05		\$278	\$2,780,047	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER TREATMENT RESEARCH	93.395	5 U10 CA180820-05	EASTERN COOPERATIVE ONCOLOGY GROUP	5 U10 CA180820-05		\$855	\$2,780,047	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER TREATMENT RESEARCH	93.395	5 U10 CA180820-05	EASTERN COOPERATIVE ONCOLOGY GROUP	5 U10 CA180820-05		-\$9,843	\$2,780,047	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER TREATMENT RESEARCH	93.395	5 U10 CA180820-05	EASTERN COOPERATIVE ONCOLOGY GROUP	5 U10 CA180820-05		\$1,145	\$2,780,047	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER TREATMENT RESEARCH	93.395	5 U10 CA180820-05	EASTERN COOPERATIVE ONCOLOGY GROUP	5 U10 CA180820-05		\$743	\$2,780,047	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER TREATMENT RESEARCH	93.395	5 U10 CA180888-06	OREGON HEALTH & SCIENCE UNIVERSITY	5 U10 CA180888-06		\$15,137	\$2,780,047	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER TREATMENT RESEARCH	93.395	5 UG1 CA189867-04	NRG ONCOLOGY FOUNDATION	5 UG1 CA189867-04		\$2,813	\$2,780,047	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER TREATMENT RESEARCH	93.395	5 UG1 CA189955-05	CHILDRENS HOSPITAL OF PHILADELPHIA	5 UG1 CA189955-05		\$2,148	\$2,780,047	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER TREATMENT RESEARCH	93.395	5 UG1 CA233259-02	EMORY UNIVERSITY	5 UG1 CA233259-02		\$25,534	\$2,780,047	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER TREATMENT RESEARCH	93.395	5 UM1 CA186689-04	YALE UNIVERSITY	5 UM1 CA186689-04		\$95	\$2,780,047	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER TREATMENT RESEARCH	93.395	5 UM1 CA186689-05	YALE UNIVERSITY	5 UM1 CA186689-05		\$120,243	\$2,780,047	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER TREATMENT RESEARCH	93.395	9 R44 CA228756-02	CUMBERLAND PHARMACEUTICALS, INC.	9 R44 CA228756-02		\$273,678	\$2,780,047	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER TREATMENT RESEARCH	93.395	ECOG/NCTN NRG NEUCC001	EASTERN COOPERATIVE ONCOLOGY GROUP	ECOG/NCTN NRG NEUCC001		\$4,538	\$2,780,047	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER TREATMENT RESEARCH	93.395	ECOG/NCTN NRG NEUR0631	EASTERN COOPERATIVE ONCOLOGY GROUP	ECOG/NCTN NRG NEUR0631		\$9,344	\$2,780,047	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER TREATMENT RESEARCH	93.395	ECOG/NCTN:BRE E4112	EASTERN COOPERATIVE ONCOLOGY GROUP	ECOG/NCTN:BRE E4112		-\$632	\$2,780,047	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER TREATMENT RESEARCH	93.395	ECOG/NCTN:BRE EA1131	EASTERN COOPERATIVE ONCOLOGY GROUP	ECOG/NCTN:BRE EA1131		\$215	\$2,780,047	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER TREATMENT RESEARCH	93.395	ECOG/NCTN:BRE EA1141	EASTERN COOPERATIVE ONCOLOGY GROUP	ECOG/NCTN:BRE EA1141		-\$336	\$2,780,047	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER TREATMENT RESEARCH	93.395	ECOG/NCTN:BRE R1304	EASTERN COOPERATIVE ONCOLOGY GROUP	ECOG/NCTN:BRE R1304		\$911	\$2,780,047	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER TREATMENT RESEARCH	93.395	ECOG/NCTN:BRE S1418	EASTERN COOPERATIVE ONCOLOGY GROUP	ECOG/NCTN:BRE S1418		-\$1,271	\$2,780,047	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER TREATMENT RESEARCH	93.395	ECOG/NCTN:GI S1505	EASTERN COOPERATIVE ONCOLOGY GROUP	ECOG/NCTN:GI S1505		-\$43	\$2,780,047	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER TREATMENT RESEARCH	93.395	ECOG/NCTN:GI S1513	EASTERN COOPERATIVE ONCOLOGY GROUP	ECOG/NCTN:GI S1513		\$1,335	\$2,780,047	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER TREATMENT RESEARCH	93.395	ECOG/NCTN:GYN GY005	EASTERN COOPERATIVE ONCOLOGY GROUP	ECOG/NCTN:GYN GY005		\$15,928	\$2,780,047	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER TREATMENT RESEARCH	93.395	ECOG/NCTN:GYN GY008	EASTERN COOPERATIVE ONCOLOGY GROUP	ECOG/NCTN:GYN GY008		-\$1,648	\$2,780,047	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER TREATMENT RESEARCH	93.395	ECOG/NCTN:HEM E4412	EASTERN COOPERATIVE ONCOLOGY GROUP	ECOG/NCTN:HEM E4412		-\$863	\$2,780,047	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER TREATMENT RESEARCH	93.395	ECOG/NCTN:HEM EAI141	EASTERN COOPERATIVE ONCOLOGY GROUP	ECOG/NCTN:HEM EAI141		\$3,000	\$2,780,047	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER TREATMENT RESEARCH	93.395	ECOG/NCTN:MD EAY131	EASTERN COOPERATIVE ONCOLOGY GROUP	ECOG/NCTN:MD EAY131		\$2,589	\$2,780,047	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER TREATMENT RESEARCH	93.395	ECOG/NCTN:MEL E1697	EASTERN COOPERATIVE ONCOLOGY GROUP	ECOG/NCTN:MEL E1697		\$10	\$2,780,047	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER TREATMENT RESEARCH	93.395	ECOG/NCTN:MEL S1404	EASTERN COOPERATIVE ONCOLOGY GROUP	ECOG/NCTN:MEL S1404		\$10	\$2,780,047	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER TREATMENT RESEARCH	93.395	ECOG/NCTN:NRG THOCC003	EASTERN COOPERATIVE ONCOLOGY GROUP	ECOG/NCTN:NRG THOCC003		\$2,453	\$2,780,047	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER TREATMENT RESEARCH	93.395	ECOG/NCTN:NRG-GI002	EASTERN COOPERATIVE ONCOLOGY GROUP	ECOG/NCTN:NRG-GI002		\$5,630	\$2,780,047	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER TREATMENT RESEARCH	93.395	ECOG/NCTN:THO A081105	EASTERN COOPERATIVE ONCOLOGY GROUP	ECOG/NCTN:THO A081105		-\$283	\$2,780,047	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER TREATMENT RESEARCH	93.395	ECOG/NCTN:THO E4512	EASTERN COOPERATIVE ONCOLOGY GROUP	ECOG/NCTN:THO E4512		-\$874	\$2,780,047	RESEARCH AND DEVELOPMENT	\$357,858,137

Vanderbilt University Medical Center
Schedule of Expenditures of Federal Awards and State Financial Assistance
Fiscal Period 7/1/2019 – 6/30/2020

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
CANCER TREATMENT RESEARCH	93.395	ECOG/NCTN:THO EA5142	EASTERN COOPERATIVE ONCOLOGY GROUP	ECOG/NCTN:THO EA5142		-\$161	\$2,780,047	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER TREATMENT RESEARCH	93.395	ECOG/NCTN:THO S1403	EASTERN COOPERATIVE ONCOLOGY GROUP	ECOG/NCTN:THO S1403		-\$1,229	\$2,780,047	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER TREATMENT RESEARCH	93.395	ECOG/NCTN:URO EA8143	EASTERN COOPERATIVE ONCOLOGY GROUP	ECOG/NCTN:URO EA8143		\$62	\$2,780,047	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER TREATMENT RESEARCH	93.395	ECOG: HEM E1906	EASTERN COOPERATIVE ONCOLOGY GROUP	ECOG: HEM E1906		\$12	\$2,780,047	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER BIOLOGY RESEARCH	93.396	1 R01 CA22594-02				\$374,092	\$6,483,190	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER BIOLOGY RESEARCH	93.396	1 R01 CA235016-01A1			\$26,353	\$447,510	\$6,483,190	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER BIOLOGY RESEARCH	93.396	1 R01 CA249424-01				\$100,736	\$6,483,190	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER BIOLOGY RESEARCH	93.396	1 R01 CA250051-01				\$61,933	\$6,483,190	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER BIOLOGY RESEARCH	93.396	1 R13 CA243567-01				\$6,361	\$6,483,190	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER BIOLOGY RESEARCH	93.396	1 UG3 CA241685-01			\$113,488	\$459,555	\$6,483,190	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER BIOLOGY RESEARCH	93.396	5 R00 CA194198-04				\$71,295	\$6,483,190	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER BIOLOGY RESEARCH	93.396	5 R01 CA095004-15				\$123,614	\$6,483,190	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER BIOLOGY RESEARCH	93.396	5 R01 CA177681-06				\$128,239	\$6,483,190	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER BIOLOGY RESEARCH	93.396	5 R01 CA193219-06				\$360,726	\$6,483,190	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER BIOLOGY RESEARCH	93.396	5 R01 CA200681-04				\$365,840	\$6,483,190	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER BIOLOGY RESEARCH	93.396	5 R01 CA217987-03			\$28,136	\$499,143	\$6,483,190	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER BIOLOGY RESEARCH	93.396	5 R01 CA227833-02				\$120,310	\$6,483,190	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER BIOLOGY RESEARCH	93.396	5 R35 CA197570-03				\$555,724	\$6,483,190	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER BIOLOGY RESEARCH	93.396	5 R35 CA197570-04				\$236,353	\$6,483,190	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER BIOLOGY RESEARCH	93.396	5 U01 CA196405-05			\$189,031	\$373,934	\$6,483,190	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER BIOLOGY RESEARCH	93.396	5 U01 CA196405-06			\$125,592	\$768,002	\$6,483,190	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER BIOLOGY RESEARCH	93.396	5 U01 CA196405-06				\$9,490	\$6,483,190	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER BIOLOGY RESEARCH	93.396	5 U19 CA179514-06			\$10,258	\$10,872	\$6,483,190	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER BIOLOGY RESEARCH	93.396	5 U24 CA163056-09				\$262,632	\$6,483,190	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER BIOLOGY RESEARCH	93.396	5 U24 CA163056-10				\$117,081	\$6,483,190	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER BIOLOGY RESEARCH	93.396	7 R01 CA211695-04				\$280,394	\$6,483,190	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER BIOLOGY RESEARCH	93.396	1 P01 CA229123-01A1	VANDERBILT UNIVERSITY	1 P01 CA229123-01A1		\$159,355	\$6,483,190	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER BIOLOGY RESEARCH	93.396	1 R01 CA226833-01A1	VANDERBILT UNIVERSITY	1 R01 CA226833-01A1		\$39,591	\$6,483,190	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER BIOLOGY RESEARCH	93.396	1 R01 CA226833-02	VANDERBILT UNIVERSITY	1 R01 CA226833-02		\$21,878	\$6,483,190	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER BIOLOGY RESEARCH	93.396	1 R01 CA234557-01A1	CEDARS-SINAI MEDICAL CENTER	1 R01 CA234557-01A1		\$1,984	\$6,483,190	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER BIOLOGY RESEARCH	93.396	1 R21 CA210210-02	UNIVERSITY OF KANSAS	1 R21 CA210210-02		\$42,693	\$6,483,190	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER BIOLOGY RESEARCH	93.396	1 U01 CA233581-01	UNIVERSITY OF ALABAMA AT BIRMINGHAM	1 U01 CA233581-01		\$40,206	\$6,483,190	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER BIOLOGY RESEARCH	93.396	5 U01 CA202229-03	VANDERBILT UNIVERSITY	5 U01 CA202229-03		\$10,315	\$6,483,190	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER BIOLOGY RESEARCH	93.396	5 U01 CA233581-02	UNIVERSITY OF ALABAMA AT BIRMINGHAM	5 U01 CA233581-02		\$51,258	\$6,483,190	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER BIOLOGY RESEARCH	93.396	5 U24 CA194215-03	TEXAS HEALTH SCIENCE HOUSTON	5 U24 CA194215-03		\$135,447	\$6,483,190	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER BIOLOGY RESEARCH	93.396	5 U24 CA194215-04	TEXAS HEALTH SCIENCE HOUSTON	5 U24 CA194215-04		\$124,673	\$6,483,190	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER BIOLOGY RESEARCH	93.396	5 U24 CA213274-03	MEMORIAL SLOAN-KETTERING CANCER CENTER	5 U24 CA213274-03		\$53,370	\$6,483,190	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER BIOLOGY RESEARCH	93.396	5 U24 CA213274-04	MEMORIAL SLOAN-KETTERING CANCER CENTER	5 U24 CA213274-04		\$24,544	\$6,483,190	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER BIOLOGY RESEARCH	93.396	HHSN261200800001E	LEIDOS BIOMEDICAL RESEARCH, INC.	HHSN261200800001E		\$44,040	\$6,483,190	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER CENTERS SUPPORT GRANTS	93.397	1 P50 CA236733-01			\$82,412	\$1,713,176	\$11,378,404	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER CENTERS SUPPORT GRANTS	93.397	2 P50 CA098131-17A1			\$1,047	\$1,242,310	\$11,378,404	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER CENTERS SUPPORT GRANTS	93.397	5 P20 CA210300-02			\$24,500	\$41,744	\$11,378,404	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER CENTERS SUPPORT GRANTS	93.397	5 P30 CA068485-22				\$4,502	\$11,378,404	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER CENTERS SUPPORT GRANTS	93.397	5 P30 CA068485-23			\$796,458	\$1,767,074	\$11,378,404	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER CENTERS SUPPORT GRANTS	93.397	5 P30 CA068485-24			\$642,317	\$4,953,615	\$11,378,404	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER CENTERS SUPPORT GRANTS	93.397	5 P50 CA098131-16			\$80,372	\$216,807	\$11,378,404	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER CENTERS SUPPORT GRANTS	93.397	5 P50 CA236733-02				\$107,530	\$11,378,404	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER CENTERS SUPPORT GRANTS	93.397	5 P50 CA98131-15			-\$9,349	-\$9,349	\$11,378,404	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER CENTERS SUPPORT GRANTS	93.397	5 U54 CA163072-09			\$265,214	\$528,312	\$11,378,404	RESEARCH AND DEVELOPMENT	\$357,858,137

Vanderbilt University Medical Center
Schedule of Expenditures of Federal Awards and State Financial Assistance
Fiscal Period 7/1/2019 – 6/30/2020

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
CANCER CENTERS SUPPORT GRANTS	93.397	5 U54 CA163072-10			\$68,990	\$569,544	\$11,378,404	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER CENTERS SUPPORT GRANTS	93.397	2 P50 CA150964-07	CASE WESTERN RESERVE UNIVERSITY	2 P50 CA150964-07		\$732	\$11,378,404	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER CENTERS SUPPORT GRANTS	93.397	3 P30 CA016086-4353	UNIVERSITY OF NORTH CAROLINA	3 P30 CA016086-4353		\$5,280	\$11,378,404	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER CENTERS SUPPORT GRANTS	93.397	5 U54 CA217450-02	VANDERBILT UNIVERSITY	5 U54 CA217450-02		\$1,339	\$11,378,404	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER CENTERS SUPPORT GRANTS	93.397	5 U54 CA217450-02	VANDERBILT UNIVERSITY	5 U54 CA217450-02		\$171,498	\$11,378,404	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER CENTERS SUPPORT GRANTS	93.397	5 U54 CA217450-03	VANDERBILT UNIVERSITY	5 U54 CA217450-03		\$45,394	\$11,378,404	RESEARCH AND DEVELOPMENT	\$357,858,137
COVID-19 CANCER CENTERS SUPPORT GRANTS	93.397	COVID-19 5 P30 CA068485-24				\$18,896	\$11,378,404	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER RESEARCH MANPOWER	93.398	1 F32 CA236309-01				\$33,479	\$3,189,252	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER RESEARCH MANPOWER	93.398	1 K08 CA241351-01A1				\$27,974	\$3,189,252	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER RESEARCH MANPOWER	93.398	1 T32 CA217834-01A1				\$19,103	\$3,189,252	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER RESEARCH MANPOWER	93.398	4 K00 CA234920-03				\$64,235	\$3,189,252	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER RESEARCH MANPOWER	93.398	5 F32 CA224962-02				\$24	\$3,189,252	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER RESEARCH MANPOWER	93.398	5 F32 CA236309-02				\$43,454	\$3,189,252	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER RESEARCH MANPOWER	93.398	5 K07 CA218247-03				\$149,528	\$3,189,252	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER RESEARCH MANPOWER	93.398	5 K07 CA225404-03				\$144,796	\$3,189,252	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER RESEARCH MANPOWER	93.398	5 K12 CA090625-19				-\$836	\$3,189,252	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER RESEARCH MANPOWER	93.398	5 K12 CA090625-20				\$1,213,792	\$3,189,252	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER RESEARCH MANPOWER	93.398	5 K23 CA204726-03				\$162,114	\$3,189,252	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER RESEARCH MANPOWER	93.398	5 K25 CA176219-06				\$74,683	\$3,189,252	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER RESEARCH MANPOWER	93.398	5 K99 CA215360-02				\$57,745	\$3,189,252	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER RESEARCH MANPOWER	93.398	5 K99 CA230205-02				\$119,055	\$3,189,252	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER RESEARCH MANPOWER	93.398	5 T32 CA106183-15				-\$462	\$3,189,252	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER RESEARCH MANPOWER	93.398	5 T32 CA106183-16				\$242,703	\$3,189,252	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER RESEARCH MANPOWER	93.398	5 T32 CA160056-08				\$60,899	\$3,189,252	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER RESEARCH MANPOWER	93.398	5 T32 CA160056-09				\$324,355	\$3,189,252	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER RESEARCH MANPOWER	93.398	5 T32 CA217834-02				\$218,778	\$3,189,252	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER RESEARCH MANPOWER	93.398	2 T32 CA009582-31	VANDERBILT UNIVERSITY	2 T32 CA009582-31		\$38,504	\$3,189,252	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER RESEARCH MANPOWER	93.398	2 T32 CA009582-31	VANDERBILT UNIVERSITY	2 T32 CA009582-31		-\$295	\$3,189,252	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER RESEARCH MANPOWER	93.398	2 T32 CA009592-31A1	VANDERBILT UNIVERSITY	2 T32 CA009592-31A1		\$11,390	\$3,189,252	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER RESEARCH MANPOWER	93.398	2 T32 CA119925-11	VANDERBILT UNIVERSITY	2 T32 CA119925-11		\$22,637	\$3,189,252	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER RESEARCH MANPOWER	93.398	2 T32 CA119925-11	VANDERBILT UNIVERSITY	2 T32 CA119925-11		\$77,410	\$3,189,252	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER RESEARCH MANPOWER	93.398	2 T32 CA119925-11	VANDERBILT UNIVERSITY	2 T32 CA119925-11		\$9,076	\$3,189,252	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER RESEARCH MANPOWER	93.398	5 T32 CA009582-32	VANDERBILT UNIVERSITY	5 T32 CA009582-32		\$3,575	\$3,189,252	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER RESEARCH MANPOWER	93.398	5 T32 CA119925-12	VANDERBILT UNIVERSITY	5 T32 CA119925-12		\$32,826	\$3,189,252	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER RESEARCH MANPOWER	93.398	5 T32 CA119925-12	VANDERBILT UNIVERSITY	5 T32 CA119925-12		\$38,710	\$3,189,252	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER CONTROL	93.399	2 UG1 CA189955-06	CHILDRENS HOSPITAL OF PHILADELPHIA	2 UG1 CA189955-06		\$24,023	\$26,243	RESEARCH AND DEVELOPMENT	\$357,858,137
CANCER CONTROL	93.399	2 UG1 CA189955-06	CHILDRENS HOSPITAL OF PHILADELPHIA	2 UG1 CA189955-06		\$2,220	\$26,243	RESEARCH AND DEVELOPMENT	\$357,858,137
ACL NATIONAL INSTITUTE ON DISABILITY, INDEPENDENT LIVING, AND REHABILITATION RESEARCH	93.433	90IFRE0001-01-00	VANDERBILT UNIVERSITY	90IFRE0001-01-00		\$2,430	\$2,430	RESEARCH AND DEVELOPMENT	\$357,858,137
COVID-19 TESTING FOR THE UNINSURED	93.461	COVID-19 HRSA COVID UNINSURED				\$1,543,288	\$1,543,288	N/A	\$0
ALZHEIMER'S DISEASE PROGRAM INITIATIVE	93.470	65462:ST TN	STATE OF TENNESSEE COMMISSION ON AGING AND DISABILITY	65462:ST TN		\$17,794	\$17,794	RESEARCH AND DEVELOPMENT	\$357,858,137
PREVENTING MATERNAL DEATHS: SUPPORTING MATERNAL MORTALITY REVIEW COMMITTEES (B)	93.478	65563:ST TN	TN DEPARTMENT OF HEALTH	65563:ST TN		\$26,982	\$26,982	N/A	\$0
ACA - STATE INNOVATION MODELS: FUNDING FOR MODEL DESIGN AND MODEL TESTING ASSISTANCE	93.624	60138:ST TN	TN DEPARTMENT OF HEALTH	60138:ST TN		\$83,667	\$83,667	RESEARCH AND DEVELOPMENT	\$357,858,137
DEVELOPMENTAL DISABILITIES BASIC SUPPORT AND ADVOCACY GRANTS	93.630	58369:ST TN	TN DEPARTMENT OF ECONOMIC AND COMMUNITY DEVELOPMENT	58369:ST TN		-\$3,720	\$142,663	N/A	\$0
DEVELOPMENTAL DISABILITIES BASIC SUPPORT AND ADVOCACY GRANTS	93.630	60173:ST TN	TN DEPARTMENT OF MENTAL HEALTH AND DEVELOPMENTAL DISABILITIE	60173:ST TN		\$63	\$142,663	N/A	\$0
ADMINISTRATION FOR COMMUNITY LIVING (ACL), HEALTH AND HUMAN SERVICES, DEPARTMENT OF	93.630	60176:ST TN	TN DEPARTMENT OF MENTAL HEALTH AND DEVELOPMENTAL DISABILITIE	60176:ST TN		-\$2,193	\$142,663	N/A	\$0
DEVELOPMENTAL DISABILITIES BASIC SUPPORT AND ADVOCACY GRANTS	93.630	62942:ST TN	TN DEPARTMENT OF MENTAL HEALTH AND DEVELOPMENTAL DISABILITIE	62942:ST TN		\$148,513	\$142,663	N/A	\$0

Vanderbilt University Medical Center
Schedule of Expenditures of Federal Awards and State Financial Assistance
Fiscal Period 7/1/2019 – 6/30/2020

<i>Federal Awarding Agency/Program Title</i>	<i>Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
DEVELOPMENTAL DISABILITIES PROJECTS OF NATIONAL SIGNIFICANCE	93.631	90DNHC0001-01-00	CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER	90DNHC0001-01-00		\$22,880	\$22,880	N/A	\$0
UNIVERSITY CENTERS FOR EXCELLENCE IN DEVELOPMENTAL DISABILITIES EDUCATION, RESEARCH, AND SERVICE	93.632	90 DD000825-03-00			\$19,823	\$20,586	\$472,479	N/A	\$0
UNIVERSITY CENTERS FOR EXCELLENCE IN DEVELOPMENTAL DISABILITIES EDUCATION, RESEARCH, AND SERVICE	93.632	90 DD000825-04-00			\$54,917	\$451,893	\$472,479	N/A	\$0
ACA-TRANSFORMING CLINICAL PRACTICE INITIATIVE: PRACTICE TRANSFORMATION NETWORKS (PTNS)	93.638	1 L1 CMS331549-03-00			\$282,928	\$2,974,744	\$2,974,744	RESEARCH AND DEVELOPMENT	\$357,858,137
FOSTER CARE_TITLE IV-E	93.658	56787:ST TN	TN DEPARTMENT OF CHILDREN'S SERVICES	56787:ST TN		\$45,411	\$138,961	N/A	\$0
FOSTER CARE_TITLE IV-E	93.658	60895:ST TN	TN DEPARTMENT OF MENTAL HEALTH AND DEVELOPMENTAL DISABILITIES	60895:ST TN		\$93,550	\$138,961	N/A	\$0
MATERNAL OPIOID MISUSE MODEL (A)	93.687	31865-00907:ST TN	TN BUREAU OF TENN CARE	31865-00907:ST TN		\$178,525	\$178,525	RESEARCH AND DEVELOPMENT	\$357,858,137
PREVENTIVE HEALTH AND HEALTH SERVICES BLOCK GRANT FUNDED SOLELY WITH PREVENTION AND PUBLIC HEALTH FUNDS (PPHF)	93.758	59366:ST TN	TN DEPARTMENT OF HEALTH	59366:ST TN		\$369,852	\$369,852	N/A	\$0
MEDICAL ASSISTANCE PROGRAM	93.778	46264:ST TN	TN BUREAU OF TENN CARE	46264:ST TN		\$1,135,916	\$5,405,982	MEDICAID CLUSTER	\$5,405,982
MEDICAL ASSISTANCE PROGRAM	93.778	52379:ST TN	TN DEPARTMENT OF MENTAL HEALTH AND DEVELOPMENTAL DISABILITIES	52379:ST TN		\$330,815	\$5,405,982	MEDICAID CLUSTER	\$5,405,982
MEDICAL ASSISTANCE PROGRAM	93.778	53068:ST TN	TN DEPARTMENT OF MENTAL HEALTH AND DEVELOPMENTAL DISABILITIES	53068:ST TN	-\$2,877	\$2,773,225	\$5,405,982	MEDICAID CLUSTER	\$5,405,982
MEDICAL ASSISTANCE PROGRAM	93.778	54867:ST TN	TN DEPARTMENT OF HEALTH	54867:ST TN	-\$36,141	\$30,654	\$5,405,982	MEDICAID CLUSTER	\$5,405,982
MEDICAL ASSISTANCE PROGRAM	93.778	54867:ST TN	TN DEPARTMENT OF HEALTH	54867:ST TN	\$9,553	\$536,338	\$5,405,982	MEDICAID CLUSTER	\$5,405,982
MEDICAL ASSISTANCE PROGRAM	93.778	61290:ST TN	TN BUREAU OF TENN CARE	61290:ST TN		\$9,861	\$5,405,982	MEDICAID CLUSTER	\$5,405,982
MEDICAL ASSISTANCE PROGRAM	93.778	CDC-BCBS	BLUECROSS BLUESHIELD OF TENNESSEE HEALTH FOUNDATION, INC.	CDC-BCBS		\$589,173	\$5,405,982	MEDICAID CLUSTER	\$5,405,982
OPIOID STR	93.788	62292:ST TN	TN DEPARTMENT OF MENTAL HEALTH AND DEVELOPMENTAL DISABILITIES	62292:ST TN		\$146,719	\$714,678	N/A	\$0
OPIOID STR	93.788	65038:ST TN	TN DEPARTMENT OF MENTAL HEALTH AND DEVELOPMENTAL DISABILITIES	65038:ST TN		\$544,140	\$714,678	N/A	\$0
OPIOID STR	93.788	65428:ST TN	TN DEPARTMENT OF MENTAL HEALTH AND DEVELOPMENTAL DISABILITIES	65428:ST TN		\$23,819	\$714,678	N/A	\$0
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 DP2 HL137166-01			\$11,369	\$616,048	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 DP2 HL152426-01				\$241,828	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 F32 HL140849-01				\$1,279	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 F32 HL143927-01A1				\$52,184	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 F32 HL144048-01				\$11,240	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 F32 HL144050-01A1				\$64,037	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 F32 HL144081-01				\$4,641	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 K08 HL145075-01				\$145,461	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 K23 HL148640-01A1				\$19,236	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 R00 HL135442-04			\$30,020	\$218,185	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 R01 HL140074-01:03				\$434,831	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 R01 HL142583-01				\$76,134	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 R01 HL142583-01A1				\$385,944	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 R01 HL142856-02				\$476,711	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 R01 HL144568-01A1				\$123,345	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 R01 HL145293-01A1				\$115,229	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 R01 HL146401-01				\$484,871	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 R01 HL146654-01A1				\$89,516	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 R01 HL148244-01				\$321,156	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 R01 HL148661-01			\$30,791	\$263,842	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 R01 HL149826-01				\$207,963	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 R01 HL149948-01				\$88,184	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 R01 HL151523-01				\$86,688	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 R21 HL140382-01A1				\$90,869	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 R35 HL144980-01				\$610,343	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 R56 HL141248-01			\$19,500	\$404,867	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137

Vanderbilt University Medical Center
Schedule of Expenditures of Federal Awards and State Financial Assistance
Fiscal Period 7/1/2019 – 6/30/2020

<i>Federal Awarding Agency/Program Title</i>	<i>Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>	
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 R56 HL141466-01				\$138,042	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137	
CARDIOVASCULAR DISEASES RESEARCH	93.837	2 R56 HL081707-12A1				\$343,990	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137	
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 F32 HL137385-02				\$10,221	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137	
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 F32 HL137385-03				\$14,283	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137	
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 F32 HL137394-02				\$2,224	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137	
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 F32 HL140849-02				\$71,218	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137	
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 F32 HL143927-02				\$13,297	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137	
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 F32 HL144048-02				\$58,010	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137	
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 F32 HL144081-02				\$52,957	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137	
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 K01 HL130497-06				\$124,643	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137	
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 K01 HL135461-03				\$159,247	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137	
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 K01 HL140278-03				\$171,963	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137	
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 K08 HL121671-06				\$11,048	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137	
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 K12 HL133117-04			\$31,352	\$703,612	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137	
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 K23 HL127104-04				\$182,348	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137	
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 K23 HL127130-04				\$78,249	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137	
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 K23 HL127704-05				\$92,761	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137	
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 K23 HL128928-04				\$168,974	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137	
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 K23 HL133477-03				\$141,602	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137	
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 P01 HL116263-05			\$74,104	\$83,320	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137	
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 P01 HL128203-03			\$387,981	\$420,300	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137	
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 P01 HL128203-04			\$1,484,533	\$2,153,934	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137	
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 P01 HL129941-03			\$459,718	\$503,714	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137	
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 P01 HL129941-04			\$524,875	\$1,708,801	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137	
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL070715-15				\$529,707	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137	
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL094786-07			\$53,990	\$53,990	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137	
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL094786-08			\$274,687	\$605,060	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137	
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL121139-05				\$49,275	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137	
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL122847-05				\$7,385	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137	
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL124116-04				\$46,739	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137	
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL124935-06				\$179,107	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137	
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL125032-05			\$11,932	\$11,932	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137	
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL125426-06			\$27,340	\$305,646	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137	
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL127173-05				\$333,061	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137	
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL128386-04				\$604,236	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137	
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL128983-03				-\$1,450	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137	
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL128983-04				\$599,845	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137	
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL128996-05				\$359,249	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137	
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL131977-03			\$45,697	\$45,697	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137	
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL131977-04			\$166,281	\$439,039	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137	
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL133127-02			\$4,774	\$363,685	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137	
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL133290-03				\$26,671	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137	
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL133786-04				\$8,552	\$358,305	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL133860-03				\$74,817	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137	
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL133860-04			\$138,381	\$458,819	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137	
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL134895-03				\$313,391	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137	
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL135011-03				\$409,042	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137	
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL138519-02				\$453,056	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137	
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL140145-02				\$172,868	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137	
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL140145-03				\$209,704	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137	
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL141466-02				\$634,082	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137	
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL144846-02			\$15,816	\$335,809	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137	
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL144943-02			\$23,059	\$247,334	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137	
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL146524-02				\$465,697	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137	
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL149386-02				\$508,677	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137	
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL149386-02				\$171,359	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137	
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R03 HL135453-02			\$5,074	\$18,465	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137	

Vanderbilt University Medical Center
Schedule of Expenditures of Federal Awards and State Financial Assistance
Fiscal Period 7/1/2019 – 6/30/2020

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R21 HL132805-02				\$58,466	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R21 HL140375-02				\$98,920	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R25 HL096223-09			-\$507	\$0	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R25 HL096223-10			\$5,606	\$24,058	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R25 HL096223-11				\$14,197	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R35 HL140016-02			\$58,871	\$266,672	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R35 HL140016-03			\$5,917	\$394,308	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R35 HL144980-02				\$217,564	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 T32 HL105334-08				\$3,354	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 T32 HL105334-09				\$446,060	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 U01 HL131911-05				\$730,612	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
CARDIOVASCULAR DISEASES RESEARCH	93.837	6 P01 HL056693-20				-\$3,418	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 OT3 HL142481-01	UNIVERSITY OF CALIFORNIA, SANTA CRUZ	1 OT3 HL142481-01		\$78,041	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 OT3 HL142481-01	UNIVERSITY OF CALIFORNIA, SANTA CRUZ	1 OT3 HL142481-01		\$17,878	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 R01 HL146134-01	BOSTON CHILDREN'S HOSPITAL	1 R01 HL146134-01		\$45,938	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 R01 HL148137-01	HARVARD UNIVERSITY	1 R01 HL148137-01		\$75,033	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 R01 HL151223-01	VANDERBILT UNIVERSITY	1 R01 HL151223-01		\$12,551	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 R03 HL144668-01	UNIVERSITY OF PITTSBURGH	1 R03 HL144668-01		\$26,629	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 R21 HL140043-01A1	BOSTON CHILDREN'S HOSPITAL	1 R21 HL140043-01A1		\$2,627	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 R21 HL140043-02	BOSTON CHILDREN'S HOSPITAL	1 R21 HL140043-02		\$24,642	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 R21 HL145420-01	BRIGHAM AND WOMEN'S HOSPITAL	1 R21 HL145420-01		\$10,245	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 R44 HL132746-01A1	THERMEDICAL, INC.	1 R44 HL132746-01A1		\$22,297	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 R56 HL136517-01	UNIVERSITY OF PITTSBURGH	1 R56 HL136517-01		\$876	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 T32 HL144446-01	VANDERBILT UNIVERSITY	1 T32 HL144446-01		\$57,500	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 T32 HL144446-01	VANDERBILT UNIVERSITY	1 T32 HL144446-01		\$61,685	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 T32 HL144446-01	VANDERBILT UNIVERSITY	1 T32 HL144446-01		\$2,982	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 T32 HL144446-02	VANDERBILT UNIVERSITY	1 T32 HL144446-02		\$1,592	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 U01 HL069294-01	UNIVERSITY OF MICHIGAN	1 U01 HL069294-01		-\$5,154	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 U01 HL105907-01	NEW YORK UNIVERSITY	1 U01 HL105907-01		\$148	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
CARDIOVASCULAR DISEASES RESEARCH	93.837	1 U01 HL123336-01	BRIGHAM AND WOMEN'S HOSPITAL	1 U01 HL123336-01		\$73,729	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
CARDIOVASCULAR DISEASES RESEARCH	93.837	2 K24 HL112827-06	UNIVERSITY OF CALIFORNIA AT SAN FRANCISCO	2 K24 HL112827-06	\$3,361	\$49,570	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
CARDIOVASCULAR DISEASES RESEARCH	93.837	2 R25 HL105446-09	STATE UNIVERSITY OF NEW YORK (SUNY)	2 R25 HL105446-09		\$4,755	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
CARDIOVASCULAR DISEASES RESEARCH	93.837	3 R01 HL135114-02S1	JOHNS HOPKINS UNIVERSITY	3 R01 HL135114-02S1		\$15,993	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
CARDIOVASCULAR DISEASES RESEARCH	93.837	4 R24 HL105333-05	CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER	4 R24 HL105333-05		-\$9,433	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
CARDIOVASCULAR DISEASES RESEARCH	93.837	4 R44 HL140669-02	VOLUMETRIX LLC	4 R44 HL140669-02		\$127,193	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
CARDIOVASCULAR DISEASES RESEARCH	93.837	4 U01 HL117904-06	DUKE UNIVERSITY	4 U01 HL117904-06		\$25,841	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
CARDIOVASCULAR DISEASES RESEARCH	93.837	4 U10 HL068270-15	NEW ENGLAND RESEARCH INSTITUTES	4 U10 HL068270-15		\$8,426	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
CARDIOVASCULAR DISEASES RESEARCH	93.837	4 U10 HL068270-15	NEW ENGLAND RESEARCH INSTITUTES	4 U10 HL068270-15		\$34,056	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 K01 HL124391-05	BRIGHAM AND WOMEN'S HOSPITAL	5 K01 HL124391-05		\$34,367	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 K01 HL142848-02	UNIVERSITY OF ARIZONA	5 K01 HL142848-02		\$1,066	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 P50 HL112349-05	BRIGHAM AND WOMEN'S HOSPITAL	5 P50 HL112349-05		\$8,318	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL11821-08	MASSACHUSETTS GENERAL HOSPITAL	5 R01 HL11821-08		\$158,616	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL122347-04	VANDERBILT UNIVERSITY	5 R01 HL122347-04		\$25,788	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL123968-06	STANFORD UNIVERSITY	5 R01 HL123968-06		\$9,826	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL123968-07	STANFORD UNIVERSITY	5 R01 HL123968-07		\$5,667	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL126557-04	INDIANA UNIVERSITY-PURDUE UNIVERSITY INDIANAPOLIS	5 R01 HL126557-04		\$3,546	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL128393-03	UNIVERSITY OF OKLAHOMA	5 R01 HL128393-03		\$127,310	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL129856-04	UNIVERSITY OF CALIFORNIA AT SAN FRANCISCO	5 R01 HL129856-04		\$94,628	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL130502-04	NORTHWESTERN UNIVERSITY	5 R01 HL130502-04		\$31,279	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL130502-05	NORTHWESTERN UNIVERSITY	5 R01 HL130502-05		\$9,179	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL130828-03	DARTMOUTH COLLEGE	5 R01 HL130828-03		\$18,717	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL130828-04	DARTMOUTH COLLEGE	5 R01 HL130828-04		\$93,431	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL132320-04	HARVARD UNIVERSITY	5 R01 HL132320-04		\$19,625	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137

Vanderbilt University Medical Center
Schedule of Expenditures of Federal Awards and State Financial Assistance
Fiscal Period 7/1/2019 – 6/30/2020

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL133790-03	TULANE UNIVERSITY	5 R01 HL133790-03		\$2,795	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL133790-04	TULANE UNIVERSITY	5 R01 HL133790-04		\$197	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL134731-03	UNIVERSITY OF KENTUCKY	5 R01 HL134731-03		\$54,474	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL134731-04	UNIVERSITY OF KENTUCKY	5 R01 HL134731-04		\$44,798	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL134905-03	UNIVERSITY OF PENNSYLVANIA	5 R01 HL134905-03		\$18,692	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL134905-04	UNIVERSITY OF PENNSYLVANIA	5 R01 HL134905-04		\$14,267	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL136679-02	UNIVERSITY OF MINNESOTA	5 R01 HL136679-02		\$12,851	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL141851-02	STANFORD UNIVERSITY	5 R01 HL141851-02		\$10,360	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL142302-03	UNIVERSITY OF NORTH CAROLINA	5 R01 HL142302-03		\$271,984	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL146134-02	BOSTON CHILDREN'S HOSPITAL	5 R01 HL146134-02		\$46,000	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL147818-22	UNIVERSITY OF PITTSBURGH	5 R01 HL147818-22		\$45,906	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R21 HL145420-02	BRIGHAM AND WOMEN'S HOSPITAL	5 R21 HL145420-02		\$7,872	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R34 HL136986-02	INDIANA UNIVERSITY	5 R34 HL136986-02		\$16,589	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL11821-09	MASSACHUSETTS GENERAL HOSPITAL	5 R01 HL11821-09		\$16,213	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 T32 HL007411-38	VANDERBILT UNIVERSITY	5 T32 HL007411-38		-\$15,731	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 T32 HL007411-39	VANDERBILT UNIVERSITY	5 T32 HL007411-39		\$59,021	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 T32 HL007411-39	VANDERBILT UNIVERSITY	5 T32 HL007411-39		\$54,756	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 T32 HL007411-39	VANDERBILT UNIVERSITY	5 T32 HL007411-39		\$18,698	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 T32 HL007411-39	VANDERBILT UNIVERSITY	5 T32 HL007411-39		\$56,911	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 T32 HL007411-39	VANDERBILT UNIVERSITY	5 T32 HL007411-39		\$9,480	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 U01 HL105462-07	DUKE UNIVERSITY	5 U01 HL105462-07		\$42,813	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 U01 HL120338-05	UNIVERSITY OF ALABAMA AT BIRMINGHAM	5 U01 HL120338-05		-\$118	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 U01 HL120338-06	UNIVERSITY OF ALABAMA AT BIRMINGHAM	5 U01 HL120338-06		\$2,140	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 U01 HL130163-02	BRIGHAM AND WOMEN'S HOSPITAL	5 U01 HL130163-02		-\$83,149	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 U01 HL130163-04	BRIGHAM AND WOMEN'S HOSPITAL	5 U01 HL130163-04		\$2,674	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 U01 HL130163-04	BRIGHAM AND WOMEN'S HOSPITAL	5 U01 HL130163-04		\$8,361	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 U10 HL084904-12	DUKE UNIVERSITY	5 U10 HL084904-12		\$14,541	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 U24 HL135691-02	NEW ENGLAND RESEARCH INSTITUTES	5 U24 HL135691-02		\$1,372	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 U24 HL135691-03	NEW ENGLAND RESEARCH INSTITUTES	5 U24 HL135691-03		\$4,107	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
CARDIOVASCULAR DISEASES RESEARCH	93.837	7 R01 HL133870-04	HARVARD UNIVERSITY	7 R01 HL133870-04		\$15,894	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
CARDIOVASCULAR DISEASES RESEARCH	93.837	7 R01 HL136824-03	UNIVERSITY OF PITTSBURGH	7 R01 HL136824-03		\$12,439	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
CARDIOVASCULAR DISEASES RESEARCH	93.837	7 R01 HL139968-02	STATE UNIVERSITY OF NEW YORK (SUNY)	7 R01 HL139968-02		\$52,833	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
CARDIOVASCULAR DISEASES RESEARCH	93.837	9 R01 HL147818-21A1	UNIVERSITY OF PITTSBURGH	9 R01 HL147818-21A1		\$106,059	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL125032-05				-\$2,032	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL131977-03				-\$1,243	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
CARDIOVASCULAR DISEASES RESEARCH	93.837	5 R01 HL133860-03				-\$104	\$27,014,205	RESEARCH AND DEVELOPMENT	\$357,858,137
LUNG DISEASES RESEARCH	93.838	1 K08 HL143051-01A1				\$133,264	\$16,086,497	RESEARCH AND DEVELOPMENT	\$357,858,137
LUNG DISEASES RESEARCH	93.838	1 K23 HL148638-01				\$136,572	\$16,086,497	RESEARCH AND DEVELOPMENT	\$357,858,137
LUNG DISEASES RESEARCH	93.838	1 K24 HL143281-01				\$67	\$16,086,497	RESEARCH AND DEVELOPMENT	\$357,858,137
LUNG DISEASES RESEARCH	93.838	1 K24 HL150312-01				\$39,557	\$16,086,497	RESEARCH AND DEVELOPMENT	\$357,858,137
LUNG DISEASES RESEARCH	93.838	1 K99 HL143441-01A1				\$100,354	\$16,086,497	RESEARCH AND DEVELOPMENT	\$357,858,137
LUNG DISEASES RESEARCH	93.838	1 R01 HL136449-01A1				-\$47	\$16,086,497	RESEARCH AND DEVELOPMENT	\$357,858,137
LUNG DISEASES RESEARCH	93.838	1 R01 HL141567-01A1			\$132,576	\$343,268	\$16,086,497	RESEARCH AND DEVELOPMENT	\$357,858,137
LUNG DISEASES RESEARCH	93.838	1 R01 HL151016-01				\$201,173	\$16,086,497	RESEARCH AND DEVELOPMENT	\$357,858,137
LUNG DISEASES RESEARCH	93.838	1 R01 HL152210-01				\$26,444	\$16,086,497	RESEARCH AND DEVELOPMENT	\$357,858,137
LUNG DISEASES RESEARCH	93.838	1 R35 HL150783-01				\$12,818	\$16,086,497	RESEARCH AND DEVELOPMENT	\$357,858,137
LUNG DISEASES RESEARCH	93.838	1 R38 HL143619-01				\$529	\$16,086,497	RESEARCH AND DEVELOPMENT	\$357,858,137
LUNG DISEASES RESEARCH	93.838	2 K24 HL103836-06				\$150,010	\$16,086,497	RESEARCH AND DEVELOPMENT	\$357,858,137
LUNG DISEASES RESEARCH	93.838	2 R01 HL095797-10				\$655,862	\$16,086,497	RESEARCH AND DEVELOPMENT	\$357,858,137
LUNG DISEASES RESEARCH	93.838	2 R01 HL16597-05A1				-\$3,154	\$16,086,497	RESEARCH AND DEVELOPMENT	\$357,858,137
LUNG DISEASES RESEARCH	93.838	2 R01 HL119503-06				-\$468	\$16,086,497	RESEARCH AND DEVELOPMENT	\$357,858,137
LUNG DISEASES RESEARCH	93.838	2 T32 HL094296-11				\$7	\$16,086,497	RESEARCH AND DEVELOPMENT	\$357,858,137
LUNG DISEASES RESEARCH	93.838	3 R01 HL146588-01S1				\$5,483	\$16,086,497	RESEARCH AND DEVELOPMENT	\$357,858,137
LUNG DISEASES RESEARCH	93.838	5 K01 HL145338-02				\$118,881	\$16,086,497	RESEARCH AND DEVELOPMENT	\$357,858,137
LUNG DISEASES RESEARCH	93.838	5 K08 HL127102-05				\$135,209	\$16,086,497	RESEARCH AND DEVELOPMENT	\$357,858,137

Vanderbilt University Medical Center
Schedule of Expenditures of Federal Awards and State Financial Assistance
Fiscal Period 7/1/2019 – 6/30/2020

<i>Federal Awarding Agency/Program Title</i>	<i>Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
LUNG DISEASES RESEARCH	93.838	5 K08 HL130595-06				\$154,999	\$16,086,497	RESEARCH AND DEVELOPMENT	\$357,858,137
LUNG DISEASES RESEARCH	93.838	5 K08 HL133484-03				\$166,775	\$16,086,497	RESEARCH AND DEVELOPMENT	\$357,858,137
LUNG DISEASES RESEARCH	93.838	5 K08 HL136888-04				\$139,185	\$16,086,497	RESEARCH AND DEVELOPMENT	\$357,858,137
LUNG DISEASES RESEARCH	93.838	5 K08 HL138088-02				\$594	\$16,086,497	RESEARCH AND DEVELOPMENT	\$357,858,137
LUNG DISEASES RESEARCH	93.838	5 K12 HL143956-02				\$238,877	\$16,086,497	RESEARCH AND DEVELOPMENT	\$357,858,137
LUNG DISEASES RESEARCH	93.838	5 K23 HL143053-02				\$187,518	\$16,086,497	RESEARCH AND DEVELOPMENT	\$357,858,137
LUNG DISEASES RESEARCH	93.838	5 K24 HL127301-06				\$115,930	\$16,086,497	RESEARCH AND DEVELOPMENT	\$357,858,137
LUNG DISEASES RESEARCH	93.838	5 P01 HL092870-08				-\$29,617	\$16,086,497	RESEARCH AND DEVELOPMENT	\$357,858,137
LUNG DISEASES RESEARCH	93.838	5 P01 HL092870-09			\$535,529	\$1,678,902	\$16,086,497	RESEARCH AND DEVELOPMENT	\$357,858,137
LUNG DISEASES RESEARCH	93.838	5 P01 HL092870-10				\$135,954	\$16,086,497	RESEARCH AND DEVELOPMENT	\$357,858,137
LUNG DISEASES RESEARCH	93.838	5 P01 HL108800-08			\$16,964	\$35,321	\$16,086,497	RESEARCH AND DEVELOPMENT	\$357,858,137
LUNG DISEASES RESEARCH	93.838	5 P01 HL108800-09			\$98,139	\$1,687,294	\$16,086,497	RESEARCH AND DEVELOPMENT	\$357,858,137
LUNG DISEASES RESEARCH	93.838	5 R01 HL111111-06			-\$3,097	\$4,628	\$16,086,497	RESEARCH AND DEVELOPMENT	\$357,858,137
LUNG DISEASES RESEARCH	93.838	5 R01 HL117074-06			\$35,769	\$35,769	\$16,086,497	RESEARCH AND DEVELOPMENT	\$357,858,137
LUNG DISEASES RESEARCH	93.838	5 R01 HL122417-05			\$4,687	\$25,877	\$16,086,497	RESEARCH AND DEVELOPMENT	\$357,858,137
LUNG DISEASES RESEARCH	93.838	5 R01 HL122554-06				\$9,281	\$16,086,497	RESEARCH AND DEVELOPMENT	\$357,858,137
LUNG DISEASES RESEARCH	93.838	5 R01 HL126176-06			\$193,950	\$462,904	\$16,086,497	RESEARCH AND DEVELOPMENT	\$357,858,137
LUNG DISEASES RESEARCH	93.838	5 R01 HL126671-06				\$310,843	\$16,086,497	RESEARCH AND DEVELOPMENT	\$357,858,137
LUNG DISEASES RESEARCH	93.838	5 R01 HL131906-04			\$5,518	\$234,415	\$16,086,497	RESEARCH AND DEVELOPMENT	\$357,858,137
LUNG DISEASES RESEARCH	93.838	5 R01 HL132338-04			\$407,805	\$607,735	\$16,086,497	RESEARCH AND DEVELOPMENT	\$357,858,137
LUNG DISEASES RESEARCH	93.838	5 R01 HL134802-02				\$368,258	\$16,086,497	RESEARCH AND DEVELOPMENT	\$357,858,137
LUNG DISEASES RESEARCH	93.838	5 R01 HL134802-03				\$334,667	\$16,086,497	RESEARCH AND DEVELOPMENT	\$357,858,137
LUNG DISEASES RESEARCH	93.838	5 R01 HL135849-04			\$16,389	\$481,619	\$16,086,497	RESEARCH AND DEVELOPMENT	\$357,858,137
LUNG DISEASES RESEARCH	93.838	5 R01 HL136664-04			\$46,883	\$451,489	\$16,086,497	RESEARCH AND DEVELOPMENT	\$357,858,137
LUNG DISEASES RESEARCH	93.838	5 R01 HL136748-04				\$586,334	\$16,086,497	RESEARCH AND DEVELOPMENT	\$357,858,137
LUNG DISEASES RESEARCH	93.838	5 R01 HL140231-03			\$125,254	\$746,804	\$16,086,497	RESEARCH AND DEVELOPMENT	\$357,858,137
LUNG DISEASES RESEARCH	93.838	5 R01 HL146588-02			\$261,191	\$661,329	\$16,086,497	RESEARCH AND DEVELOPMENT	\$357,858,137
LUNG DISEASES RESEARCH	93.838	5 R21 HL133742-02				\$1,025	\$16,086,497	RESEARCH AND DEVELOPMENT	\$357,858,137
LUNG DISEASES RESEARCH	93.838	5 R34 HL136989-02			\$18,590	\$26,463	\$16,086,497	RESEARCH AND DEVELOPMENT	\$357,858,137
LUNG DISEASES RESEARCH	93.838	5 R34 HL136989-03			\$70,567	\$253,590	\$16,086,497	RESEARCH AND DEVELOPMENT	\$357,858,137
LUNG DISEASES RESEARCH	93.838	5 R38 HL143619-02				\$387,804	\$16,086,497	RESEARCH AND DEVELOPMENT	\$357,858,137
LUNG DISEASES RESEARCH	93.838	5 T32 HL087738-13				-\$5,119	\$16,086,497	RESEARCH AND DEVELOPMENT	\$357,858,137
LUNG DISEASES RESEARCH	93.838	5 T32 HL087738-14				\$312,429	\$16,086,497	RESEARCH AND DEVELOPMENT	\$357,858,137
LUNG DISEASES RESEARCH	93.838	5 T32 HL087738-15				\$88,658	\$16,086,497	RESEARCH AND DEVELOPMENT	\$357,858,137
LUNG DISEASES RESEARCH	93.838	5 T32 HL094296-12				\$307,049	\$16,086,497	RESEARCH AND DEVELOPMENT	\$357,858,137
LUNG DISEASES RESEARCH	93.838	5 U01 HL123033-06			\$40,067	\$308,991	\$16,086,497	RESEARCH AND DEVELOPMENT	\$357,858,137
LUNG DISEASES RESEARCH	93.838	5 U01 HL123033-07				\$48,883	\$16,086,497	RESEARCH AND DEVELOPMENT	\$357,858,137
LUNG DISEASES RESEARCH	93.838	5 U01 HL125212-06				\$50,755	\$16,086,497	RESEARCH AND DEVELOPMENT	\$357,858,137
LUNG DISEASES RESEARCH	93.838	5R01 HL142720-02				\$603,546	\$16,086,497	RESEARCH AND DEVELOPMENT	\$357,858,137
LUNG DISEASES RESEARCH	93.838	7 K23 HL141539-03				\$216,723	\$16,086,497	RESEARCH AND DEVELOPMENT	\$357,858,137
LUNG DISEASES RESEARCH	93.838	1 R01 HL134015-01	UNIVERSITY OF PENNSYLVANIA	1 R01 HL134015-01		\$11,639	\$16,086,497	RESEARCH AND DEVELOPMENT	\$357,858,137
LUNG DISEASES RESEARCH	93.838	1 R01 HL135144-02	UNIVERSITY OF PITTSBURGH	1 R01 HL135144-02		\$124,893	\$16,086,497	RESEARCH AND DEVELOPMENT	\$357,858,137
LUNG DISEASES RESEARCH	93.838	1 R01 HL144624-01	INTERMOUNTAIN MEDICAL CENTER	1 R01 HL144624-01		\$21,203	\$16,086,497	RESEARCH AND DEVELOPMENT	\$357,858,137
LUNG DISEASES RESEARCH	93.838	1 R01 HL145372-01	TRANSLATIONAL GENOMICS RESEARCH INSTITUTE	1 R01 HL145372-01		\$222,054	\$16,086,497	RESEARCH AND DEVELOPMENT	\$357,858,137
LUNG DISEASES RESEARCH	93.838	1 R01 HL149422-01	HARVARD UNIVERSITY	1 R01 HL149422-01		\$19,383	\$16,086,497	RESEARCH AND DEVELOPMENT	\$357,858,137
LUNG DISEASES RESEARCH	93.838	1 R21 HL145246-01A1	BRIGHAM AND WOMEN'S HOSPITAL	1 R21 HL145246-01A1		\$1,875	\$16,086,497	RESEARCH AND DEVELOPMENT	\$357,858,137
LUNG DISEASES RESEARCH	93.838	1 R41 HL140709-01	VIRTUOSO SURGICAL	1 R41 HL140709-01		\$11,398	\$16,086,497	RESEARCH AND DEVELOPMENT	\$357,858,137
LUNG DISEASES RESEARCH	93.838	1 U01 HL145561-01	CORNELL UNIVERSITY	1 U01 HL145561-01		\$17,608	\$16,086,497	RESEARCH AND DEVELOPMENT	\$357,858,137
LUNG DISEASES RESEARCH	93.838	15FED1511233-0005	VETERANS AFFAIRS	15FED1511233-0005	\$95,763	\$161,796	\$16,086,497	RESEARCH AND DEVELOPMENT	\$357,858,137
LUNG DISEASES RESEARCH	93.838	15FED1511233-0006	VETERANS AFFAIRS	15FED1511233-0006		\$238,537	\$16,086,497	RESEARCH AND DEVELOPMENT	\$357,858,137
LUNG DISEASES RESEARCH	93.838	2 R01 HL113326-06A1	OKLAHOMA MEDICAL RESEARCH FOUNDATION	2 R01 HL113326-06A1		\$31,197	\$16,086,497	RESEARCH AND DEVELOPMENT	\$357,858,137
COVID-19 LUNG DISEASES RESEARCH	93.838	COVID-19 3 U01 HL 123009-06S1	MASSACHUSETTS GENERAL HOSPITAL	3 U01 HL 123009-06S1		\$17,018	\$16,086,497	RESEARCH AND DEVELOPMENT	\$357,858,137
COVID-19 LUNG DISEASES RESEARCH	93.838	COVID-19 3 U01 HL123009-06S1	MASSACHUSETTS GENERAL HOSPITAL	3 U01 HL123009-06S1		\$8,566	\$16,086,497	RESEARCH AND DEVELOPMENT	\$357,858,137

Vanderbilt University Medical Center
Schedule of Expenditures of Federal Awards and State Financial Assistance
Fiscal Period 7/1/2019 – 6/30/2020

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
LUNG DISEASES RESEARCH	93.838	5 R01 HL116473-07	BRIGHAM AND WOMEN'S HOSPITAL	5 R01 HL116473-07		\$27,663	\$16,086,497	RESEARCH AND DEVELOPMENT	\$357,858,137
LUNG DISEASES RESEARCH	93.838	5 R01 HL122477-05	NORTHWESTERN UNIVERSITY	5 R01 HL122477-05	\$9,638	\$16,086,497	\$16,086,497	RESEARCH AND DEVELOPMENT	\$357,858,137
LUNG DISEASES RESEARCH	93.838	5 R01 HL132153-03	JOHNS HOPKINS UNIVERSITY	5 R01 HL132153-03	-\$228	\$16,086,497	\$16,086,497	RESEARCH AND DEVELOPMENT	\$357,858,137
LUNG DISEASES RESEARCH	93.838	5 R01 HL132153-04	JOHNS HOPKINS UNIVERSITY	5 R01 HL132153-04	\$3,564	\$16,086,497	\$16,086,497	RESEARCH AND DEVELOPMENT	\$357,858,137
LUNG DISEASES RESEARCH	93.838	5 R01 HL135114-03	JOHNS HOPKINS UNIVERSITY	5 R01 HL135114-03	\$27,042	\$16,086,497	\$16,086,497	RESEARCH AND DEVELOPMENT	\$357,858,137
LUNG DISEASES RESEARCH	93.838	5 R01 HL135114-04	JOHNS HOPKINS UNIVERSITY	5 R01 HL135114-04	\$26,221	\$16,086,497	\$16,086,497	RESEARCH AND DEVELOPMENT	\$357,858,137
LUNG DISEASES RESEARCH	93.838	5 R35 HL140026-02	UNIVERSITY OF CALIFORNIA AT SAN FRANCISCO	5 R35 HL140026-02		\$25,064	\$16,086,497	RESEARCH AND DEVELOPMENT	\$357,858,137
LUNG DISEASES RESEARCH	93.838	5 R35 HL140026-03	UNIVERSITY OF CALIFORNIA AT SAN FRANCISCO	5 R35 HL140026-03		\$69,997	\$16,086,497	RESEARCH AND DEVELOPMENT	\$357,858,137
LUNG DISEASES RESEARCH	93.838	5 U01 HL121518-04	UNIVERSITY OF COLORADO	5 U01 HL121518-04	\$18,334	\$16,086,497	\$16,086,497	RESEARCH AND DEVELOPMENT	\$357,858,137
LUNG DISEASES RESEARCH	93.838	5 U01 HL123009-06	MASSACHUSETTS GENERAL HOSPITAL	5 U01 HL123009-06	\$112,718	\$16,086,497	\$16,086,497	RESEARCH AND DEVELOPMENT	\$357,858,137
LUNG DISEASES RESEARCH	93.838	5 U01 HL123009-06	MASSACHUSETTS GENERAL HOSPITAL	5 U01 HL123009-06	\$115,887	\$16,086,497	\$16,086,497	RESEARCH AND DEVELOPMENT	\$357,858,137
LUNG DISEASES RESEARCH	93.838	5 U01 HL123009-06	MASSACHUSETTS GENERAL HOSPITAL	5 U01 HL123009-06	\$11,175	\$148,133	\$16,086,497	RESEARCH AND DEVELOPMENT	\$357,858,137
LUNG DISEASES RESEARCH	93.838	5 U01 HL123009-06	MASSACHUSETTS GENERAL HOSPITAL	5 U01 HL123009-06	\$9,193	\$16,086,497	\$16,086,497	RESEARCH AND DEVELOPMENT	\$357,858,137
LUNG DISEASES RESEARCH	93.838	5 U01 HL123009-07	MASSACHUSETTS GENERAL HOSPITAL	5 U01 HL123009-07	\$6,295	\$16,086,497	\$16,086,497	RESEARCH AND DEVELOPMENT	\$357,858,137
LUNG DISEASES RESEARCH	93.838	5 U01 HL125177-05	CLEVELAND CLINIC FOUNDATION	5 U01 HL125177-05	\$103,985	\$16,086,497	\$16,086,497	RESEARCH AND DEVELOPMENT	\$357,858,137
LUNG DISEASES RESEARCH	93.838	5 U01 HL128954-04	UNIVERSITY OF PITTSBURGH	5 U01 HL128954-04	\$22,470	\$16,086,497	\$16,086,497	RESEARCH AND DEVELOPMENT	\$357,858,137
LUNG DISEASES RESEARCH	93.838	5 U01 HL131755-03	CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER	5 U01 HL131755-03	-\$3,043	\$16,086,497	\$16,086,497	RESEARCH AND DEVELOPMENT	\$357,858,137
LUNG DISEASES RESEARCH	93.838	5 U01 HL145561-02	CORNELL UNIVERSITY	5 U01 HL145561-02	\$5,424	\$16,086,497	\$16,086,497	RESEARCH AND DEVELOPMENT	\$357,858,137
LUNG DISEASES RESEARCH	93.838	5 U01HL123009-06	MASSACHUSETTS GENERAL HOSPITAL	5 U01HL123009-06	-\$8,671	\$16,086,497	\$16,086,497	RESEARCH AND DEVELOPMENT	\$357,858,137
LUNG DISEASES RESEARCH	93.838	5 R01 HL117074-06			-\$28,008	\$16,086,497	\$16,086,497	RESEARCH AND DEVELOPMENT	\$357,858,137
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	1 K24 HL147017-01			\$82,104	\$3,686,674	\$3,686,674	RESEARCH AND DEVELOPMENT	\$357,858,137
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	1 OT3 HL147810-01			\$383,805	\$3,686,674	\$3,686,674	RESEARCH AND DEVELOPMENT	\$357,858,137
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	5 K23 HL138291-03			\$157,877	\$3,686,674	\$3,686,674	RESEARCH AND DEVELOPMENT	\$357,858,137
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	5 K23 HL141447-03			\$161,368	\$3,686,674	\$3,686,674	RESEARCH AND DEVELOPMENT	\$357,858,137
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	5 R01 HL106812-09			\$80,962	\$3,686,674	\$3,686,674	RESEARCH AND DEVELOPMENT	\$357,858,137
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	5 R01 HL124159-05			\$1,568	\$3,111	\$3,686,674	RESEARCH AND DEVELOPMENT	\$357,858,137
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	5 R01 HL124159-07			\$575,442	\$3,686,674	\$3,686,674	RESEARCH AND DEVELOPMENT	\$357,858,137
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	5 R01 HL130018-04			\$35,727	\$333,377	\$3,686,674	RESEARCH AND DEVELOPMENT	\$357,858,137
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	5 R01 HL133559-03			\$476,349	\$3,686,674	\$3,686,674	RESEARCH AND DEVELOPMENT	\$357,858,137
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	5 R01 HL141943-02			\$289,953	\$3,686,674	\$3,686,674	RESEARCH AND DEVELOPMENT	\$357,858,137
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	5 R35 HL140025-02			\$375,508	\$3,686,674	\$3,686,674	RESEARCH AND DEVELOPMENT	\$357,858,137
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	5 R35 HL140025-03			\$405,064	\$3,686,674	\$3,686,674	RESEARCH AND DEVELOPMENT	\$357,858,137
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	6 R01 HL114518-04			-\$2,195	\$3,686,674	\$3,686,674	RESEARCH AND DEVELOPMENT	\$357,858,137
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	1 R01 HL144113-01	OREGON HEALTH & SCIENCE UNIVERSITY	1 R01 HL144113-01	\$5	\$3,686,674	\$3,686,674	RESEARCH AND DEVELOPMENT	\$357,858,137
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	1 U24 HL138660-01	NATIONAL MARROW DONOR PROGRAM	1 U24 HL138660-01	\$12,704	\$3,686,674	\$3,686,674	RESEARCH AND DEVELOPMENT	\$357,858,137
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	2 R01 HL101972-10	OREGON HEALTH & SCIENCE UNIVERSITY	2 R01 HL101972-10	\$71,748	\$3,686,674	\$3,686,674	RESEARCH AND DEVELOPMENT	\$357,858,137
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	2 R01 HL101972-11	OREGON HEALTH & SCIENCE UNIVERSITY	2 R01 HL101972-11	\$32,222	\$3,686,674	\$3,686,674	RESEARCH AND DEVELOPMENT	\$357,858,137
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	2 R01 HL118979-05	UNIVERSITY OF MINNESOTA	2 R01 HL118979-05	\$42,702	\$3,686,674	\$3,686,674	RESEARCH AND DEVELOPMENT	\$357,858,137
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	5 R01 HL089456-08	CORNELL UNIVERSITY	5 R01 HL089456-08	\$26,464	\$3,686,674	\$3,686,674	RESEARCH AND DEVELOPMENT	\$357,858,137
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	5 R01 HL133896-02	UNIVERSITY OF ALABAMA AT BIRMINGHAM	5 R01 HL133896-02	\$32,966	\$3,686,674	\$3,686,674	RESEARCH AND DEVELOPMENT	\$357,858,137
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	5 R01 HL144113-02	OREGON HEALTH & SCIENCE UNIVERSITY	5 R01 HL144113-02	\$77,263	\$3,686,674	\$3,686,674	RESEARCH AND DEVELOPMENT	\$357,858,137
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	5 U01 HL128568-05	EMORY UNIVERSITY	5 U01 HL128568-05	\$17,083	\$3,686,674	\$3,686,674	RESEARCH AND DEVELOPMENT	\$357,858,137
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	5 U01 HL133996-04	ST. JUDE HOSPITAL	5 U01 HL133996-04	\$19,522	\$3,686,674	\$3,686,674	RESEARCH AND DEVELOPMENT	\$357,858,137
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	5 U10 CA180820-05	EASTERN COOPERATIVE ONCOLOGY GROUP	5 U10 CA180820-05	\$9,264	\$3,686,674	\$3,686,674	RESEARCH AND DEVELOPMENT	\$357,858,137
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	5 UG1 HL138645-03	MOUNT SINAI SCHOOL OF MEDICINE	5 UG1 HL138645-03	\$22,006	\$3,686,674	\$3,686,674	RESEARCH AND DEVELOPMENT	\$357,858,137
TRANSLATION AND IMPLEMENTATION SCIENCE RESEARCH FOR HEART, LUNG, BLOOD DISEASES, AND SLEEP DISORDERS	93.840	5 K12 HL137943-02			\$176,984	\$733,219	\$755,905	RESEARCH AND DEVELOPMENT	\$357,858,137
COVID-19 TRANSLATION AND IMPLEMENTATION SCIENCE RESEARCH FOR HEART, LUNG, BLOOD DISEASES, AND SLEEP DISORDERS	93.840	COVID-19 1 OT2 HL156812-01	RESEARCH TRIANGLE INSTITUTE	1 OT2 HL156812-01		\$4,096	\$755,905	RESEARCH AND DEVELOPMENT	\$357,858,137
TRANSLATION AND IMPLEMENTATION SCIENCE RESEARCH FOR HEART, LUNG, BLOOD DISEASES, AND SLEEP DISORDERS	93.840	1 R01 HL146781-01	OHIO STATE UNIVERSITY	1 R01 HL146781-01		\$18,590	\$755,905	RESEARCH AND DEVELOPMENT	\$357,858,137
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1 R01 AR073764-01A1				\$960,069	\$3,599,080	RESEARCH AND DEVELOPMENT	\$357,858,137

Vanderbilt University Medical Center
Schedule of Expenditures of Federal Awards and State Financial Assistance
Fiscal Period 7/1/2019 – 6/30/2020

<i>Federal Awarding Agency/Program Title</i>	<i>Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2 R01 DK056942-15A1				\$80,738	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2 R01 DK062794-17			\$425,487	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137	
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2 R01 DK065138-18			\$556,149	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137	
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2 R01 DK081134-10A1			\$26,585	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137	
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2 R01 DK093660-08A1			\$356,196	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137	
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2 T32 DK007673-27			\$407,994	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137	
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2 T35 DK007383-39			-\$1,454	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137	
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	3 R01 DK116625-02S1			\$2,002	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137	
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	3 R25 DK096999-08S1			\$19,440	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137	
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 F32 DK108492-04			-\$542	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137	
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 F32 DK116520-03			\$54,427	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137	
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 F32 DK116520-04			\$5,729	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137	
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 K01 DK099473-05			\$937	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137	
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 K01 DK106306-05			\$17,195	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137	
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 K01 DK106311-04			\$129,192	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137	
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 K01 DK109019-03			\$75,274	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137	
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 K01 DK121869-02			\$106,423	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137	
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 K08 DK106472-05			\$134,164	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137	
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 K23 DK101689-04			\$9,583	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137	
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 K23 DK103910-06			\$134,307	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137	
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 K23 DK106511-04			\$142,612	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137	
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 K23 DK114566-02			\$168,026	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137	
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 K23 DK118118-02			\$145,033	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137	
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 P30 DK020593-41			\$2,997	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137	
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 P30 DK020593-42			\$762,308	\$2,643,631	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 P30 DK020593-43			\$4,939	\$313,578	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 P30 DK058404-17			-\$24,094	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137	
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 P30 DK058404-18			\$994,392	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137	
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 P30 DK058404-19			\$39,327	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137	
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 P30 DK092986-09			\$38,877	\$83,161	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 P30 DK092986-10			\$93,524	\$578,060	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 P30 DK114809-02			-\$750	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137	
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 P30 DK114809-03			\$19,997	\$918,160	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK018381-48				\$518,058	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK048370-24				\$399,880	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK051265-24				\$243,726	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK058587-19				\$328,043	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK066358-13			\$193,546	\$369,969	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK069921-14				\$97,710	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK078158-08				\$18,786	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK081134-09				\$91,312	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK081646-12				\$536,030	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK084246-10			\$5,894	\$40,784	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK093501-10			\$365,635	\$760,623	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK095785-08				\$598,472	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK096994-06			\$3,936	\$3,936	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK099467-08				\$423,673	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK100431-04				\$108,228	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK101332-06			\$11,467	\$521,222	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK101791-05				\$11,410	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK103935-06			\$25,178	\$161,194	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK104817-05				\$277,153	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK105371-06				\$348,922	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK105550-08			\$11,178	\$410,892	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK105847-05				\$286,394	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK108159-05			\$266,657	\$363,065	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK108968-05			\$16,718	\$202,471	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137

Vanderbilt University Medical Center
Schedule of Expenditures of Federal Awards and State Financial Assistance
Fiscal Period 7/1/2019 – 6/30/2020

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK109102-06			\$18,401	\$321,788	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK110166-04			\$99,535	\$355,060	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK111554-04			\$26,888	\$423,457	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK111671-03				\$385,863	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK112688-04				\$405,117	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK113423-03				\$319,647	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK115545-02			\$125,092	\$439,404	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK116957-02			\$82,126	\$164,678	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK116964-03				\$421,552	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK117144-03				\$456,740	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK117875-03				\$491,044	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK119212-02			\$13,653	\$397,213	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R03 DK110399-03				\$47,567	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R03 DK119735-02				\$58,954	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R21 DK110657-02				\$7,319	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R24 DK103067-06			\$47,467	\$1,282,673	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R24 DK106755-06			\$1,002,338	\$1,529,288	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R25 DK096999-09				\$70,550	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R56 DK108352-03			\$8,900	\$8,900	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 T32 DK007061-45				\$31	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 T32 DK007061-46				\$302,571	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 T32 DK007569-30			\$21,190	\$21,190	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 T32 DK007569-31				\$245,452	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 T32 DK007673-26				-\$178	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 T35 DK007383-40				\$108,815	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 T35 DK007383-41				\$5,080	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 U01 DK082192-11				\$137,230	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 U01 DK085465-10				\$202,919	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 U01 DK099923-06			\$90,084	\$245,225	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 U01 DK110804-04			\$38,978	\$38,978	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 U01 DK110804-05			\$56,981	\$579,583	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 U01 DK110804-06				\$16,557	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 U01 DK112271-02			\$93,685	\$144,496	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 U01 DK112271-03			\$120,929	\$388,450	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 U01 DK116093-02				\$353	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 U01 DK116093-03			\$9,450	\$254,163	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 U01 DK116093-04				\$22,700	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	6 R01 DK100694-05				\$283,119	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	6 R01 DK112262-05			\$1,372	\$729,820	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	6 UC4 DK104211-02			\$853	\$853	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	7 F32 DK116520-02				-\$1,651	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	7 R01 DK051610-25				\$343,623	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	7 U01 DK105565-05			\$246,373	\$555,676	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1 DP3 DK114812-01	CASE WESTERN RESERVE UNIVERSITY	1 DP3 DK114812-01		\$12,274	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1 R01 DK108438-02	BRIGHAM AND WOMEN'S HOSPITAL	1 R01 DK108438-02		\$3,686	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1 R01 DK110375-02	UNIVERSITY OF MARYLAND	1 R01 DK110375-02		\$68,770	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1 R01 DK113201-01A1	DARTMOUTH COLLEGE	1 R01 DK113201-01A1	\$9,531	\$15,398	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1 R01 DK114485-01A1	STATE UNIVERSITY OF NEW YORK (SUNY)	1 R01 DK114485-01A1		\$7,131	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1 R01 DK117147-01A1	VANDERBILT UNIVERSITY	1 R01 DK117147-01A1		\$343,685	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1 R01 DK119508-01A1	VANDERBILT UNIVERSITY	1 R01 DK119508-01A1		\$11,575	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1 R01 DK121520-01A1	VANDERBILT UNIVERSITY	1 R01 DK121520-01A1		\$45,017	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1 R01 DK122797-01	UNIVERSITY OF CALIFORNIA AT SAN FRANCISCO	1 R01 DK122797-01		\$113,299	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1 R01 DL103831-01A1	VANDERBILT UNIVERSITY	1 R01 DL103831-01A1		\$284	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1 R18 DK118471-01	ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY	1 R18 DK118471-01		\$3,853	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137

Vanderbilt University Medical Center
Schedule of Expenditures of Federal Awards and State Financial Assistance
Fiscal Period 7/1/2019 – 6/30/2020

<i>Federal Awarding Agency/Program Title</i>	<i>Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 U2C DK059637-18	VANDERBILT UNIVERSITY	5 U2C DK059637-18		\$106	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 U2C DK059637-19	VANDERBILT UNIVERSITY	5 U2C DK059637-19		\$259,166	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 UM1 DK100866-04	NATIONWIDE CHILDREN'S HOSPITAL	5 UM1 DK100866-04		-\$4,605	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 UM1 DK100867-06	UNIVERSITY OF NORTH CAROLINA	5 UM1 DK100867-06		-\$499	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R01 DK096994-06				-\$3,936	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 R56 DK108352-03				-\$7,697	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 T32 DK007569-30				-\$1,274	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5 U01 DK110804-04				-\$19,368	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	6 UC4 DK104211-02				-\$853	\$37,991,080	RESEARCH AND DEVELOPMENT	\$357,858,137
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1 K23 NS113858-01				\$156,568	\$10,035,909	RESEARCH AND DEVELOPMENT	\$357,858,137
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1 R01 NS108445-02				\$266,024	\$10,035,909	RESEARCH AND DEVELOPMENT	\$357,858,137
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1 R01 NS110661-01A1				\$33,794	\$10,035,909	RESEARCH AND DEVELOPMENT	\$357,858,137
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1 R01 NS113171-01			\$300,995	\$782,055	\$10,035,909	RESEARCH AND DEVELOPMENT	\$357,858,137
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1 R01 NS113832-01				\$58,732	\$10,035,909	RESEARCH AND DEVELOPMENT	\$357,858,137
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1 R03 NS111486-01				\$90,690	\$10,035,909	RESEARCH AND DEVELOPMENT	\$357,858,137
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1 U01 NS107666-01			\$340,132	\$626,625	\$10,035,909	RESEARCH AND DEVELOPMENT	\$357,858,137
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1 U24 NS107128-01				-\$4,566	\$10,035,909	RESEARCH AND DEVELOPMENT	\$357,858,137
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	3 R01 NS100980-01				\$721,324	\$10,035,909	RESEARCH AND DEVELOPMENT	\$357,858,137
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 K23 NS080988-06				\$80	\$10,035,909	RESEARCH AND DEVELOPMENT	\$357,858,137
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 R00 NS097618-05				\$259,839	\$10,035,909	RESEARCH AND DEVELOPMENT	\$357,858,137
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 R01 NS078680-09			\$13,687	\$676,098	\$10,035,909	RESEARCH AND DEVELOPMENT	\$357,858,137
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 R01 NS092961-06			\$2,608	\$376,393	\$10,035,909	RESEARCH AND DEVELOPMENT	\$357,858,137
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 R01 NS093669-05			\$262,998	\$468,528	\$10,035,909	RESEARCH AND DEVELOPMENT	\$357,858,137
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 R01 NS094041-04			\$40,074	\$85,146	\$10,035,909	RESEARCH AND DEVELOPMENT	\$357,858,137
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 R01 NS094041-05			\$359,612	\$928,542	\$10,035,909	RESEARCH AND DEVELOPMENT	\$357,858,137
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 R01 NS096127-06				\$256,739	\$10,035,909	RESEARCH AND DEVELOPMENT	\$357,858,137
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 R01 NS097763-05				\$234,833	\$10,035,909	RESEARCH AND DEVELOPMENT	\$357,858,137
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 R01 NS097783-05			\$16,381	\$521,873	\$10,035,909	RESEARCH AND DEVELOPMENT	\$357,858,137
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 R01 NS097821-04			\$9,742	\$101,164	\$10,035,909	RESEARCH AND DEVELOPMENT	\$357,858,137
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 R01 NS104149-04				\$368,031	\$10,035,909	RESEARCH AND DEVELOPMENT	\$357,858,137
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 R01 NS107424-02				\$363,013	\$10,035,909	RESEARCH AND DEVELOPMENT	\$357,858,137
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 R01 NS109114-03			\$38,637	\$364,736	\$10,035,909	RESEARCH AND DEVELOPMENT	\$357,858,137
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 R01 NS110130-02			\$28,570	\$339,437	\$10,035,909	RESEARCH AND DEVELOPMENT	\$357,858,137

Vanderbilt University Medical Center
Schedule of Expenditures of Federal Awards and State Financial Assistance
Fiscal Period 7/1/2019 – 6/30/2020

<i>Federal Awarding Agency/Program Title</i>	<i>Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 R01 NS112252-02			\$198,908	\$346,395	\$10,035,909	RESEARCH AND DEVELOPMENT	\$357,858,137
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 R21 NS107877-02			\$10,534	\$126,687	\$10,035,909	RESEARCH AND DEVELOPMENT	\$357,858,137
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 T32 NS007491-18			\$33,046	\$33,046	\$10,035,909	RESEARCH AND DEVELOPMENT	\$357,858,137
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 T32 NS007491-19			\$73,199	\$137,661	\$10,035,909	RESEARCH AND DEVELOPMENT	\$357,858,137
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 U10 NS086492-05				\$5,824	\$10,035,909	RESEARCH AND DEVELOPMENT	\$357,858,137
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 U24 NS107128-02				\$293,709	\$10,035,909	RESEARCH AND DEVELOPMENT	\$357,858,137
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 U54 NS065736-10			\$234,909	\$298,245	\$10,035,909	RESEARCH AND DEVELOPMENT	\$357,858,137
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1 R01 NS096173-01A1	UNIVERSITY OF CALIFORNIA AT SAN FRANCISCO	1 R01 NS096173-01A1		\$38,827	\$10,035,909	RESEARCH AND DEVELOPMENT	\$357,858,137
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1 R01 NS100996-02	UNIV OF LOUISVILLE	1 R01 NS100996-02		\$49,978	\$10,035,909	RESEARCH AND DEVELOPMENT	\$357,858,137
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1 R01 NS104094-01	UNIVERSITY OF CALIFORNIA AT SAN FRANCISCO	1 R01 NS104094-01		\$9,240	\$10,035,909	RESEARCH AND DEVELOPMENT	\$357,858,137
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1 R01 NS104497-01	VANDERBILT UNIVERSITY	1 R01 NS104497-01		\$8,978	\$10,035,909	RESEARCH AND DEVELOPMENT	\$357,858,137
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1 R01 NS105746-01A1	MASSACHUSETTS GENERAL HOSPITAL	1 R01 NS105746-01A1		\$11,251	\$10,035,909	RESEARCH AND DEVELOPMENT	\$357,858,137
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1 R01 NS107281-01A1	WASHINGTON UNIVERSITY IN ST. LOUIS	1 R01 NS107281-01A1		\$163,856	\$10,035,909	RESEARCH AND DEVELOPMENT	\$357,858,137
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1 R21 NS106510-01	VANDERBILT UNIVERSITY	1 R21 NS106510-01		\$23,559	\$10,035,909	RESEARCH AND DEVELOPMENT	\$357,858,137
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1 R21 NS109521-01	VANDERBILT UNIVERSITY	1 R21 NS109521-01		\$11,823	\$10,035,909	RESEARCH AND DEVELOPMENT	\$357,858,137
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1 RF1 NS113285-01	UNIVERSITY OF NORTH CAROLINA	1 RF1 NS113285-01		\$16,438	\$10,035,909	RESEARCH AND DEVELOPMENT	\$357,858,137
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1 U01 NS088312-01	MASSACHUSETTS GENERAL HOSPITAL	1 U01 NS088312-01		\$20,908	\$10,035,909	RESEARCH AND DEVELOPMENT	\$357,858,137
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1 U01 NS090259-02	MASSACHUSETTS GENERAL HOSPITAL	1 U01 NS090259-02		\$2,370	\$10,035,909	RESEARCH AND DEVELOPMENT	\$357,858,137
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1 U01 NS092764-01A1	UNIVERSITY OF CALIFORNIA AT SAN FRANCISCO	1 U01 NS092764-01A1		\$3,767	\$10,035,909	RESEARCH AND DEVELOPMENT	\$357,858,137
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1 U01 NS096767-01	MASSACHUSETTS GENERAL HOSPITAL	1 U01 NS096767-01		\$17,742	\$10,035,909	RESEARCH AND DEVELOPMENT	\$357,858,137
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1 U01 NS100699-01A1	UNIVERSITY OF CINCINNATI	1 U01 NS100699-01A1		\$5,559	\$10,035,909	RESEARCH AND DEVELOPMENT	\$357,858,137
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1 U01 NS107486-01A1	UNIVERSITY OF UTAH	1 U01 NS107486-01A1		\$15,224	\$10,035,909	RESEARCH AND DEVELOPMENT	\$357,858,137
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1 U24 NS114416-01	DUKE UNIVERSITY	1 U24 NS114416-01		\$13,816	\$10,035,909	RESEARCH AND DEVELOPMENT	\$357,858,137
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	2 U01 NS061799-07	UNIVERSITY OF ROCHESTER	2 U01 NS061799-07		\$878	\$10,035,909	RESEARCH AND DEVELOPMENT	\$357,858,137
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	4 R33 NS109521-02	VANDERBILT UNIVERSITY	4 R33 NS109521-02		\$12,802	\$10,035,909	RESEARCH AND DEVELOPMENT	\$357,858,137
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 R01 NS049251-11	VANDERBILT UNIVERSITY	5 R01 NS049251-11		\$27,664	\$10,035,909	RESEARCH AND DEVELOPMENT	\$357,858,137
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 R01 NS095291-12	VANDERBILT UNIVERSITY	5 R01 NS095291-12		\$5,972	\$10,035,909	RESEARCH AND DEVELOPMENT	\$357,858,137
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 R01 NS096238-04	VANDERBILT UNIVERSITY	5 R01 NS096238-04		\$19,438	\$10,035,909	RESEARCH AND DEVELOPMENT	\$357,858,137

Vanderbilt University Medical Center
Schedule of Expenditures of Federal Awards and State Financial Assistance
Fiscal Period 7/1/2019 – 6/30/2020

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 R01 NS097512-02	THE MCLEAN HOSPITAL CORPORATION	5 R01 NS097512-02		-\$1,533	\$10,035,909	RESEARCH AND DEVELOPMENT	\$357,858,137
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 R01 NS097512-04	THE MCLEAN HOSPITAL CORPORATION	5 R01 NS097512-04		\$56,000	\$10,035,909	RESEARCH AND DEVELOPMENT	\$357,858,137
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 R01 NS102371-02	MASSACHUSETTS GENERAL HOSPITAL	5 R01 NS102371-02		\$17,150	\$10,035,909	RESEARCH AND DEVELOPMENT	\$357,858,137
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 R01 NS102371-03	MASSACHUSETTS GENERAL HOSPITAL	5 R01 NS102371-03		\$4,406	\$10,035,909	RESEARCH AND DEVELOPMENT	\$357,858,137
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 R01 NS104339-02	UNIVERSITY OF ALABAMA AT BIRMINGHAM	5 R01 NS104339-02		\$9,836	\$10,035,909	RESEARCH AND DEVELOPMENT	\$357,858,137
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 R01 NS104339-03	UNIVERSITY OF ALABAMA AT BIRMINGHAM	5 R01 NS104339-03		\$14,053	\$10,035,909	RESEARCH AND DEVELOPMENT	\$357,858,137
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 R01 NS105746-02	MASSACHUSETTS GENERAL HOSPITAL	5 R01 NS105746-02		\$31,105	\$10,035,909	RESEARCH AND DEVELOPMENT	\$357,858,137
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 U01 NS080168-05	MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH	5 U01 NS080168-05		\$25,146	\$10,035,909	RESEARCH AND DEVELOPMENT	\$357,858,137
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 U01 NS092764-04	UNIVERSITY OF CALIFORNIA AT SAN FRANCISCO	5 U01 NS092764-04		\$26,559	\$10,035,909	RESEARCH AND DEVELOPMENT	\$357,858,137
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5 U01 NS095869-02	UNIVERSITY OF CINCINNATI	5 U01 NS095869-02		\$9,265	\$10,035,909	RESEARCH AND DEVELOPMENT	\$357,858,137
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	7 R01 NS097821-05	BARROW NEUROLOGICAL INSTITUTE	7 R01 NS097821-05		\$46,567	\$10,035,909	RESEARCH AND DEVELOPMENT	\$357,858,137
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 F32 AI143005-01				\$34,898	\$38,584,082	RESEARCH AND DEVELOPMENT	\$357,858,137
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 K08 AI151100-01				\$29,469	\$38,584,082	RESEARCH AND DEVELOPMENT	\$357,858,137
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 K23 AI141621-02				\$167,566	\$38,584,082	RESEARCH AND DEVELOPMENT	\$357,858,137
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 K24 AI148459-01				\$10,889	\$38,584,082	RESEARCH AND DEVELOPMENT	\$357,858,137
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 R01 AI125642-04				\$187,534	\$38,584,082	RESEARCH AND DEVELOPMENT	\$357,858,137
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 R01 AI131771-03				\$249,618	\$38,584,082	RESEARCH AND DEVELOPMENT	\$357,858,137
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 R01 AI134036-03				\$126,116	\$38,584,082	RESEARCH AND DEVELOPMENT	\$357,858,137
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 R01 AI137082-01A1				\$1,600	\$38,584,082	RESEARCH AND DEVELOPMENT	\$357,858,137
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 R01 AI139046-01A1				\$214,640	\$38,584,082	RESEARCH AND DEVELOPMENT	\$357,858,137
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 R01 AI141448-01A1				\$208,892	\$38,584,082	RESEARCH AND DEVELOPMENT	\$357,858,137
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 R01 AI143710-01				\$1,320	\$38,584,082	RESEARCH AND DEVELOPMENT	\$357,858,137
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 R01 AI145992-01A1				\$61,149	\$38,584,082	RESEARCH AND DEVELOPMENT	\$357,858,137
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 R01 AI149722-01				\$224,186	\$38,584,082	RESEARCH AND DEVELOPMENT	\$357,858,137
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 R01 AI150701-01				\$67,575	\$38,584,082	RESEARCH AND DEVELOPMENT	\$357,858,137
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 R01 AI151210-01				\$121,937	\$38,584,082	RESEARCH AND DEVELOPMENT	\$357,858,137
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 R01 AI153167-01				\$9,600	\$38,584,082	RESEARCH AND DEVELOPMENT	\$357,858,137
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 R13 AI147694-01				\$7,864	\$38,584,082	RESEARCH AND DEVELOPMENT	\$357,858,137
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 R21 AI128281-02				\$84,676	\$38,584,082	RESEARCH AND DEVELOPMENT	\$357,858,137
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 R21 AI139012-01-02				\$164,681	\$38,584,082	RESEARCH AND DEVELOPMENT	\$357,858,137
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 R21 AI142042-01A1				\$3,926	\$38,584,082	RESEARCH AND DEVELOPMENT	\$357,858,137
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 R21 AI142321-01A1				\$123,536	\$38,584,082	RESEARCH AND DEVELOPMENT	\$357,858,137
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 R21 AI144193-01-02				\$129,051	\$38,584,082	RESEARCH AND DEVELOPMENT	\$357,858,137
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 R21 AI145686-01A1				\$19,297	\$38,584,082	RESEARCH AND DEVELOPMENT	\$357,858,137
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 R21 AI149207-01				\$88,477	\$38,584,082	RESEARCH AND DEVELOPMENT	\$357,858,137
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 R21 AI149262-01A1				\$9,013	\$38,584,082	RESEARCH AND DEVELOPMENT	\$357,858,137
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 R21 AI149303-01				\$28,641	\$38,584,082	RESEARCH AND DEVELOPMENT	\$357,858,137
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 R21 AI150302-01				\$5,630	\$38,584,082	RESEARCH AND DEVELOPMENT	\$357,858,137
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 R21 AI150384-01A1				\$49,996	\$38,584,082	RESEARCH AND DEVELOPMENT	\$357,858,137
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 R21 AI153769-01				\$6,724	\$38,584,082	RESEARCH AND DEVELOPMENT	\$357,858,137
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 R21 AI154016-01				\$28,517	\$38,584,082	RESEARCH AND DEVELOPMENT	\$357,858,137
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 R21 AI154064-01				\$8,870	\$38,584,082	RESEARCH AND DEVELOPMENT	\$357,858,137
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 R34 AI136815-01				\$22,317	\$100,573	RESEARCH AND DEVELOPMENT	\$357,858,137
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 R56 AI118361-01A1				\$1,023	\$38,584,082	RESEARCH AND DEVELOPMENT	\$357,858,137
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 U01 AI150739-01				\$43,468	\$38,584,082	RESEARCH AND DEVELOPMENT	\$357,858,137
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1 UM1 AI148452-01				\$5,078	\$92,133	RESEARCH AND DEVELOPMENT	\$357,858,137

Vanderbilt University Medical Center
Schedule of Expenditures of Federal Awards and State Financial Assistance
Fiscal Period 7/1/2019 – 6/30/2020

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R01 AI127469-04	JOHNS HOPKINS UNIVERSITY	5 R01 AI127469-04		\$14,143	\$38,584,082	RESEARCH AND DEVELOPMENT	\$357,858,137
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R01 AI132178-02	UNIVERSITY OF NORTH CAROLINA	5 R01 AI132178-02		\$387,183	\$38,584,082	RESEARCH AND DEVELOPMENT	\$357,858,137
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R01 AI134430-02	BOSTON UNIVERSITY	5 R01 AI134430-02		\$68,144	\$38,584,082	RESEARCH AND DEVELOPMENT	\$357,858,137
			UNIVERSITY OF ALABAMA AT BIRMINGHAM						
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R01 AI134648-03	BIRMINGHAM	5 R01 AI134648-03		\$305,338	\$38,584,082	RESEARCH AND DEVELOPMENT	\$357,858,137
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R01 AI139406-02	EMORY UNIVERSITY	5 R01 AI139406-02		\$6,773	\$38,584,082	RESEARCH AND DEVELOPMENT	\$357,858,137
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R01 AI141661-02	UNIVERSITY OF TEXAS	5 R01 AI141661-02		\$60,455	\$38,584,082	RESEARCH AND DEVELOPMENT	\$357,858,137
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R01 AI143370-02	DUKE UNIVERSITY	5 R01 AI143370-02		\$4,944	\$38,584,082	RESEARCH AND DEVELOPMENT	\$357,858,137
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 T32 AI112541-05	VANDERBILT UNIVERSITY	5 T32 AI112541-05		\$6,993	\$38,584,082	RESEARCH AND DEVELOPMENT	\$357,858,137
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 U01 AI069918-13	JOHNS HOPKINS UNIVERSITY	5 U01 AI069918-13		-\$72	\$38,584,082	RESEARCH AND DEVELOPMENT	\$357,858,137
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 U01 AI069918-14	JOHNS HOPKINS UNIVERSITY	5 U01 AI069918-14		\$117,771	\$38,584,082	RESEARCH AND DEVELOPMENT	\$357,858,137
			ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY						
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 U01 AI096299-11	UNIVERSITY OF ALABAMA AT BIRMINGHAM	5 U01 AI096299-11		\$76,147	\$38,584,082	RESEARCH AND DEVELOPMENT	\$357,858,137
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 U19 AI142759-02	BIRMINGHAM	5 U19 AI142759-02		\$176,166	\$38,584,082	RESEARCH AND DEVELOPMENT	\$357,858,137
			FRED HUTCHINSON CANCER RESEARCH CENTER						
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 UM1 AI068614-13	FRED HUTCHINSON CANCER RESEARCH CENTER	5 UM1 AI068614-13		-\$855	\$38,584,082	RESEARCH AND DEVELOPMENT	\$357,858,137
			FRED HUTCHINSON CANCER RESEARCH CENTER						
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 UM1 AI068614-13	FRED HUTCHINSON CANCER RESEARCH CENTER	5 UM1 AI068614-13		\$22,617	\$38,584,082	RESEARCH AND DEVELOPMENT	\$357,858,137
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 UM1 AI068614-13	FRED HUTCHINSON CANCER RESEARCH CENTER	5 UM1 AI068614-13		\$18,010	\$38,584,082	RESEARCH AND DEVELOPMENT	\$357,858,137
COVID-19 ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	COVID-19 5 UM1 AI068614-14	FRED HUTCHINSON CANCER RESEARCH CENTER	5 UM1 AI068614-14		\$1,632	\$38,584,082	RESEARCH AND DEVELOPMENT	\$357,858,137
			FRED HUTCHINSON CANCER RESEARCH CENTER						
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 UM1 AI068614-14	FRED HUTCHINSON CANCER RESEARCH CENTER	5 UM1 AI068614-14		\$52,400	\$38,584,082	RESEARCH AND DEVELOPMENT	\$357,858,137
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 UM1 AI068619-12	FAMILY HEALTH INTERNATIONAL	5 UM1 AI068619-12	\$90,749	\$90,749	\$38,584,082	RESEARCH AND DEVELOPMENT	\$357,858,137
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 UM1 AI068632-14	JOHNS HOPKINS UNIVERSITY	5 UM1 AI068632-14		\$2,194	\$38,584,082	RESEARCH AND DEVELOPMENT	\$357,858,137
			UNIVERSITY OF CALIFORNIA AT LOS ANGELES						
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 UM1 AI068636-13	UNIVERSITY OF CALIFORNIA AT LOS ANGELES	5 UM1 AI068636-13		\$2,853	\$38,584,082	RESEARCH AND DEVELOPMENT	\$357,858,137
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 UM1 AI068636-13	UNIVERSITY OF CALIFORNIA AT LOS ANGELES	5 UM1 AI068636-13		\$83,812	\$38,584,082	RESEARCH AND DEVELOPMENT	\$357,858,137
			UNIVERSITY OF CALIFORNIA AT LOS ANGELES						
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 UM1 AI068636-14	UNIVERSITY OF CALIFORNIA AT LOS ANGELES	5 UM1 AI068636-14		\$6,059	\$38,584,082	RESEARCH AND DEVELOPMENT	\$357,858,137
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 UM1 AI106701-06	UNIVERSITY OF CALIFORNIA AT LOS ANGELES	5 UM1 AI106701-06		\$243,908	\$38,584,082	RESEARCH AND DEVELOPMENT	\$357,858,137
			UNIVERSITY OF CALIFORNIA AT LOS ANGELES						
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 UM1 AI106701-07	UNIVERSITY OF CALIFORNIA AT LOS ANGELES	5 UM1 AI106701-07		\$47,410	\$38,584,082	RESEARCH AND DEVELOPMENT	\$357,858,137
			BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON						
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 UM1 AI109565-05	BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON	5 UM1 AI109565-05		\$252	\$38,584,082	RESEARCH AND DEVELOPMENT	\$357,858,137
			BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON						
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 UM1 AI109565-06	UNIVERSITY OF CALIFORNIA AT LOS ANGELES	5 UM1 AI109565-06		\$29,192	\$38,584,082	RESEARCH AND DEVELOPMENT	\$357,858,137
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	7 UM1 AI068636-13	UNIVERSITY OF CALIFORNIA AT LOS ANGELES	7 UM1 AI068636-13		\$5,863	\$38,584,082	RESEARCH AND DEVELOPMENT	\$357,858,137
			UNIVERSITY OF CALIFORNIA AT LOS ANGELES						
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	7 UM1 AI068636-14	UNIVERSITY OF CALIFORNIA AT LOS ANGELES	7 UM1 AI068636-14		\$8,379	\$38,584,082	RESEARCH AND DEVELOPMENT	\$357,858,137
			UNIVERSITY OF CALIFORNIA AT LOS ANGELES						
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	7 UM1 AI068636-14	UNIVERSITY OF CALIFORNIA AT LOS ANGELES	7 UM1 AI068636-14		\$99,376	\$38,584,082	RESEARCH AND DEVELOPMENT	\$357,858,137
			WASHINGTON UNIVERSITY IN ST. LOUIS						
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	HHSN272201400018C	WASHINGTON UNIVERSITY IN ST. LOUIS	HHSN272201400018C		\$33,096	\$38,584,082	RESEARCH AND DEVELOPMENT	\$357,858,137
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	HHSN272201400058C	INTEGRAL MOLECULAR	HHSN272201400058C		\$1,353	\$38,584,082	RESEARCH AND DEVELOPMENT	\$357,858,137
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 R21 AI121549-02				-\$135,744	\$38,584,082	RESEARCH AND DEVELOPMENT	\$357,858,137
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 U01 AI104336-06				-\$67,719	\$38,584,082	RESEARCH AND DEVELOPMENT	\$357,858,137
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5 U01 AI125135-02				-\$2,735	\$38,584,082	RESEARCH AND DEVELOPMENT	\$357,858,137
COVID-19 ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	COVID-19 1 R21 AI142321-01A1				\$369	\$38,584,082	RESEARCH AND DEVELOPMENT	\$357,858,137
COVID-19 ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	COVID-19 1 UM1 AI148452-01				\$245,829	\$38,584,082	RESEARCH AND DEVELOPMENT	\$357,858,137

Vanderbilt University Medical Center
Schedule of Expenditures of Federal Awards and State Financial Assistance
Fiscal Period 7/1/2019 – 6/30/2020

<i>Federal Awarding Agency/Program Title</i>	<i>Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5 K12 HD043483-19				\$388,772	\$8,773,959	RESEARCH AND DEVELOPMENT	\$357,858,137
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5 K12 HD087023-05				\$108,748	\$8,773,959	RESEARCH AND DEVELOPMENT	\$357,858,137
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5 K12 HD087023-06				\$190,676	\$8,773,959	RESEARCH AND DEVELOPMENT	\$357,858,137
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5 R01 HD059794-11			\$49,615	\$49,615	\$8,773,959	RESEARCH AND DEVELOPMENT	\$357,858,137
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5 R01 HD074584-06				\$39,302	\$8,773,959	RESEARCH AND DEVELOPMENT	\$357,858,137
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5 R01 HD074711-05				\$87,096	\$8,773,959	RESEARCH AND DEVELOPMENT	\$357,858,137
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5 R01 HD076983-06			\$56,979	\$248,501	\$8,773,959	RESEARCH AND DEVELOPMENT	\$357,858,137
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5 R01 HD081121-05			\$102,974	\$102,974	\$8,773,959	RESEARCH AND DEVELOPMENT	\$357,858,137
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5 R01 HD081121-06			\$73,126	\$73,126	\$8,773,959	RESEARCH AND DEVELOPMENT	\$357,858,137
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5 R01 HD084461-06				\$460,372	\$8,773,959	RESEARCH AND DEVELOPMENT	\$357,858,137
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5 R01 HD084500-05			\$34,793	\$167,062	\$8,773,959	RESEARCH AND DEVELOPMENT	\$357,858,137
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5 R01 HD084500-06				\$130,100	\$8,773,959	RESEARCH AND DEVELOPMENT	\$357,858,137
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5 R01 HD086792-05			\$128,296	\$412,897	\$8,773,959	RESEARCH AND DEVELOPMENT	\$357,858,137
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5 R01 HD088662-03			\$22,241	\$262,246	\$8,773,959	RESEARCH AND DEVELOPMENT	\$357,858,137
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5 R01 HD090061-04			\$156,457	\$648,738	\$8,773,959	RESEARCH AND DEVELOPMENT	\$357,858,137
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5 R01 HD093671-03			\$94,986	\$519,657	\$8,773,959	RESEARCH AND DEVELOPMENT	\$357,858,137
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5 R01 HD094946-02				\$460,653	\$8,773,959	RESEARCH AND DEVELOPMENT	\$357,858,137
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5 R01 HD097344-02				\$450,289	\$8,773,959	RESEARCH AND DEVELOPMENT	\$357,858,137
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5 R01 HD098213-02				\$367,547	\$8,773,959	RESEARCH AND DEVELOPMENT	\$357,858,137
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5 R21 HD080148-03				\$812	\$8,773,959	RESEARCH AND DEVELOPMENT	\$357,858,137
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5 R21 HD088830-02				\$59,324	\$8,773,959	RESEARCH AND DEVELOPMENT	\$357,858,137
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5 T32 HD060554-09				-\$88,836	\$8,773,959	RESEARCH AND DEVELOPMENT	\$357,858,137
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5 T32 HD060554-10				\$445,356	\$8,773,959	RESEARCH AND DEVELOPMENT	\$357,858,137
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5 U01 HD076733-05			\$25,203	\$46,958	\$8,773,959	RESEARCH AND DEVELOPMENT	\$357,858,137
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5 U01 HD076733-06			\$100,458	\$304,912	\$8,773,959	RESEARCH AND DEVELOPMENT	\$357,858,137
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5 U54 HD083211-05			\$78,454	\$78,454	\$8,773,959	RESEARCH AND DEVELOPMENT	\$357,858,137
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5 U54 HD083211-06			\$313,734	\$1,379,076	\$8,773,959	RESEARCH AND DEVELOPMENT	\$357,858,137
			GEORGIA REGENTS UNIVERSITY/MEDICAL						
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1 R01 HD092505-01A1	COLLEGE OF GA	1 R01 HD092505-01A1		\$28,070	\$8,773,959	RESEARCH AND DEVELOPMENT	\$357,858,137
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1 R01 HD093661-02	CASE WESTERN RESERVE UNIVERSITY	1 R01 HD093661-02		\$45,276	\$8,773,959	RESEARCH AND DEVELOPMENT	\$357,858,137
			NORTHSHORE UNIVERSITY						
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1 R01 HD096332-01	HEALTHSYSTEM	1 R01 HD096332-01		\$541	\$8,773,959	RESEARCH AND DEVELOPMENT	\$357,858,137
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1 R21 HD098454-01A1	VANDERBILT UNIVERSITY	1 R21 HD098454-01A1		\$18,468	\$8,773,959	RESEARCH AND DEVELOPMENT	\$357,858,137
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1 R43 HD095351-01	PRAGMADY INC	1 R43 HD095351-01		\$621	\$8,773,959	RESEARCH AND DEVELOPMENT	\$357,858,137
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1 R61 HD099742-01	WASHINGTON UNIVERSITY IN ST. LOUIS	1 R61 HD099742-01		\$81,332	\$8,773,959	RESEARCH AND DEVELOPMENT	\$357,858,137
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	2 K12 HD047349-16	UNIVERSITY OF UTAH	2 K12 HD047349-16		\$7,947	\$8,773,959	RESEARCH AND DEVELOPMENT	\$357,858,137
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	2 R01 HD024356-24	UNIVERSITY OF CALIFORNIA, DAVIS	2 R01 HD024356-24		-\$5,115	\$8,773,959	RESEARCH AND DEVELOPMENT	\$357,858,137
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	2 R01 HD024356-25	UNIVERSITY OF CALIFORNIA, DAVIS	2 R01 HD024356-25		\$167,962	\$8,773,959	RESEARCH AND DEVELOPMENT	\$357,858,137
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	2 R01 HD067126-07	UNIVERSITY OF MARYLAND	2 R01 HD067126-07		\$8,225	\$8,773,959	RESEARCH AND DEVELOPMENT	\$357,858,137
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	2 R01 HD093665-02	TULANE UNIVERSITY	2 R01 HD093665-02		\$17,095	\$8,773,959	RESEARCH AND DEVELOPMENT	\$357,858,137
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	3 UG3 HD096920-02S1	NORTHWESTERN UNIVERSITY	3 UG3 HD096920-02S1		\$33,921	\$8,773,959	RESEARCH AND DEVELOPMENT	\$357,858,137
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5 K12 HD000850-34	DUKE UNIVERSITY	5 K12 HD000850-34		\$111,752	\$8,773,959	RESEARCH AND DEVELOPMENT	\$357,858,137
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5 R01 HD0044073-14	VANDERBILT UNIVERSITY	5 R01 HD0044073-14		\$1,291	\$8,773,959	RESEARCH AND DEVELOPMENT	\$357,858,137
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5 R01 HD064727-10	VANDERBILT UNIVERSITY	5 R01 HD064727-10		\$4,223	\$8,773,959	RESEARCH AND DEVELOPMENT	\$357,858,137
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5 R01 HD079625-05	UNIVERSITY OF TEXAS	5 R01 HD079625-05		\$34,433	\$8,773,959	RESEARCH AND DEVELOPMENT	\$357,858,137
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5 R01 HD081044-02	DUKE UNIVERSITY	5 R01 HD081044-02		\$572	\$8,773,959	RESEARCH AND DEVELOPMENT	\$357,858,137
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5 R01 HD081120-05	NATIONWIDE CHILDREN'S HOSPITAL	5 R01 HD081120-05		\$22,654	\$8,773,959	RESEARCH AND DEVELOPMENT	\$357,858,137
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5 R01 HD083181-02	BAYLOR COLLEGE	5 R01 HD083181-02		\$210,406	\$8,773,959	RESEARCH AND DEVELOPMENT	\$357,858,137
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5 R01 HD084606-03	WAKE FOREST UNIVERSITY	5 R01 HD084606-03		\$7,301	\$8,773,959	RESEARCH AND DEVELOPMENT	\$357,858,137
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5 R01 HD089474-03	VANDERBILT UNIVERSITY	5 R01 HD089474-03		\$12,574	\$8,773,959	RESEARCH AND DEVELOPMENT	\$357,858,137
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5 R01 HD089474-03	VANDERBILT UNIVERSITY	5 R01 HD089474-03		\$1,276	\$8,773,959	RESEARCH AND DEVELOPMENT	\$357,858,137
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5 R01 HD089474-03	VANDERBILT UNIVERSITY	5 R01 HD089474-03		\$2,538	\$8,773,959	RESEARCH AND DEVELOPMENT	\$357,858,137
			NORTHSHORE UNIVERSITY						
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5 R01 HD096332-02	HEALTHSYSTEM	5 R01 HD096332-02		\$18,646	\$8,773,959	RESEARCH AND DEVELOPMENT	\$357,858,137
			UNIVERSITY OF ALABAMA AT BIRMINGHAM						
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5 U54 HD061222-13	BIRMINGHAM	5 U54 HD061222-13		\$74,252	\$8,773,959	RESEARCH AND DEVELOPMENT	\$357,858,137

Vanderbilt University Medical Center
Schedule of Expenditures of Federal Awards and State Financial Assistance
Fiscal Period 7/1/2019 – 6/30/2020

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5 U54 HD061222-14	UNIVERSITY OF ALABAMA AT BIRMINGHAM	5 U54 HD061222-14		\$393	\$8,773,959	RESEARCH AND DEVELOPMENT	\$357,858,137
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5 U54 HD061222-15	UNIVERSITY OF ALABAMA AT BIRMINGHAM	5 U54 HD061222-15		\$52,388	\$8,773,959	RESEARCH AND DEVELOPMENT	\$357,858,137
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	7 R01 HD082127-05	UNIVERSITY OF KANSAS	7 R01 HD082127-05		\$49,452	\$8,773,959	RESEARCH AND DEVELOPMENT	\$357,858,137
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HHSN275201000003I	DUKE UNIVERSITY	HHSN275201000003I		\$7,001	\$8,773,959	RESEARCH AND DEVELOPMENT	\$357,858,137
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5 R01 HD059794-11				-\$17,651	\$8,773,959	RESEARCH AND DEVELOPMENT	\$357,858,137
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5 R01 HD081121-05				-\$102,974	\$8,773,959	RESEARCH AND DEVELOPMENT	\$357,858,137
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5 R01 HD081121-06				-\$9,593	\$8,773,959	RESEARCH AND DEVELOPMENT	\$357,858,137
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5 U54 HD083211-05				-\$2,733	\$8,773,959	RESEARCH AND DEVELOPMENT	\$357,858,137
AGING RESEARCH	93.866	1 F32 AG058395-01				-\$738	\$12,805,845	RESEARCH AND DEVELOPMENT	\$357,858,137
AGING RESEARCH	93.866	1 F32 AG062045-01A1				\$54,382	\$12,805,845	RESEARCH AND DEVELOPMENT	\$357,858,137
AGING RESEARCH	93.866	1 K76 AG060001-01A1				\$208,306	\$12,805,845	RESEARCH AND DEVELOPMENT	\$357,858,137
AGING RESEARCH	93.866	1 R01 AG058639-01A1			\$8,200	\$505,897	\$12,805,845	RESEARCH AND DEVELOPMENT	\$357,858,137
AGING RESEARCH	93.866	1 R01 AG061161-01A1				\$39,963	\$12,805,845	RESEARCH AND DEVELOPMENT	\$357,858,137
AGING RESEARCH	93.866	1 R01 AG061351-01			\$205,812	\$443,875	\$12,805,845	RESEARCH AND DEVELOPMENT	\$357,858,137
AGING RESEARCH	93.866	1 R01 AG061518-02			\$194,141	\$541,875	\$12,805,845	RESEARCH AND DEVELOPMENT	\$357,858,137
AGING RESEARCH	93.866	1 R01 AG062574-01A1				\$62,109	\$12,805,845	RESEARCH AND DEVELOPMENT	\$357,858,137
AGING RESEARCH	93.866	1 R01 AG062826-01A1				\$3,546	\$12,805,845	RESEARCH AND DEVELOPMENT	\$357,858,137
AGING RESEARCH	93.866	1 R01 AG065249-01				\$29,666	\$12,805,845	RESEARCH AND DEVELOPMENT	\$357,858,137
AGING RESEARCH	93.866	1 R03 AG060085-01				\$154,409	\$12,805,845	RESEARCH AND DEVELOPMENT	\$357,858,137
AGING RESEARCH	93.866	1 R03 AG063217-01				\$79,492	\$12,805,845	RESEARCH AND DEVELOPMENT	\$357,858,137
AGING RESEARCH	93.866	1 R21 AG059941-01				\$190,889	\$12,805,845	RESEARCH AND DEVELOPMENT	\$357,858,137
AGING RESEARCH	93.866	1 R21 AG063126-01A1				\$51,212	\$12,805,845	RESEARCH AND DEVELOPMENT	\$357,858,137
AGING RESEARCH	93.866	1 R21 AG065859-01				\$22,782	\$12,805,845	RESEARCH AND DEVELOPMENT	\$357,858,137
AGING RESEARCH	93.866	2 K24 AG046373-08				\$158,844	\$12,805,845	RESEARCH AND DEVELOPMENT	\$357,858,137
AGING RESEARCH	93.866	2 R01 AG034962-08A1				\$24,752	\$12,805,845	RESEARCH AND DEVELOPMENT	\$357,858,137
AGING RESEARCH	93.866	5 F32 AG058395-02				\$4,968	\$12,805,845	RESEARCH AND DEVELOPMENT	\$357,858,137
AGING RESEARCH	93.866	5 K01 AG049164-04				\$130,555	\$12,805,845	RESEARCH AND DEVELOPMENT	\$357,858,137
AGING RESEARCH	93.866	5 K01 AG058700-03				\$111,488	\$12,805,845	RESEARCH AND DEVELOPMENT	\$357,858,137
AGING RESEARCH	93.866	5 K23 AG045966-06				\$147,067	\$12,805,845	RESEARCH AND DEVELOPMENT	\$357,858,137
AGING RESEARCH	93.866	5 K76 AG054864-04				\$1,608	\$12,805,845	RESEARCH AND DEVELOPMENT	\$357,858,137
AGING RESEARCH	93.866	5 R01 AG043471-06				\$2,330	\$12,805,845	RESEARCH AND DEVELOPMENT	\$357,858,137
AGING RESEARCH	93.866	5 R01 AG047992-05			\$621,243	\$621,243	\$12,805,845	RESEARCH AND DEVELOPMENT	\$357,858,137
AGING RESEARCH	93.866	5 R01 AG047992-06			\$2,065,890	\$2,228,560	\$12,805,845	RESEARCH AND DEVELOPMENT	\$357,858,137
AGING RESEARCH	93.866	5 R01 AG048915-04				491877	\$12,805,845	RESEARCH AND DEVELOPMENT	357858137
AGING RESEARCH	93.866	5 R01 AG053264-06			\$52,941	\$633,796	\$12,805,845	RESEARCH AND DEVELOPMENT	\$357,858,137
AGING RESEARCH	93.866	5 R01 AG056534-04			\$16,649	\$840,831	\$12,805,845	RESEARCH AND DEVELOPMENT	\$357,858,137
AGING RESEARCH	93.866	5 R01 AG058639-02			\$1,462	\$602,568	\$12,805,845	RESEARCH AND DEVELOPMENT	\$357,858,137
AGING RESEARCH	93.866	5 R01 AG058856-03				\$443,528	\$12,805,845	RESEARCH AND DEVELOPMENT	\$357,858,137
AGING RESEARCH	93.866	5 R01 AG059716-03			\$339,995	\$881,860	\$12,805,845	RESEARCH AND DEVELOPMENT	\$357,858,137
AGING RESEARCH	93.866	5 R01 AG061138-02			\$7,775	\$446,515	\$12,805,845	RESEARCH AND DEVELOPMENT	\$357,858,137
AGING RESEARCH	93.866	5 R01 AG061325-02			\$227,557	\$472,989	\$12,805,845	RESEARCH AND DEVELOPMENT	\$357,858,137
AGING RESEARCH	93.866	5 R01 AG062499-02			\$2,114	\$276,736	\$12,805,845	RESEARCH AND DEVELOPMENT	\$357,858,137
AGING RESEARCH	93.866	6 R01 AG034962-07				\$288,347	\$12,805,845	RESEARCH AND DEVELOPMENT	\$357,858,137
AGING RESEARCH	93.866	6 R01 AG035117-06				\$519	\$12,805,845	RESEARCH AND DEVELOPMENT	\$357,858,137
AGING RESEARCH	93.866	7 R21 AG049332-03			\$32,648	\$93,928	\$12,805,845	RESEARCH AND DEVELOPMENT	\$357,858,137
AGING RESEARCH	93.866	1 R01 AG006159-01	UNIVERSITY OF VERMONT	1 R01 AG006159-01		\$397,868	\$12,805,845	RESEARCH AND DEVELOPMENT	\$357,858,137
AGING RESEARCH	93.866	1 R01 AG050716-04	UNIVERSITY OF VERMONT	1 R01 AG050716-04		\$14,716	\$12,805,845	RESEARCH AND DEVELOPMENT	\$357,858,137
AGING RESEARCH	93.866	1 R01 AG056368-01A1	BRIGHAM AND WOMEN'S HOSPITAL	1 R01 AG056368-01A1		-\$241	\$12,805,845	RESEARCH AND DEVELOPMENT	\$357,858,137
AGING RESEARCH	93.866	1 R01 AG062563-01	UNIVERSITY OF CALIFORNIA AT SAN FRANCISCO	1 R01 AG062563-01		\$25,002	\$12,805,845	RESEARCH AND DEVELOPMENT	\$357,858,137
AGING RESEARCH	93.866	1 R01 AG062685-01A1	VANDERBILT UNIVERSITY	1 R01 AG062685-01A1		\$3,150	\$12,805,845	RESEARCH AND DEVELOPMENT	\$357,858,137
AGING RESEARCH	93.866	1 R01 AG064800-01	UNIVERSITY OF WASHINGTON	1 R01 AG064800-01		\$78,989	\$12,805,845	RESEARCH AND DEVELOPMENT	\$357,858,137
AGING RESEARCH	93.866	1 R01 AG064950-01	VANDERBILT UNIVERSITY	1 R01 AG064950-01		\$2,141	\$12,805,845	RESEARCH AND DEVELOPMENT	\$357,858,137
AGING RESEARCH	93.866	1 R01 AG064950-01	VANDERBILT UNIVERSITY	1 R01 AG064950-01		\$42,142	\$12,805,845	RESEARCH AND DEVELOPMENT	\$357,858,137
AGING RESEARCH	93.866	1 R24 AG054259-02	HARVARD UNIVERSITY	1 R24 AG054259-02		\$14,456	\$12,805,845	RESEARCH AND DEVELOPMENT	\$357,858,137

Vanderbilt University Medical Center
Schedule of Expenditures of Federal Awards and State Financial Assistance
Fiscal Period 7/1/2019 – 6/30/2020

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
AGING RESEARCH	93.866	1 R24 AG064025-01	UNIVERSITY OF CALIFORNIA AT SAN FRANCISCO	1 R24 AG064025-01		\$57,750	\$12,805,845	RESEARCH AND DEVELOPMENT	\$357,858,137
AGING RESEARCH	93.866	1 R44 AG055184-01	METABOLIC TECHNOLOGIES, INC.	1 R44 AG055184-01		\$7,374	\$12,805,845	RESEARCH AND DEVELOPMENT	\$357,858,137
AGING RESEARCH	93.866	1 R56 AG061522-01A1	DARTMOUTH COLLEGE	1 R56 AG061522-01A1		\$38,082	\$12,805,845	RESEARCH AND DEVELOPMENT	\$357,858,137
AGING RESEARCH	93.866	1 R61 AG066543-01	UNIVERSITY OF SOUTHERN CALIFORNIA	1 R61 AG066543-01		\$2,835	\$12,805,845	RESEARCH AND DEVELOPMENT	\$357,858,137
AGING RESEARCH	93.866	1 RF1 AG059869-01	JOHNS HOPKINS UNIVERSITY	1 RF1 AG059869-01		\$49,419	\$12,805,845	RESEARCH AND DEVELOPMENT	\$357,858,137
AGING RESEARCH	93.866	1 RF1 AG063755-01	THE JACKSON LABORATORY	1 RF1 AG063755-01		\$56,380	\$12,805,845	RESEARCH AND DEVELOPMENT	\$357,858,137
AGING RESEARCH	93.866	1 T32 AG058524-01	VANDERBILT UNIVERSITY	1 T32 AG058524-01		\$13,882	\$12,805,845	RESEARCH AND DEVELOPMENT	\$357,858,137
AGING RESEARCH	93.866	1 U19 AG065188-01	DUKE UNIVERSITY	1 U19 AG065188-01		\$184,879	\$12,805,845	RESEARCH AND DEVELOPMENT	\$357,858,137
AGING RESEARCH	93.866	2 U19 AG024904-11	UNIVERSITY OF SOUTHERN CALIFORNIA	2 U19 AG024904-11		\$129,699	\$12,805,845	RESEARCH AND DEVELOPMENT	\$357,858,137
AGING RESEARCH	93.866	3 T32 AG058524-01S1	VANDERBILT UNIVERSITY	3 T32 AG058524-01S1		\$13,774	\$12,805,845	RESEARCH AND DEVELOPMENT	\$357,858,137
AGING RESEARCH	93.866	3 T32 AG058524-02	VANDERBILT UNIVERSITY	3 T32 AG058524-02		\$42,712	\$12,805,845	RESEARCH AND DEVELOPMENT	\$357,858,137
AGING RESEARCH	93.866	4 R44 AG058268-02	XYKEN, LLC	4 R44 AG058268-02		\$5,584	\$12,805,845	RESEARCH AND DEVELOPMENT	\$357,858,137
AGING RESEARCH	93.866	5 R01 AG037120-05	UNIVERSITY OF MARYLAND	5 R01 AG037120-05		\$374	\$12,805,845	RESEARCH AND DEVELOPMENT	\$357,858,137
AGING RESEARCH	93.866	5 R01 AG054366-03	UNIVERSITY OF CALIFORNIA AT LOS ANGELES	5 R01 AG054366-03		\$386	\$12,805,845	RESEARCH AND DEVELOPMENT	\$357,858,137
AGING RESEARCH	93.866	5 R01 AG054622-02	VANDERBILT UNIVERSITY	5 R01 AG054622-02		\$6,922	\$12,805,845	RESEARCH AND DEVELOPMENT	\$357,858,137
AGING RESEARCH	93.866	5 R01 AG056368-02	BRIGHAM AND WOMEN'S HOSPITAL	5 R01 AG056368-02		\$13,473	\$12,805,845	RESEARCH AND DEVELOPMENT	\$357,858,137
AGING RESEARCH	93.866	5 R01 AG059861-02	OHIO STATE UNIVERSITY	5 R01 AG059861-02		\$53,595	\$12,805,845	RESEARCH AND DEVELOPMENT	\$357,858,137
AGING RESEARCH	93.866	5 R01 AG062563-02	UNIVERSITY OF CALIFORNIA AT SAN FRANCISCO	5 R01 AG062563-02		\$10,906	\$12,805,845	RESEARCH AND DEVELOPMENT	\$357,858,137
AGING RESEARCH	93.866	5 R24 AG052459-03	HARVARD UNIVERSITY	5 R24 AG052459-03		\$4,426	\$12,805,845	RESEARCH AND DEVELOPMENT	\$357,858,137
AGING RESEARCH	93.866	5 R24 AG054259-05	HARVARD UNIVERSITY	5 R24 AG054259-05		\$1,459	\$12,805,845	RESEARCH AND DEVELOPMENT	\$357,858,137
AGING RESEARCH	93.866	5 R44 AG055184-02	VANDERBILT UNIVERSITY	5 R44 AG055184-02		-\$565	\$12,805,845	RESEARCH AND DEVELOPMENT	\$357,858,137
AGING RESEARCH	93.866	5 T32 AG058524-02	VANDERBILT UNIVERSITY	5 T32 AG058524-02		\$1,284	\$12,805,845	RESEARCH AND DEVELOPMENT	\$357,858,137
AGING RESEARCH	93.866	5 T32 AG058524-02	VANDERBILT UNIVERSITY	5 T32 AG058524-02		\$49,882	\$12,805,845	RESEARCH AND DEVELOPMENT	\$357,858,137
AGING RESEARCH	93.866	5 T32 AG058524-02	VANDERBILT UNIVERSITY	5 T32 AG058524-02		\$1,215	\$12,805,845	RESEARCH AND DEVELOPMENT	\$357,858,137
AGING RESEARCH	93.866	6 R01 AG047992-02	UNIVERSITY OF SOUTHERN CALIFORNIA	6 R01 AG047992-02		\$172,961	\$12,805,845	RESEARCH AND DEVELOPMENT	\$357,858,137
AGING RESEARCH	93.866	9 R44 AG059371-02	AVATAR MEDICAL LLC	9 R44 AG059371-02		\$4,921	\$12,805,845	RESEARCH AND DEVELOPMENT	\$357,858,137
AGING RESEARCH	93.866	5 R01 AG047992-05				-\$8,111	\$12,805,845	RESEARCH AND DEVELOPMENT	\$357,858,137
COVID-19 AGING RESEARCH	93.866	COVID-19 1 R01 AG058639-01A1				\$19,550	\$12,805,845	RESEARCH AND DEVELOPMENT	\$357,858,137
VISION RESEARCH	93.867	1 U24 EY029893-01			\$385,743	\$497,576	\$6,696,100	RESEARCH AND DEVELOPMENT	\$357,858,137
VISION RESEARCH	93.867	2 P30 EY008126-32			\$62,815	\$396,912	\$6,696,100	RESEARCH AND DEVELOPMENT	\$357,858,137
VISION RESEARCH	93.867	2 R01 EY020496-06A1			-\$1,237	\$30,352	\$6,696,100	RESEARCH AND DEVELOPMENT	\$357,858,137
VISION RESEARCH	93.867	5 K08 EY027464-04				\$198,672	\$6,696,100	RESEARCH AND DEVELOPMENT	\$357,858,137
VISION RESEARCH	93.867	5 K08 EY029006-03				\$172,156	\$6,696,100	RESEARCH AND DEVELOPMENT	\$357,858,137
VISION RESEARCH	93.867	5 P30 EY008126-31			\$84,309	\$143,936	\$6,696,100	RESEARCH AND DEVELOPMENT	\$357,858,137
VISION RESEARCH	93.867	5 R01 EY007533-30				\$217,953	\$6,696,100	RESEARCH AND DEVELOPMENT	\$357,858,137
VISION RESEARCH	93.867	5 R01 EY013760-13				\$1,581	\$6,696,100	RESEARCH AND DEVELOPMENT	\$357,858,137
VISION RESEARCH	93.867	5 R01 EY017427-12				\$372,405	\$6,696,100	RESEARCH AND DEVELOPMENT	\$357,858,137
VISION RESEARCH	93.867	5 R01 EY020894-09				\$301,017	\$6,696,100	RESEARCH AND DEVELOPMENT	\$357,858,137
VISION RESEARCH	93.867	5 R01 EY022349-09			\$51,631	\$587,924	\$6,696,100	RESEARCH AND DEVELOPMENT	\$357,858,137
VISION RESEARCH	93.867	5 R01 EY022618-06			\$18,534	\$25,584	\$6,696,100	RESEARCH AND DEVELOPMENT	\$357,858,137
VISION RESEARCH	93.867	5 R01 EY023240-05				\$45,126	\$6,696,100	RESEARCH AND DEVELOPMENT	\$357,858,137
VISION RESEARCH	93.867	5 R01 EY023397-08				-\$4,550	\$6,696,100	RESEARCH AND DEVELOPMENT	\$357,858,137
VISION RESEARCH	93.867	5 R01 EY023397-06				\$299,173	\$6,696,100	RESEARCH AND DEVELOPMENT	\$357,858,137
VISION RESEARCH	93.867	5 R01 EY024373-05				\$216,808	\$6,696,100	RESEARCH AND DEVELOPMENT	\$357,858,137
VISION RESEARCH	93.867	5 R01 EY024997-06				\$191,783	\$6,696,100	RESEARCH AND DEVELOPMENT	\$357,858,137
VISION RESEARCH	93.867	5 R01 EY027746-03				\$410,568	\$6,696,100	RESEARCH AND DEVELOPMENT	\$357,858,137
VISION RESEARCH	93.867	5 R01 EY028113-02			\$49,309	\$203,313	\$6,696,100	RESEARCH AND DEVELOPMENT	\$357,858,137
VISION RESEARCH	93.867	5 R01 EY029693-02			\$57,127	\$379,227	\$6,696,100	RESEARCH AND DEVELOPMENT	\$357,858,137
VISION RESEARCH	93.867	5 U01 EY027265-03			\$146,753	\$380,384	\$6,696,100	RESEARCH AND DEVELOPMENT	\$357,858,137
VISION RESEARCH	93.867	5 U24 EY029893-02			\$148,496	\$576,236	\$6,696,100	RESEARCH AND DEVELOPMENT	\$357,858,137
VISION RESEARCH	93.867	7 R01 EY024063-04				\$370,497	\$6,696,100	RESEARCH AND DEVELOPMENT	\$357,858,137
VISION RESEARCH	93.867	1 R01 EY030490-01	VANDERBILT UNIVERSITY	1 R01 EY030490-01		\$2,520	\$6,696,100	RESEARCH AND DEVELOPMENT	\$357,858,137
VISION RESEARCH	93.867	1 U10 EY026869-01	NEW YORK UNIVERSITY	1 U10 EY026869-01		\$539	\$6,696,100	RESEARCH AND DEVELOPMENT	\$357,858,137

Vanderbilt University Medical Center
Schedule of Expenditures of Federal Awards and State Financial Assistance
Fiscal Period 7/1/2019 – 6/30/2020

<i>Federal Awarding Agency/Program Title</i>	<i>Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
VISION RESEARCH	93.867	1 U24 EY029903-01	STANFORD UNIVERSITY	1 U24 EY029903-01		\$52,592	\$6,696,100	RESEARCH AND DEVELOPMENT	\$357,858,137
VISION RESEARCH	93.867	1 UG1 EY028091-01A1	JOHNS HOPKINS UNIVERSITY	1 UG1 EY028091-01A1		\$625	\$6,696,100	RESEARCH AND DEVELOPMENT	\$357,858,137
VISION RESEARCH	93.867	2 R01 EY002686-42	VANDERBILT UNIVERSITY	2 R01 EY002686-42		\$7,302	\$6,696,100	RESEARCH AND DEVELOPMENT	\$357,858,137
VISION RESEARCH	93.867	2 UG1 EY011751-23	JAEB CENTER FOR HEALTH RESEARCH	2 UG1 EY011751-23		\$7,580	\$6,696,100	RESEARCH AND DEVELOPMENT	\$357,858,137
VISION RESEARCH	93.867	2 UG1 EY011751-23	JAEB CENTER FOR HEALTH RESEARCH	2 UG1 EY011751-23		\$64,439	\$6,696,100	RESEARCH AND DEVELOPMENT	\$357,858,137
VISION RESEARCH	93.867	2 UG1 EY011751-23	JAEB CENTER FOR HEALTH RESEARCH	2 UG1 EY011751-23		\$27,860	\$6,696,100	RESEARCH AND DEVELOPMENT	\$357,858,137
VISION RESEARCH	93.867	2 UG1 EY023533-06	UNIVERSITY OF PENNSYLVANIA	2 UG1 EY023533-06		\$1,499	\$6,696,100	RESEARCH AND DEVELOPMENT	\$357,858,137
VISION RESEARCH	93.867	5 R01 EY027729-02	VANDERBILT UNIVERSITY	5 R01 EY027729-02		\$34,745	\$6,696,100	RESEARCH AND DEVELOPMENT	\$357,858,137
VISION RESEARCH	93.867	5 R01 EY027729-03	VANDERBILT UNIVERSITY	5 R01 EY027729-03		\$92,493	\$6,696,100	RESEARCH AND DEVELOPMENT	\$357,858,137
VISION RESEARCH	93.867	5 R21 EY028671-02	AUGUSTA UNIVERSITY	5 R21 EY028671-02		\$1,874	\$6,696,100	RESEARCH AND DEVELOPMENT	\$357,858,137
VISION RESEARCH	93.867	5 T32 EY007135-24	VANDERBILT UNIVERSITY	5 T32 EY007135-24		\$4,609	\$6,696,100	RESEARCH AND DEVELOPMENT	\$357,858,137
VISION RESEARCH	93.867	5 T32 EY007135-25	VANDERBILT UNIVERSITY	5 T32 EY007135-25		\$51,928	\$6,696,100	RESEARCH AND DEVELOPMENT	\$357,858,137
VISION RESEARCH	93.867	5 T32 EY021453-08	VANDERBILT UNIVERSITY	5 T32 EY021453-08		\$45,632	\$6,696,100	RESEARCH AND DEVELOPMENT	\$357,858,137
VISION RESEARCH	93.867	5 U01 EY023533-05	UNIVERSITY OF PENNSYLVANIA	5 U01 EY023533-05		-\$1,426	\$6,696,100	RESEARCH AND DEVELOPMENT	\$357,858,137
VISION RESEARCH	93.867	5 U10 EY011751-22	JAEB CENTER FOR HEALTH RESEARCH	5 U10 EY011751-22		\$112,337	\$6,696,100	RESEARCH AND DEVELOPMENT	\$357,858,137
VISION RESEARCH	93.867	5 U10 EY024527-04	JOHNS HOPKINS UNIVERSITY	5 U10 EY024527-04		\$30,602	\$6,696,100	RESEARCH AND DEVELOPMENT	\$357,858,137
VISION RESEARCH	93.867	5 U10 EY025990-02	MOUNT SINAI SCHOOL OF MEDICINE	5 U10 EY025990-02		-\$3,696	\$6,696,100	RESEARCH AND DEVELOPMENT	\$357,858,137
VISION RESEARCH	93.867	5 U24 EY029903-02	STANFORD UNIVERSITY	5 U24 EY029903-02		\$141,195	\$6,696,100	RESEARCH AND DEVELOPMENT	\$357,858,137
VISION RESEARCH	93.867	5 UG1 EY025553-04	EMORY UNIVERSITY	5 UG1 EY025553-04		\$570	\$6,696,100	RESEARCH AND DEVELOPMENT	\$357,858,137
VISION RESEARCH	93.867	5 UG1 EY028091-02	JOHNS HOPKINS UNIVERSITY	5 UG1 EY028091-02		\$5,648	\$6,696,100	RESEARCH AND DEVELOPMENT	\$357,858,137
MEDICAL LIBRARY ASSISTANCE	93.879	1 R01 LM012854-01A1				\$221,380	\$1,918,744	RESEARCH AND DEVELOPMENT	\$357,858,137
MEDICAL LIBRARY ASSISTANCE	93.879	2 R01 LM010685-09				\$796,217	\$1,918,744	RESEARCH AND DEVELOPMENT	\$357,858,137
MEDICAL LIBRARY ASSISTANCE	93.879	5 R01 LM010207-09				\$321,301	\$1,918,744	RESEARCH AND DEVELOPMENT	\$357,858,137
MEDICAL LIBRARY ASSISTANCE	93.879	7 R01 LM011966-05				\$197,685	\$1,918,744	RESEARCH AND DEVELOPMENT	\$357,858,137
MEDICAL LIBRARY ASSISTANCE	93.879	7 R21 LM012448-03			\$26,858	\$41,358	\$1,918,744	RESEARCH AND DEVELOPMENT	\$357,858,137
MEDICAL LIBRARY ASSISTANCE	93.879	3 T15 LM007450-1752	VANDERBILT UNIVERSITY	3 T15 LM007450-1752		\$361	\$1,918,744	RESEARCH AND DEVELOPMENT	\$357,858,137
MEDICAL LIBRARY ASSISTANCE	93.879	5 R01 LM012806-02	TEXAS HEALTH SCIENCE HOUSTON	5 R01 LM012806-02		\$9,407	\$1,918,744	RESEARCH AND DEVELOPMENT	\$357,858,137
MEDICAL LIBRARY ASSISTANCE	93.879	5 R01 LM012806-03	TEXAS HEALTH SCIENCE HOUSTON	5 R01 LM012806-03		\$52,476	\$1,918,744	RESEARCH AND DEVELOPMENT	\$357,858,137
MEDICAL LIBRARY ASSISTANCE	93.879	5 T15 LM007450-17	VANDERBILT UNIVERSITY	5 T15 LM007450-17		\$54,796	\$1,918,744	RESEARCH AND DEVELOPMENT	\$357,858,137
MEDICAL LIBRARY ASSISTANCE	93.879	5 T15 LM007450-17	VANDERBILT UNIVERSITY	5 T15 LM007450-17		\$32,943	\$1,918,744	RESEARCH AND DEVELOPMENT	\$357,858,137
MEDICAL LIBRARY ASSISTANCE	93.879	5 T15 LM007450-17	VANDERBILT UNIVERSITY	5 T15 LM007450-17		\$7,502	\$1,918,744	RESEARCH AND DEVELOPMENT	\$357,858,137
MEDICAL LIBRARY ASSISTANCE	93.879	5 T15 LM007450-17	VANDERBILT UNIVERSITY	5 T15 LM007450-17		\$57,377	\$1,918,744	RESEARCH AND DEVELOPMENT	\$357,858,137
MEDICAL LIBRARY ASSISTANCE	93.879	5 T15 LM007450-18	VANDERBILT UNIVERSITY	5 T15 LM007450-18		\$69,742	\$1,918,744	RESEARCH AND DEVELOPMENT	\$357,858,137
MEDICAL LIBRARY ASSISTANCE	93.879	5 T15 LM007450-18	VANDERBILT UNIVERSITY	5 T15 LM007450-18		\$56,199	\$1,918,744	RESEARCH AND DEVELOPMENT	\$357,858,137
NATIONAL BIOTERRORISM HOSPITAL PREPAREDNESS PROGRAM	93.889	197578:ST TN	TN DEPARTMENT OF HEALTH	197578:ST TN		\$6,000	\$6,000	N/A	\$0
COVID-19 ASSISTANT SECRETARY FOR PREPAREDNESS AND RESPONSE	93.899	COVID-19 U3 REP 200654-01-00	TENNESSEE HOSPITAL ASSOCIATION METRO-NASH. AND DAVIDSON COUNTY, TENNESSEE	U3 REP 200654-01-00		\$226,308	\$226,308	N/A	\$0
HIV EMERGENCY RELIEF PROJECT GRANTS	93.914	379959:METRO		379959:METRO		\$643,203	\$643,203	N/A	\$0
HIV CARE FORMULA GRANTS	93.917	34349-48620:ST TN	TN DEPARTMENT OF HEALTH	34349-48620:ST TN		\$238,307	\$968,488	N/A	\$0
HIV CARE FORMULA GRANTS	93.917	63994:ST TN	TN DEPARTMENT OF HEALTH	63994:ST TN		\$730,181	\$968,488	N/A	\$0
COVID-19 GRANTS TO PROVIDE OUTPATIENT EARLY INTERVENTION SERVICES WITH RESPECT TO HIV DISEASE	93.918	COVID-19 1 H7C HA37168-01-00				\$25,630	\$664,849	N/A	\$0
GRANTS TO PROVIDE OUTPATIENT EARLY INTERVENTION SERVICES WITH RESPECT TO HIV DISEASE	93.918	5 H76 HA30761-04-00				\$538,310	\$664,849	N/A	\$0
GRANTS TO PROVIDE OUTPATIENT EARLY INTERVENTION SERVICES WITH RESPECT TO HIV DISEASE	93.918	5 H76 HA30761-05-00				\$100,909	\$664,849	N/A	\$0
HIV PREVENTION ACTIVITIES_NON-GOVERNMENTAL ORGANIZATION BASED	93.939	1 R01 CA225005-01A1				\$301,056	\$633,809	RESEARCH AND DEVELOPMENT	\$357,858,137
BLOCK GRANTS FOR COMMUNITY MENTAL HEALTH SERVICES	93.958	60895:ST TN	TN DEPARTMENT OF MENTAL HEALTH AND DEVELOPMENTAL DISABILITIES	60895:ST TN		\$2,430	\$3,135	N/A	\$0
PPHF GERIATRIC EDUCATION CENTERS	93.969	1 U1Q HP033085-01-00			\$183,961	\$328,044	\$328,044	RESEARCH AND DEVELOPMENT	\$357,858,137
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	1 D43 TW011544-01				\$8,112	\$2,651,940	RESEARCH AND DEVELOPMENT	\$357,858,137
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	1 U2R TW011248-01			\$40,444	\$144,167	\$2,651,940	RESEARCH AND DEVELOPMENT	\$357,858,137
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	2 D43 TW009745-07				\$7,920	\$2,651,940	RESEARCH AND DEVELOPMENT	\$357,858,137
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	2 R25 TW009722-07			\$36,710	\$78,226	\$2,651,940	RESEARCH AND DEVELOPMENT	\$357,858,137
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	5 D43 TW009337-08			\$357,429	\$364,754	\$2,651,940	RESEARCH AND DEVELOPMENT	\$357,858,137

Vanderbilt University Medical Center
Schedule of Expenditures of Federal Awards and State Financial Assistance
Fiscal Period 7/1/2019 – 6/30/2020

<i>Federal Awarding Agency/Program Title</i>	<i>Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	5 D43 TW009337-09			\$614,903	\$1,068,861	\$2,651,940	RESEARCH AND DEVELOPMENT	\$357,858,137
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	5 D43 TW009744-04				-\$468	\$2,651,940	RESEARCH AND DEVELOPMENT	\$357,858,137
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	5 D43 TW009744-05			\$10,826	\$10,826	\$2,651,940	RESEARCH AND DEVELOPMENT	\$357,858,137
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	5 D43 TW009744-06			\$59,456	\$240,056	\$2,651,940	RESEARCH AND DEVELOPMENT	\$357,858,137
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	5 D43 TW009745-05				-\$11,068	\$2,651,940	RESEARCH AND DEVELOPMENT	\$357,858,137
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	5 D43 TW009745-06			\$80,296	\$304,435	\$2,651,940	RESEARCH AND DEVELOPMENT	\$357,858,137
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	5 R21 TW010899-02			\$8,300	\$88,853	\$2,651,940	RESEARCH AND DEVELOPMENT	\$357,858,137
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	5 R21 TW011327-02				\$41,393	\$2,651,940	RESEARCH AND DEVELOPMENT	\$357,858,137
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	5 R25 TW009722-06				-\$8,582	\$2,651,940	RESEARCH AND DEVELOPMENT	\$357,858,137
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	5 R25 TW009722-08			\$71,562	\$93,372	\$2,651,940	RESEARCH AND DEVELOPMENT	\$357,858,137
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	5 U2R TW011248-02				\$12,026	\$2,651,940	RESEARCH AND DEVELOPMENT	\$357,858,137
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	3 R21 TW010620-02S1	PURDUE UNIVERSITY	3 R21 TW010620-02S1		\$51,298	\$2,651,940	RESEARCH AND DEVELOPMENT	\$357,858,137
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	5 D43 TW010559-02	UNIVERSITY OF CAPE TOWN (SOUTH AFRICA)	5 D43 TW010559-02		\$55,158	\$2,651,940	RESEARCH AND DEVELOPMENT	\$357,858,137
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	59823:ST TN	TN DEPARTMENT OF HEALTH	59823:ST TN		\$102,997	\$2,651,940	RESEARCH AND DEVELOPMENT	\$357,858,137
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	5 D43 TW009744-05				-\$396	\$2,651,940	RESEARCH AND DEVELOPMENT	\$357,858,137
MATERNAL AND CHILD HEALTH SERVICES BLOCK GRANT TO THE STATES	93.994	54083:ST TN	TN DEPARTMENT OF HEALTH	54083:ST TN		\$236,997	\$274,110	RESEARCH AND DEVELOPMENT	\$357,858,137
MATERNAL AND CHILD HEALTH SERVICES BLOCK GRANT TO THE STATES	93.994	57826:ST TN	TN DEPARTMENT OF HEALTH	57826:ST TN		\$37,253	\$274,110	RESEARCH AND DEVELOPMENT	\$357,858,137
MATERNAL AND CHILD HEALTH SERVICES BLOCK GRANT TO THE STATES	93.994	57826:ST TN	TN DEPARTMENT OF MENTAL HEALTH AND DEVELOPMENTAL DISABILITIE	57826:ST TN		-\$140	\$274,110	RESEARCH AND DEVELOPMENT	\$357,858,137
AUTISM AND OTHER DEVELOPMENTAL DISABILITIES, SURVEILLANCE, RESEARCH, AND PREVENTION	93.998	1 NU53 DD000010-02-00				\$381,400	\$381,400	N/A	\$0
200-2012-50430	93.RD	200-2012-50430				\$89,025	\$8,892,664	RESEARCH AND DEVELOPMENT	\$357,858,137
200-2012-50430	93.RD	200-2012-50430				\$312,836	\$8,892,664	RESEARCH AND DEVELOPMENT	\$357,858,137
200-2012-50430	93.RD	200-2012-50430				\$111,914	\$8,892,664	RESEARCH AND DEVELOPMENT	\$357,858,137
200-2012-50430	93.RD	200-2012-50430				\$22,350	\$8,892,664	RESEARCH AND DEVELOPMENT	\$357,858,137
200-2015-63553	93.RD	200-2015-63553				\$67,008	\$8,892,664	RESEARCH AND DEVELOPMENT	\$357,858,137
200-2016-91801	93.RD	200-2016-91801				\$243,980	\$8,892,664	RESEARCH AND DEVELOPMENT	\$357,858,137
75D301-19-C-05670	93.RD	75D301-19-C-05670			\$911,318	\$1,433,772	\$8,892,664	RESEARCH AND DEVELOPMENT	\$357,858,137
COVID-19 75D30120C07637	93.RD	COVID-19 75D30120C07637			\$224,400	\$421,473	\$8,892,664	RESEARCH AND DEVELOPMENT	\$357,858,137
75N93019C00074	93.RD	75N93019C00074				\$424,038	\$8,892,664	RESEARCH AND DEVELOPMENT	\$357,858,137
COVID-19 75N93019C00074	93.RD	COVID-19 75N93019C00074			\$64,269	\$473,524	\$8,892,664	RESEARCH AND DEVELOPMENT	\$357,858,137
75N95D19P00178	93.RD	75N95D19P00178				\$17,660	\$8,892,664	RESEARCH AND DEVELOPMENT	\$357,858,137
75N97019P00279	93.RD	75N97019P00279				\$207,675	\$8,892,664	RESEARCH AND DEVELOPMENT	\$357,858,137
HHSN261201600027I	93.RD	HHSN261201600027I				\$55,125	\$8,892,664	RESEARCH AND DEVELOPMENT	\$357,858,137
HHSN271201800393P	93.RD	HHSN271201800393P				\$5,151	\$8,892,664	RESEARCH AND DEVELOPMENT	\$357,858,137
HHSN272201300023I	93.RD	HHSN272201300023I				\$121,929	\$8,892,664	RESEARCH AND DEVELOPMENT	\$357,858,137
HHSN272201300023I	93.RD	HHSN272201300023I				\$21,477	\$8,892,664	RESEARCH AND DEVELOPMENT	\$357,858,137
HHSN272201300023I	93.RD	HHSN272201300023I				\$9,795	\$8,892,664	RESEARCH AND DEVELOPMENT	\$357,858,137
HHSN272201300023I	93.RD	HHSN272201300023I				\$132,270	\$8,892,664	RESEARCH AND DEVELOPMENT	\$357,858,137
HHSN272201300023I	93.RD	HHSN272201300023I				\$252,087	\$8,892,664	RESEARCH AND DEVELOPMENT	\$357,858,137
HHSN272201300023I	93.RD	HHSN272201300023I			\$352,000	\$471,403	\$8,892,664	RESEARCH AND DEVELOPMENT	\$357,858,137
HHSN272201300023I	93.RD	HHSN272201300023I			\$36,000	\$100,243	\$8,892,664	RESEARCH AND DEVELOPMENT	\$357,858,137
HHSN272201300023I	93.RD	HHSN272201300023I				\$515,936	\$8,892,664	RESEARCH AND DEVELOPMENT	\$357,858,137
HHSN272201300023I	93.RD	HHSN272201300023I				\$64,350	\$8,892,664	RESEARCH AND DEVELOPMENT	\$357,858,137
HHSN272201300023I	93.RD	HHSN272201300023I				\$96,730	\$8,892,664	RESEARCH AND DEVELOPMENT	\$357,858,137
HHSN272201300023I	93.RD	HHSN272201300023I				\$393,529	\$8,892,664	RESEARCH AND DEVELOPMENT	\$357,858,137
HHSN272201300023I	93.RD	HHSN272201300023I				\$207,117	\$8,892,664	RESEARCH AND DEVELOPMENT	\$357,858,137
HHSN272201300023I	93.RD	HHSN272201300023I			\$501,616	\$699,137	\$8,892,664	RESEARCH AND DEVELOPMENT	\$357,858,137
HHSN272201300023I	93.RD	HHSN272201300023I				\$356,270	\$8,892,664	RESEARCH AND DEVELOPMENT	\$357,858,137
HHSN272201700071C	93.RD	HHSN272201700071C			\$258,732	\$351,665	\$8,892,664	RESEARCH AND DEVELOPMENT	\$357,858,137
HHSN272201700071C	93.RD	HHSN272201700071C				\$106,714	\$8,892,664	RESEARCH AND DEVELOPMENT	\$357,858,137
HHSN272201700071C	93.RD	HHSN272201700071C				\$135,271	\$8,892,664	RESEARCH AND DEVELOPMENT	\$357,858,137
HHSP223201700050C	93.RD	HHSP223201700050C				\$14,644	\$8,892,664	RESEARCH AND DEVELOPMENT	\$357,858,137
HHSP223201700051C	93.RD	HHSP223201700051C				\$18,819	\$8,892,664	RESEARCH AND DEVELOPMENT	\$357,858,137
200-2011-41276	93.RD	200-2011-41276	DUKE UNIVERSITY	200-2011-41276	\$59,767	\$155,734	\$8,892,664	RESEARCH AND DEVELOPMENT	\$357,858,137
4I-WDR5-MLL1	93.RD	4I-WDR5-MLL1	VANDERBILT UNIVERSITY	4I-WDR5-MLL1		\$5,842	\$8,892,664	RESEARCH AND DEVELOPMENT	\$357,858,137

Vanderbilt University Medical Center
Schedule of Expenditures of Federal Awards and State Financial Assistance
Fiscal Period 7/1/2019 – 6/30/2020

<i>Federal Awarding Agency/Program Title</i>	<i>Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
4I-WDR5-MLL1	93.RD	4I-WDR5-MLL1	VANDERBILT UNIVERSITY	4I-WDR5-MLL1		\$5,828	\$8,892,664	RESEARCH AND DEVELOPMENT	\$357,858,137
4I-WDR5-MLL1	93.RD	4I-WDR5-MLL1	VANDERBILT UNIVERSITY	4I-WDR5-MLL1		\$9,956	\$8,892,664	RESEARCH AND DEVELOPMENT	\$357,858,137
75D301-19-C-05584	93.RD	75D301-19-C-05584	BOSTON CHILDREN'S HOSPITAL	75D301-19-C-05584		\$32,001	\$8,892,664	RESEARCH AND DEVELOPMENT	\$357,858,137
75D301-19-C-05584	93.RD	75D301-19-C-05584	BOSTON CHILDREN'S HOSPITAL	75D301-19-C-05584		\$5,101	\$8,892,664	RESEARCH AND DEVELOPMENT	\$357,858,137
75N91019D00024	93.RD	75N91019D00024	LEIDOS BIOMEDICAL RESEARCH, INC.	75N91019D00024		\$248,232	\$8,892,664	RESEARCH AND DEVELOPMENT	\$357,858,137
75N93019C00055	93.RD	75N93019C00055	UNIVERSITY OF MARYLAND	75N93019C00055		\$6,179	\$8,892,664	RESEARCH AND DEVELOPMENT	\$357,858,137
75N93019C00062	93.RD	75N93019C00062	WASHINGTON UNIVERSITY IN ST. LOUIS	75N93019C00062		\$122,138	\$8,892,664	RESEARCH AND DEVELOPMENT	\$357,858,137
75N93019C00073	93.RD	75N93019C00073	INTEGRAL MOLECULAR	75N93019C00073		\$56,912	\$8,892,664	RESEARCH AND DEVELOPMENT	\$357,858,137
HHSF223201400030I	93.RD	HHSF223201400030I	HARVARD PILGRIM HEALTH CARE	HHSF223201400030I		\$166,981	\$8,892,664	RESEARCH AND DEVELOPMENT	\$357,858,137
HHSF223201400042I	93.RD	HHSF223201400042I	HARVARD PILGRIM HEALTH CARE	HHSF223201400042I		\$26,271	\$8,892,664	RESEARCH AND DEVELOPMENT	\$357,858,137
HHSN272201600018C	93.RD	HHSN272201600018C	UNIVERSITY OF ALABAMA AT BIRMINGHAM	HHSN272201600018C		\$24,382	\$8,892,664	RESEARCH AND DEVELOPMENT	\$357,858,137
HHSP233201500024I	93.RD	HHSP233201500024I	RESEARCH TRIANGLE INSTITUTE	HHSP233201500024I		\$72,190	\$8,892,664	RESEARCH AND DEVELOPMENT	\$357,858,137
TOTAL DEPARTMENT OF HEALTH AND HUMAN SERVICES					\$62,500,836	\$378,400,331			
U.S. AGENCY FOR INTERNATIONAL DEVELOPMENT									
USAID FOREIGN ASSISTANCE FOR PROGRAMS OVERSEAS	98.001	720-656-18-C-00001	CHEMONICS INTERNATIONAL INC.	720-656-18-C-00001		\$336,184	\$571,186	N/A	\$0
USAID FOREIGN ASSISTANCE FOR PROGRAMS OVERSEAS	98.001	AID-OAA-A-11-00012	THE NATIONAL ACADEMIES OF SCIENCES, ENGINEERING AND MEDICINE	AID-OAA-A-11-00012	\$21,125	\$242,742	\$571,186	N/A	\$0
USAID FOREIGN ASSISTANCE FOR PROGRAMS OVERSEAS	98.001	AID-OAA-A-11-00012	VANDERBILT UNIVERSITY	AID-OAA-A-11-00012		-\$7,740	\$571,186	N/A	\$0
USAID DEVELOPMENT PARTNERSHIPS FOR UNIVERSITY COOPERATION AND DEVELOPMENT	98.012	720-OAA-18-CA-00019			\$56,113	\$337,028	\$337,028	N/A	\$0
TOTAL U.S. AGENCY FOR INTERNATIONAL DEVELOPMENT					\$77,238	\$908,214			
TOTAL EXPENDITURE OF FEDERAL AWARDS					\$66,023,283	\$400,472,553			

Please Note:
Italicized award lines indicate pass-through funding

The accompanying Notes to the Schedule of Expenditures of Federal Awards are an integral part of the schedule.

Vanderbilt University Medical Center
Schedule of Expenditures of Federal Awards and State Financial Assistance
Fiscal Period 7/1/2019 – 6/30/2020

<i>Federal Awarding Agency/Program Title</i>	<i>Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
TOTAL EXPENDITURE OF FEDERAL AWARDS					\$66,023,283	\$400,472,553			
STATE FINANCIAL ASSISTANCE									
PSYLDHDDFET MW				6442:STTN BOP		\$204,075			
DOC (BOP) RISK ASSESSMENTS				6442:STTN BOP		\$46,878			
COMMUNITY FORENSIC-JUV CT EVALUATIONS				6442:STTN CFJCE		\$98,473			
42139:COMPREHENSIVE CARE CLINIC FOR STATE APPROVED CLIENTS				42139:ST TN		-\$347			
54788:COVID 19 HOTLINE SUPPORT				54788:ST TN		\$197,342			
57826:CHILDREN AND YOUTH WITH SPECIAL HEALTH CARE CYSHCN				57826:ST TN		-\$42			
57826:CHILDREN AND YOUTH WITH SPECIAL HEALTH CARE CYSHCN				57826:ST TN		\$29,676			
59045:COMMUNITY SUPPORTS THROUGH INFORMATION AND REFER				59045:ST TN		-\$1,974			
64198:COMPREHENSIVE CARE CLINIC FOR STATE APPROVED CLIENTS				64198:ST TN		\$86,331			
54083:GENETIC SCREENING,TESTING, COUNSELING-STATE FUND				54083:ST TN		-\$45			
54083:GENETIC SCREENING, TESTING, COUNSELING-STATE FUNDS				54083:ST TN		\$751,900			
56787:CPS ASSESSMENT TRACK TRAINING ACADEMY				56787:ST TN		\$289,461			
58795:MITIGATING ACES IN PEDIATRIC PRIMARY CARE AND A HOME V				58795:ST TN	\$1,623	\$3,247			
58795:MITIGATING ACES IN PEDIATRIC PRIMARY CARE AND A HOME V				58795:ST TN		\$3,540			
59263:CLOVER BOTTOM NEUROLOGY SPASTICITY CLINICS				59263:ST TN		\$9,950			
59366:POISON CONTROL SERVICES				59366:ST TN		\$374,115			
61290:NETWORK OF OPIOID USE DISORDERS (OUD) STUDIES				61290:ST TN		\$15,136			
62445:COMMUNITY SUPPORTS THROUGH INFORMATION AND REFERRAL F				62445:ST TN		\$48,941			
62967:MED-ASSISTED TREATMENT SERVICES				62967:MED-ASSISTED TRT		\$10,015			
63051:TENNESSEE INTEGRATED COURT SCREENING AND REFERRAL PROJ				63051:ST TN		\$59,922			
64491:STRATEGIC TRAINING, ANALYSIS AND RESOURCES FOR				64491:ST TN		\$194,972			
INTERNAL CAR SEAT PROGRAM				STATE OF TENNESSEE		\$8,322			
JJ CANS 2.0				ST OF TN-AOC		\$28,581			
TOTAL STATE FINANCIAL ASSISTANCE					\$1,623	\$2,458,469			
TOTAL EXPENDITURE OF FEDERAL AWARDS AND STATE FINANCIAL ASSISTANCE					\$66,024,906	\$402,931,022			

Please Note:

The accompanying Notes to the Schedule of Expenditures of Federal Awards are an integral part of the schedule.

Vanderbilt University Medical Center
Notes to the Schedule of Expenditures of Federal Awards
and State Financial Assistance
For the Year Ended June 30, 2020

1. Significant Accounting Policies Used in Preparing the SEFA

The accompanying Schedule of Expenditures of Federal Awards and State Financial Assistance (the Schedule) includes the activity of Vanderbilt University Medical Center (VUMC) under programs of the federal government and of the state of Tennessee for the year ended June 30, 2020. The information in the Schedule is presented in accordance with the requirements of Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance) and the State of Tennessee Audit Manual. For purposes of the Schedule, federal and state awards include all grants, contracts, and similar agreements entered into directly between VUMC and agencies and departments of the federal government and all subawards to VUMC by organizations pursuant to federal grants, contracts, and similar agreements, and agencies and departments of the Tennessee state government, including federal awards passed through by the state of Tennessee.

2. 10% De Minimis Cost Rate

VUMC did not use the de minimis cost rate.

3. Summary of Significant Accounting Policies for the Schedule

For purposes of the Schedule, expenditures for federal and state programs are recognized on the accrual basis, which is consistent with accounting principles generally accepted in the United States. Expenditures for federal and state awards of VUMC are determined using the cost accounting principles and procedures set forth in the Uniform Guidance and the State of Tennessee Audit Manual. Under these cost principles, certain expenditures are not allowable or are limited as to reimbursement. Negative amounts represent adjustments or credits made in the normal course of business to amounts reported as expenditures in prior years.

4. Personal Protective Equipment (Unaudited)

VUMC received \$2,283,840 of donated personal protective equipment (PPE) from the federal stockpile for the year ended June 30, 2020, which is valued based on the fair value of the PPE at the time of donation.

Uniform Guidance Reports and Schedule



Ernst & Young LLP
Suite 2100
222 2nd Avenue South
Nashville, TN 37201

Tel: +1 615 252 2000
ey.com

Report of Independent Auditors on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance With *Government Auditing Standards*

Senior Management and the Board of Directors
Vanderbilt University Medical Center

We have audited, in accordance with auditing standards generally accepted in the United States and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States, the financial statements of Vanderbilt University Medical Center, which comprise the consolidated balance sheet as of June 30, 2020, and the related consolidated statements of operations, changes in net assets, and cash flows for the year then ended, and the related notes to the consolidated financial statements, and have issued our report thereon dated October 13, 2020.

Internal Control Over Financial Reporting

In planning and performing our audit of the financial statements, we considered Vanderbilt University Medical Center's internal control over financial reporting (internal control) as a basis for designing audit procedures that are appropriate in the circumstances for the purpose of expressing our opinion on the financial statements, but not for the purpose of expressing an opinion on the effectiveness of Vanderbilt University Medical Center's internal control. Accordingly, we do not express an opinion on the effectiveness of Vanderbilt University Medical Center's internal control.

A *deficiency in internal control* exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, misstatements on a timely basis. A *material weakness* is a deficiency, or combination of deficiencies, in internal control, such that there is a reasonable possibility that a material misstatement of the entity's financial statements will not be prevented, or detected and corrected, on a timely basis. A *significant deficiency* is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses may exist that have not been identified.



Compliance and Other Matters

As part of obtaining reasonable assurance about whether Vanderbilt University Medical Center's financial statements are free of material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements, noncompliance with which could have a direct and material effect on the financial statements. However, providing an opinion on compliance with those provisions was not an objective of our audit, and accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.

Purpose of This Report

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the entity's internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the entity's internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

Ernst + Young LLP

October 13, 2020



Ernst & Young LLP
Suite 2100
222 2nd Avenue South
Nashville, TN 37201

Tel: +1 615 252 2000
ey.com

Report of Independent Auditors on Compliance With Requirements for Each Major Federal Program and Report on Internal Control Over Compliance Required by the Uniform Guidance

Senior Management and the Board of Directors
Vanderbilt University Medical Center

Report on Compliance for Each Major Federal Program

We have audited Vanderbilt University Medical Center's compliance with the types of compliance requirements described in the U.S. Office of Management and Budget (OMB) Compliance Supplement that could have a direct and material effect on each of Vanderbilt University Medical Center's major federal programs for the year ended June 30, 2020. Vanderbilt University Medical Center's major federal programs are identified in the summary of auditor's results section of the accompanying schedule of findings and questioned costs.

Management's Responsibility

Management is responsible for compliance with federal statutes, regulations, and the terms and conditions of its federal awards applicable to its federal programs.

Auditor's Responsibility

Our responsibility is to express an opinion on compliance for each of Vanderbilt University Medical Center's major federal programs based on our audit of the types of compliance requirements referred to above. We conducted our audit of compliance in accordance with auditing standards generally accepted in the United States; the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States; and the audit requirements of Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance). Those standards and the Uniform Guidance require that we plan and perform the audit to obtain reasonable assurance about whether noncompliance with the types of compliance requirements referred to above that could have a direct and material effect on a major federal program occurred. An audit includes examining, on a test basis, evidence about Vanderbilt University Medical Center's compliance with those requirements and performing such other procedures as we considered necessary in the circumstances.

We believe that our audit provides a reasonable basis for our opinion on compliance for each major federal program. However, our audit does not provide a legal determination of Vanderbilt University Medical Center's compliance.

Opinion on Each Major Federal Program

In our opinion, Vanderbilt University Medical Center complied, in all material respects, with the types of compliance requirements referred to above that could have a direct and material effect on each of its major federal programs for the year ended June 30, 2020.

Other Matters

The results of our auditing procedures disclosed an instance of noncompliance which is required to be reported in accordance with the Uniform Guidance, and which is described in the accompanying schedule of findings and questioned costs as item 2020–001 related to the Global Aids major program over Procurement Suspension and Debarment. Our opinion on each major federal program is not modified with respect to this matter.

Vanderbilt University Medical Center’s response to the noncompliance finding identified in our audit is described in the accompanying schedule of findings and questioned costs. Vanderbilt University Medical Center’s response was not subjected to the auditing procedures applied in the audit of compliance and, accordingly, we express no opinion on the response.

Report on Internal Control Over Compliance

Management of Vanderbilt University Medical Center is responsible for establishing and maintaining effective internal control over compliance with the types of compliance requirements referred to above. In planning and performing our audit of compliance, we considered Vanderbilt University Medical Center’s internal control over compliance with the types of requirements that could have a direct and material effect on each major federal program to determine the auditing procedures that are appropriate in the circumstances for the purpose of expressing an opinion on compliance for each major federal program and to test and report on internal control over compliance in accordance with the Uniform Guidance, but not for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly, we do not express an opinion on the effectiveness of Vanderbilt University Medical Center’s internal control over compliance.

A deficiency in internal control over compliance exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, noncompliance with a type of compliance requirement of a federal program on a timely basis. *A material weakness in internal control over compliance* is a deficiency, or a combination of deficiencies, in internal control over compliance, such that there is a reasonable possibility that material noncompliance with a type of compliance requirement of a federal program will not be prevented, or detected and corrected, on a timely basis. *A significant deficiency in internal control over compliance* is a deficiency, or a combination of deficiencies, in internal control over compliance with a type of compliance requirement of a federal program that is less severe than a material weakness in internal control over compliance, yet important enough to merit attention by those charged with governance.

Our consideration of internal control over compliance was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control over compliance that might be material weaknesses or significant deficiencies and, therefore, material weaknesses or significant deficiencies may exist that have not been identified. We did identify a deficiency in internal control over compliance, as described in the accompanying schedule of findings and questioned costs as item 2020–001 related to the Global Aids major program over Procurement Suspension and Debarment, that we consider to be a material weakness.



Vanderbilt University Medical Center's response to the internal control over the compliance finding identified in our audit is described in the accompanying schedule of findings and questioned costs. Vanderbilt University Medical Center's response was not subjected to the auditing procedures applied in the audit of compliance and, accordingly, we express no opinion on the response.

The purpose of this report on internal control over compliance is solely to describe the scope of our testing of internal control over compliance and the results of that testing based on the requirements of the Uniform Guidance. Accordingly, this report is not suitable for any other purpose.

Ernst + Young LLP

June 14, 2021

**Vanderbilt University Medical Center
 Schedule of Findings and Questioned Costs
 For the Year Ended June 30, 2020**

Section I—Summary of Auditor’s Results

Financial Statements

Type of report the auditor issued on whether the financial statements audited were prepared in accordance with GAAP:

Unmodified

Internal control over financial reporting:

Material weakness(es) identified?

 yes X **no**

Significant deficiency(ies) identified?

 yes X **none reported**

Noncompliance material to financial statements noted?

 yes X **no**

Federal Awards

Internal control over major federal programs:

Material weakness(es) identified?

 X **yes** **no**

Significant deficiency(ies) identified?

 yes X **none reported**

Type of auditor’s report issued on compliance for major federal programs:

Unmodified

Any audit findings disclosed that are required to be reported in accordance with 2 CFR 200.516(a)?

 X **yes** **no**

Identification of major federal programs:

Assistance Listing numbers

Name of federal program or cluster

Various
 93.067
 93.778

Research & Development Cluster
 Global Aids
 Medicaid Cluster

Dollar threshold used to distinguish between Type A and Type B programs:

\$3,000,000

Auditee qualified as low-risk auditee?

 X **yes** **no**

**Vanderbilt University Medical Center
Schedule of Findings and Questioned Costs
For the Year Ended June 30, 2020**

Section II—Financial Statement Findings

No findings reported.

**Vanderbilt University Medical Center
Schedule of Findings and Questioned Costs
For the Year Ended June 30, 2020**

Section III—Federal Award Findings and Questioned Costs

2020–001 SUSPENSION AND DEBARMENT

Federal Program Information:	Federal Agency and Program Name	Assistance Listing #
	Global Aids	93.067
	Grant Award 5 NU2 GGH001943-04-00	
	Grant Award 6 NU2 GGH001943-03-10	

Criteria: 2 CFR 200.303 requires that a non-federal entity must “(a) establish and maintain effective internal control over the Federal award that provides reasonable assurance that the non-Federal entity is managing the Federal award in compliance with Federal statutes, regulations, and the terms and conditions of the Federal award. These internal controls should be in compliance with guidance in “Standards for Internal Control in the Federal Government” issued by the Comptroller General of the United States and the “Internal Control Integrated Framework,” issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).”

2 CFR 200.213 states that “Non-federal entities are subject to the non-procurement debarment and suspension regulations implementing Executive Orders 12549 and 12689, 2 CFR part 180. These regulations restrict awards, subawards, and contracts with certain parties that are debarred, suspended, or otherwise excluded from or ineligible for participation in Federal assistance programs or activities.”

Condition: During our testing of 40 transactions, totaling \$337,363 for suspension and debarment of the Global Aids program, we noted that for 11 transactions, totaling \$20,269, there was a lack of supporting documentation demonstrating that management was monitoring the contractors to ensure they were not suspended or debarred when the purchase was made; this was determined to be a systemic issue.

Questioned Costs: \$20,269 – Assistance Listing Number 93.067 - \$20,193 related to Grant Award NU2 GGH001943-03-10 and \$76 related to Grant Award NU2 GGH001943-04.

Context: Total federal expenditures for the Global Aids program were \$23,253,711 of which approximately \$6.3 million were expenditures subject to suspension and debarment requirements for the year ended June 30, 2020.

Cause: Vanderbilt University Medical Center does not have adequately designed internal controls and policies and procedures in place to ensure that contractors are being properly monitored for suspension and debarment.

Effect: Vanderbilt University Medical Center is not in compliance with federal statutes, regulations, and the terms and conditions of the federal award. Federal monies may be expended to contractors who are suspended or debarred.

**Vanderbilt University Medical Center
Schedule of Findings and Questioned Costs
For the Year Ended June 30, 2020**

Section III—Federal Award Findings and Questioned Costs (continued)

2020-001 SUSPENSION AND DEBARMENT (continued)

Recommendation: We recommend that Vanderbilt University Medical Center implement adequate internal controls and policies and procedures to ensure that all contractors are not suspended or debarred.

Views of Responsible Officials: Management concurs with the findings and has developed a plan to correct the finding.

EY | Building a better working world

EY exists to build a better working world, helping to create long-term value for clients, people and society and build trust in the capital markets.

Enabled by data and technology, diverse EY teams in over 150 countries provide trust through assurance and help clients grow, transform and operate.

Working across assurance, consulting, law, strategy, tax and transactions, EY teams ask better questions to find new answers for the complex issues facing our world today.

EY refers to the global organization, and may refer to one or more, of the member firms of Ernst & Young Global Limited, each of which is a separate legal entity. Ernst & Young Global Limited, a UK company limited by guarantee, does not provide services to clients. Information about how EY collects and uses personal data and a description of the rights individuals have under data protection legislation are available via ey.com/privacy. EY member firms do not practice law where prohibited by local laws. For more information about our organization, please visit ey.com.

Ernst & Young LLP is a client-serving member firm of Ernst & Young Global Limited operating in the US.

© 2021 Ernst & Young LLP.
All Rights Reserved.

ey.com

**Summary Schedule of Prior Audit Findings****Section III - Federal Award Findings and Questioned Costs – Year Ended June 30, 2019****2019-001 – SUSPENSION AND DEBARMENT****Federal Program Information:****Federal Agency and Program Name**

Research and Development Cluster

Special Education Cluster (IDEA)

CFDA #

Various

84.027/84.173

Finding: During testing of transactions for suspension and debarment of the Research and Development Cluster, one transaction, for \$41, of the 37 transactions tested for \$2,061,516, lacked supporting documentation demonstrating that management was monitoring the contractors to ensure they were not suspended or debarred when the purchase was made; this was determined to be a systemic issue. Further, management has internal controls to assess potential suspension and debarment matches it receives from its a third-party servicer who performs suspension and debarment searches for them. However, the internal controls are not precise enough to ensure a resolution has been completed for each match identified.

Status: The corrective action plan was taken.



**MANAGEMENT'S CORRECTIVE ACTION PLAN
for the Year Ended June 30, 2020**

2020-001

The Vanderbilt University Medical Center (VUMC) Global Aids program has controls to monitor vendors to ensure that contractors are not suspended or debarred. However, VUMC could not produce adequate documentation to evidence performance of the control. VUMC has improved the performance of this control by using a 3rd party vendor to perform the suspension and debarment testing. VUMC also adjusted its existing policy to ensure adequate supporting evidence is retained to evidence performance of the control.

Paula Yarbrough, VUMC Director – Grants and Contracts, will be responsible for implementation of the planned corrective action by fiscal year end 2021.